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AbstrAct
In vitro epithelial cell cultures are increasingly used to model drug permeability, as 
predictive tools for absorption in humans.  Medical regulatory agencies recommend in 
vitro permeability screening for biopharmaceutical classification of novel therapeutic 
compounds, and recently published guidelines on investigating interactions of novel 
therapeutic compounds with clinically relevant transporters.  the expression and 
functionality of drug transporters in the lung is poorly characterised, and insufficient 
to allow detailed understanding of drug-transporter interactions in the airways. 
Additionally, as human in vitro permeability is used to predict absorption from rat 
in vivo, a rat bronchial epithelium in vitro cell line would aid the understanding of 
interspecies differences in transporter-mediated drug trafficking.
this thesis investigates the morphological and physiological barrier properties of calu-
3, normal human bronchial epithelial (NHbE) cell layers and rat airway epithelial cell 
(rL-65) cultures.  the morphology and barrier integrity of rL-65 layers were shown to 
be in agreement with existing human bronchial epithelial cell models after culture for 8 
days at air-liquid interface.  the expression of >30 Abc, sLc and sLcO transporters 
in human models was in general agreement with published expression levels in human 
lungs.  MDr1 functionality was investigated, and whilst no asymmetric transport of 
3H-digoxin was observed in rL-65 cell layers, net secretory transport was observed 
for calu-3 cell layers at both low (25-30) and high (45-45) passage number and for 
some batches of NHbE cell layers.  chemical, metabolic and biological inhibitors were 
employed to evaluate MDr1 contribution to 3H-digoxin trafficking, however the exact 
transporter(s) involved could not be determined.  Whilst MDr1 functionality could not 
be ruled out, results suggest that it is unlikely to be the main transporter involved in 
3H-digoxin trafficking in the bronchial epithelium.  these studies have highlighted the 
need for more specific approaches to investigating transporter functionality in in vitro 
systems.  
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1. INtrODUctION
1.1. OVErVIEW: trANsPOrtErs IN tHE LUNg
research exploring physiologically-relevant pharmacokinetic modelling for absorption 
across epithelial barriers has intensified over the past decade [Pang and Durk, 
2010].  this has predominantly been driven by the necessity to understand the 
pharmacokinetics of drug candidates for successful regulatory approval [Ayrton and 
Morgan, 2008].  In August 2000, the biopharmaceutics classification system (bcs) 
was introduced into the FDA’s regulatory guideline (guidance notes ucm070246), 
providing a framework to classify oral drug substances according to their aqueous 
solubility and intestinal permeability.  More recently this guideline has been updated 
to include the extent of drug metabolism to help address drug-drug interactions 
and transporter-enzyme interplay, and is now termed the biopharmaceutics Drug 
Disposition classification system (bDDcs) [benet et al., 2011].  these guidelines 
have recognised the value of in vitro epithelial cell cultures for predicting the extent of 
drug absorption across the gastrointestinal (gI) tract [http://www.fda.gov].  As such, 
apparent permeability coefficients (P
app
) derived from in vitro permeability screening 
assays are now commonly used to predict the absorption of novel therapeutics 
[steimer et al., 2005].  both the FDA and EMA regulatory bodies have acknowledged 
the increasing occurrence of clinically relevant transporter-based drug interactions, 
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and newer regulatory guidance (guidance notes 05/Wc500090112) suggests the use 
of in vitro models to screen candidate drug compounds for interactions with clinically 
relevant transporters [Huang et al., 2007; [http://www.ema.europa.eu].  More recently 
the International transporter consortium has also published guidance regarding in 
vitro screening for novel therapeutics [giacomini et al., 2010].  As such, awareness 
and characterisation of transporter-mediated drug trafficking across epithelial barriers 
in organs relevant to oral drug absorption (small intestine), metabolism (liver) and 
elimination (kidney) has become a large research field [szakács et al., 2008].  
research characterising the transporters present in airway epithelium has emerged 
in the last decade, primarily spurred by the increasing interest in the lung as a site 
for drug delivery for both local and systemic therapies [gonda, 2000; sanjar and 
Matthews, 2001].  this research has been supported by the development of animal 
and human in vitro airway epithelial cell culture models [Forbes and Ehrhardt, 2005; 
sakagami, 2006].  In comparison with ex vivo and in vivo animal models, in vitro 
models provide a simple cell layer system in which to investigate epithelial barrier 
permeability in isolation.  this allows analysis of specific transport mechanisms 
involved in substrate translocation across the epithelial barrier which cannot be 
assessed in a whole animal system. 
Although the focus of transporter research in the lung has been directed towards drug 
trafficking across the airway epithelial barrier, there are other important avenues of 
transporter research including understanding their physiological function(s), and role 
in lung cancer and other respiratory diseases.  It has been well established that some 
Abc transporters are able to extrude several classes of anti-cancer agents, and these 
are associated with acquired multi-drug resistance in many malignant cells [borst 
and Elferink, 2002].  cystic fibrosis is an example of a lung disease caused directly 
by a genetic mutation in a gene encoding for an Abc transporter in the bronchial 
epithelium, namely the cystic fibrosis transmembrane conductance regulator (cFtr/
Abcc7).  When the cFtr chloride channel malfunctions, mucus in the airways 
becomes dehydrated and difficult to clear, remaining in the airways where it can 
harbour lethal bacterial infections [gadsby et al., 2006]
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Figure 1.1.  Structure of the lung 
 
schematic of the branches of the respiratory tree. the trachea branches forming two bronchi 
which further divide forming bronchioles and finally terminal bronchioles.  the first 16 divisions 
of the respiratory tree constitute the conducting airways and extend from trachea to terminal 
bronchioles.  From approximately the 17th division of the respiratory tree, alveoli appear on 
the walls of the airways.  these branches are then termed respiratory bronchioles, signifying 
the portion of the airways that is able to carry out gas exchange.  the airways branch further 
into alveolar ducts and finally terminate in alveolar sacs.  Diagram taken from Hickey, 1992.
1.2. LUNg strUctUrE AND FUNctION
the primary function of the lung is gas exchange, conducting a supply of oxygen to 
the alveoli for absorption into the blood stream and facilitating the removal of carbon 
dioxide [Moran and rowley, 1988; West, 1995].  In addition to respiration, the lung 
also functions to conduct and filter inhaled air, metabolise xenobiotics and filter toxic 
material from the circulation [West, 1995; ross and Pawlina, 2006]. 
the overall structure of the respiratory airways is outlined in Figure 1.1.  On inspiration 
air passes through the nasal cavities, larynx and pharynx down into the trachea 
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[Moran and rowley, 1988].  Here the airways divide into two main bronchi before 
further subdivisions, forming a network of branching tubes which become increasingly 
narrower and more numerous with each generation [Hickey, 1992; West, 1995].  
the conducting airways span from the nasal cavities to the terminal bronchioles 
(approximately the 16th generation) where the diameter diminishes to approximately 
0.5 mm [taylor and kellaway, 2001].  
In the airway generations below the terminal bronchioles, alveoli begin to emerge in the 
airway walls.  these airways, termed the respiratory bronchioles signify the beginning 
of the respiratory airways where gas exchange is able to occur.  Further branching 
leads to increased frequency of alveoli before the terminal airway divisions open out 
into alveolar ducts and alveolar sacs [Moran and rowley, 1988].  this branching of 
the airways dramatically increases the surface area available for drug deposition.  An 
adult lung has approximately 200 million alveoli with a combined internal surface area 
of over 75 m2, making the lung an attractive target for both local and systemic drug 
delivery [von Wichert and seifart, 2005; ross and Pawlina, 2006].
1.2.1.       tissue structure
the walls of the trachea and bronchi are regarded as having 4 layers, namely the mucosa, 
submucosa, fibro-elastic layer and adventitia (Figure 1.2).  the airway epithelium is 
approximately 25 to 40 µm thick and sits above a densely packed region of collagenous 
fibres termed the basement membrane.  below this lies the lamina propria made up of 
a loose network of connective tissue containing lymphocytes, plasma cells, mast cells, 
eosinophils and fibroblasts and housing a rich capillary network to supply the epithelium 
with nutrients and oxygen.  the submucosa sits beneath, and constitutes mainly 
connective tissue containing lymphatics, larger distributing vessels and submucosal 
glands.  gland ducts extend through the lamina propria to the epithelial surface to 
enable delivery of mucus and glycoproteins into the respiratory lumen.  Underneath 
the submucosa lies a cartilaginous layer composed of horizontally stacked c-shaped 
hyaline cartilage and smooth muscle which keep the upper airways permanently open. 
the cartilage is covered by the perichondrium which is further attached to a layer of 
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loose connective tissue called the adventitia.  this sheath of connective tissue binds 
the trachea to adjacent structures in the neck and mediastinum and contains the largest 
blood vessels and nerves that supply the trachea as well as the larger lymphatics that 
drain the wall [Moran and rowley, 1988; ross and Pawlina, 2006].
Further down the respiratory tract, as the bronchi descend into the lungs, the 
cartilage rings are replaced by an irregular shaped circular tube of cartilage plates 
which decrease in size and number until they disappear in the bronchioles.  As the 
cartilage in the bronchi wall decreases, it is gradually replaced with a layer of smooth 
muscle termed the muscularis.  the smooth muscle allows control of the airflow in the 
bronchioles to the more distal regions of the lung via parasympathetic (constriction) 
and sympathetic (dilatation) nervous control.  the air space terminates at the alveoli 
which are the sites where gas exchange between the blood and air occur.  Each 
alveolus is a spherical chamber roughly 50 µm in diameter and opens up into an 
Figure 1.2. Tissue structure of the tracheo-bronchial region
cross section of tracheo-bronchial tissue stained with haematoxylin and eosin.  Diagram 
depicts the four layers of tracheo-bronchial tissue mucosa (1), submucosa (2), fibro-elastic 
layer (3)  and adventitia (4).  the mucosa comprises the epithelium (5), lamina propria (6) and 
lamina muscularis (7) whilst secretory glands (8) are highlighted in the submucosa and hyaline 
cartilage (9) is visible in the fibro-elastic layer.   Image taken from http://www.histol.chuvashia.
com/atlas-en/respir-en.htm.
50 µm
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alveolar sac.  the interalveolar septum consists of two walls of simple squamous 
epithelium, namely that of the alveolus and the capillary. the thickness of the septum 
can be as thin as 0.1 µm allowing rapid exchange of gases and an exploitable system 
for systemic drug delivery [Moran and rowley, 1988; ross and Pawlina, 2006].  
1.2.2.       structure of the epithelial barrier
the airway epithelium separates the internal environment of the body from the external 
environment of the airway lumen, and as such provides the main barrier controlling 
the absorption of inhaled substances into the body [Hickey, 1992].  there are over 40 
different cell types present in the lung and more than six of these line the respiratory 
lumen [taylor and kellaway, 2001].  the distribution of cell types varies through the 
length of the airway epithelium to optimise the physiological function required at 
specific regions of the airway [Moran and rowley, 1988; Hickey, 1992; ross and 
Pawlina, 2006].
1.2.2.1.  conducting airway epithelium  
In the bronchi, the airway mucosa is composed of a ciliated, pseudostratified, columnar 
epithelium, approximately 25 to 40 µm in thickness (Figure 1.3).  the major cell types 
constituting the bronchial epithelium are ciliated columnar cells, goblet cells and 
basal cells, but other cell types including brush cells and small granule cells appear 
in smaller numbers with increasing airway generations.  the ciliated cell is the most 
abundant cell type in the bronchial epithelium.  It extends the full thickness of the 
membrane, producing the characteristic pseudostratified columnar appearance of the 
epithelium in this region [Moran and rowley, 1988; ross and Pawlina, 2006].  there 
are approximately 250 cilia per ciliated cell, interspersed with numerous microvilli from 
the apical surface projecting into the respiratory lumen.  the cilia beat in unison along 
the airway at approximately 1000 strokes per minute, propelling trapped particles 
and mucus towards the trachea and pharynx.  this feature is termed the mucociliary 
clearance and offers protection for the lung by facilitating the removal of small inhaled 
particles trapped in the mucus [Hickey, 1992; taylor and kellaway, 2001].  
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After ciliated cells, goblet cells are the next most numerous cell types in the bronchial 
epithelium.  they also span the full depth of the epithelium and are packed with mucus-
filled vesicles.  these are released into the trachea lumen to form a protective layer 
of mucus on the epithelial cell surface.  successful ciliary clearance is only achieved 
in the presence of adequate mucus.  the mucus secreted by goblet cells and mucus 
glands covers the luminal surface of the epithelium and carries out three main 
functions; prevention of dehydration of the epithelium, saturation of inhaled air with 
water molecules, and airway protection [Hickey, 1992; ross and Pawlina, 2006].  
basal cells do not extend into the respiratory lumen and lie deeper in the mucosa, 
located adjacent to the basement membrane.  they are part of the epithelium and 
act as a reserve cell population, able to differentiate and replenish ciliated and goblet 
cells.  brush cells and small granule cells are also present in the epithelium of the 
bronchus but in smaller numbers.  brush cells are columnar cells which exhibit large, 
blunt microvilli on their apical surface and are thought to be involved in transduction 
Figure 1.3.  Structure of the tracheo-bronchial epithelium
the epithelium of the trachea is histologically classified as a pseudostratified columnar 
epithelium.  ciliated cells (cc) are the most numerous cells in the tracheal endothelium, 
spanning the membrane with cilia projecting from the apical surface.  goblet cells (gc) lie in 
between ciliated cells, also spanning the membrane and releasing mucus into the respiratory 
lumen.  basal cells (bc) are located just above the basement membrane (bM) and are the 
progenitors for ciliated and goblet cells.  sensory cells and small granule cells are also located 
in the epithelium but in much fewer numbers. Image taken from http://www.mc.vanderbilt.edu/
histology/labmanual2002/labsection2/respiratory03.htm
CC
BM
BC
GC
5 µm
8ŚĂƉƚĞƌ ? 琀 /ŶƚƌŽĚƵĐƟŽŶ
of general sensory stimulation of the mucosa.  small granule cells are also present 
in the bronchial epithelium and are often innervated and appear in groups associated 
with nerve fibres.  they produce catecholamines and polypeptide hormones including 
serotonin, calcitonin and bombesin and are thought to function in reflexes regulating 
the airway or vascular calibre [Moran and rowley, 1988; ross and Pawlina, 2006].  
As the bronchi decrease in diameter, the height of the epithelial cells also decreases 
alongside a reduction in thickness of the basement membrane and lamina propria.  the 
larger bronchioles possess a ciliated, pseudostratified columnar epithelium, but with 
increasing airway generations the epithelium changes to a simple ciliated columnar 
structure, and with further narrowing finally results in a simple cuboidal arrangement 
in the terminal bronchioles.  the largest bronchioles have goblet cells present, but 
these deplete with progression through the airways and are absent in the terminal 
bronchioles of healthy lung tissue.  similarly, as the bronchioles narrow, ciliated cells 
also become fewer in number and have a reduced amount of cilia present on each cell 
surface.  In their place, clara cells are substituted and become more prevalent with 
narrowing airways.  clara cells project to the apical membrane surface and secrete 
a surface active lipoprotein which acts as a pulmonary surfactant, reducing surface 
tension and preventing luminal adhesion during expiration [Moran and rowley, 1988; 
ross and Pawlina, 2006].  
1.2.2.2.      respiratory airway epithelium  
the epithelium of the respiratory bronchioles is transitional between that of the terminal 
bronchioles and alveoli.  the alveolar epithelium is made up of several specialised 
cell types, namely type I pneumocytes, type II pneumocytes and brush cells.  type I 
pneumocytes cover 95% of the alveolar surface and provide a thin squamous cell layer 
suitable for gas exchange.  In comparison, type II pneumocytes are smaller, cuboidal 
secretory cells and cover the remaining 5% of the alveolar surface, despite being as 
numerous as the type I pneumocytes.  the cytoplasm of type II pneumocytes is filled 
with lamellar bodies in the apical compartment, rich in a mixture of phospholipids, 
neutral lipids and protein.  these are released via exocytosis onto the alveolar 
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epithelium and act as surfactant to prevent adherence of the alveolar walls.  type II 
pneumocytes are also the progenitor cells for type I and type II pneumocytes, able 
to proliferate and restore both cell types in the event of injury.  Finally brush cells 
are present in low numbers and may have a role in monitoring air quality in the lung. 
Macrophages also reside within the interior of the alveolar walls, providing a defence 
against foreign matter [Moran and rowley, 1988; Mason and crystal, 1998; Hollande 
et al., 2004; ross and Pawlina, 2006].
1.3. trANsPOrt AcrOss tHE EPItHELIAL bArrIEr  
substances traverse the epithelium via both passive and active processes.  Molecules 
may pass between adjacent cells (paracellular transport) or partition through the 
phospholipid bilayer (transcellular transport) by diffusion or more complex mechanisms 
including endocytosis and carrier-mediated transport (Figure 1.4) [Hillery, 2001]. 
Historically it has been thought that lipophilic drug compounds were absorbed by 
passive diffusion through the plasma membrane, with the rate of permeability 
governed by the lipophilicity and molecular weight of the compound [brown et al., 
1983; schanker, 1983; camenisch et al., 1998].  Furthermore, transport of hydrophilic 
drug molecules was demonstrated via the paracellular route and the rate of transport 
was considered to be inversely proportional to molecular weight [schanker and burton, 
1976; schneeberger, 1991].  Until recently, carrier-mediated transport in the lung was 
thought to play only a minimal role in trafficking of drug molecules across epithelial 
barriers.  However, current research indicates the contribution of transporters in drug 
trafficking may have been underestimated [Dobson and kell, 2008].  the increasing 
occurrence of clinically relevant transporter-based drug interactions has also been 
acknowledged by the FDA and EMA (guidance notes 05/Wc500090112) as well 
as the International transporter symposium which recommend in vitro screening 
of candidate drug compounds for interactions with clinically relevant transporters 
[Huang et al., 2007, gumbleton et al., 2010; giacomini et al., 2010; Patton et al., 
2010; Forbes et al., 2011].
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1.3.1.       Paracellular transport
Polarised airway epithelial cells have highly specialised cellular components termed 
junctional complexes which exist between adjacent cells and act as a selectively 
permeable barrier separating the external surroundings from the internal environment 
of the lung [Hillery, 2001].  In airway epithelial cells, three intercellular membrane 
specialisations constitute the junctional complex, namely tight junctions, adherent 
junctions and desmosomes (Figure 1.5) [Denker and Nigam, 1998].  the tight junctions 
are the components situated closest to the apical membrane and form a continuous 
intercellular barrier between adjacent epithelial cells [Anderson and van Itallie, 1995]. 
this forms the major barrier to the permeation of substances via the paracellular 
pathway and as such, functions to regulate selective movement of solutes across 
the epithelium [Mitic et al., 2000].  tight junctions are composed of over 40 different 
proteins including claudins, occludin, junction adhesion proteins and cytoplasmic 
plaque proteins such as zonula occludens proteins (ZO-1, ZO-2 and ZO-3) [Anderson 
Figure 1.4. Trafficking pathways across the epithelial barrier
several pathways exist for substances to cross the bronchial epithelial barrier.  Hydrophilic 
molecules smaller than 40 kDa can traverse the bronchial epithelial barrier by paracellular 
trafficking between adjacent cells.  In contrast, small, uncharged, lipophilic molecules can 
passively diffuse through the phospholipid bilayer.  Alternatively several endocytic pathways 
have been established to uptake macromolecules into cells.  carrier mediated transport 
can traffic substances in and out of the cell either with the concentration gradient (facilitated 
diffusion) or against it (active transport). schematic adapted from Hillery, 2001.
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and van Itallie, 2009; Furuse, 2010].  beneath the tight junctions lie adherens junctions 
which form a continuous belt around the circumference of the cell.  these junctions 
are formed from cadherin proteins, linked to actin and myosin filaments which function 
to join adjoining cells together in a calcium-dependent manner [Denker and Nigam, 
1998; baum and georgiou, 2011].  Desmosomes (macula adherens) make up the third 
component and consist of desmosomal plaques between the plasma membranes of 
adjacent cells [thomason et al., 2010].
Figure 1.5. Epithelial cell junctions and junctional complexes
Epithelial cells are bound together by several types of junctional specialisations.  these 
include tight junctions, adherens junctions, desmosomes and gap junctions.  In tight junctions 
the plasma membranes of adjacent cells are fused via specific proteins.  below these, 
adherent junctions appear where opposing membranes diverge.  Desmosomes  provide 
strong cohesions between cells.  gap junctions are 2-3 nm wide and allow the exchange of 
intracellular cytoplasm, ions and other small molecules.   
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small, hydrophilic molecules such as mannitol are able to passively diffuse through 
the junctional complexes between adjacent cells.  the rate of paracellular transport 
is therefore governed by Fick’s Law, driven by a concentration gradient and inversely 
proportional to molecular weight [Hillery, 2001].  solute permeability through tight 
junctions is variable between different epithelia [Anderson and van Itallie, 1995]. 
However, it has been established that macromolecules less than 40 kDa in size 
can be passively absorbed across the bronchial epithelium through tight junctions 
[Patton, 1996; Matsukawa et al., 1997; Li et al., 2006].  Large macromolecules (>40 
kDa) can therefore not traverse cells paracellularly and can only permeate biological 
membranes by transcellular means.  
1.3.2.       transcellular diffusion
transcellular uptake of drug molecules from the airspace into the bronchial epithelium 
requires partitioning through the apical mucus layer, into the lipid membrane and 
out into the aqueous environment inside the cell.  Depending on the site of action 
of the drug, transport across the basolateral membrane of the epithelial cells and 
across other cells in the mucosa is required before the drug moiety can pass into 
the blood stream via capillaries in the lamina propria.  Due to the lipophilic nature 
of the phospholipid bilayer, low molecular weight lipophilic drug molecules can be 
absorbed transcellularly by passive diffusion [Hillery, 2001].  Larger molecular 
weight drugs (Mw>500-700), and particularly charged molecules have been shown 
to possess restricted movement across cell membranes [camenisch et al., 1998]. 
Macromolecules are known to be translocated by phagocytosis, macropinocytosis and 
clathrin- or caveolin-mediated endocytosis [Le roy and Wrana, 2005].  Importantly, 
drug moieties reaching the market and in development are becoming larger and more 
difficult to formulate, and it is likely these may use pathways of absorption alternative 
to simple passive diffusion [von Wichert and seifart, 2005].  Additionally, the lung 
provides a potentially attractive delivery route for other therapeutic moieties such as 
antibodies and proteins which would be rendered inactive if administered by the oral 
route [savani and chien, 1996].  
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 1.3.3. carrier mediated transport
several different classes of specialised membrane proteins, embedded within the 
phospholipid bilayer have been established.  these are able to transport substances 
in and out of the cell, both with (facilitated diffusion) and against (active transport) 
the concentration gradient [Hillery, 2001].  In epithelial barriers the localisation of the 
transporter is important as this determines the direction of substrate trafficking.  It is 
generally accepted that the tight junction provides the physiological divide between 
the apical membrane (which borders the lumen or the external environment) and 
the basolateral membrane (below the tight junction between adjacent cells and the 
intracellular contents) [He et al., 2008].  Efflux transporters extrude molecules from 
the membrane or inner leaflet and out of the cell, whereas uptake transporters traffic 
molecules through the plasma membrane into the cell.  therefore the net impact of 
both apical efflux and basolateral uptake transporters would be to traffic molecules to 
the apical surface and prevent permeability into the cell.  conversely, apical uptake 
and basolateral efflux transporters traffic molecules to the basolateral surface and 
retain substances in the tissues (Figure 1.6).
transporters have an important role in the uptake of small molecules, essential for the 
cell to function.  they are also key in the efflux of waste products and protection of the 
cell from xenobiotics [Hillery, 2001].  Many transporters have the ability to transport 
a diverse range of structurally and chemically similar substrates and amongst them, 
therapeutic drug moieties [Zhou et al., 2008; bosquillon, 2010].  transporters are 
important to consider during the drug discovery process as better understanding 
of drug-transporter interactions will help limit variable pharmacokinetics, deepen 
understanding of interspecies differences and help predict and negate toxicities or 
drug-drug interactions.  It may also allow candidate drugs to be targeted to avoid 
transporters that eject substances into the external environment, or to be substrates 
for transporters that retain or traffic molecules internally, thus increasing bioavailability 
[kim, 2002].  Herein, selected classes of transporters known to impact drug absorption 
and elimination in other epithelial barriers are considered.  Firstly, structure and 
function of specific classes of AtP binding cassette (Abc) efflux pump transporters 
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will be discussed.  Additionally selected and established uptake transporters from the 
solute carrier (sLc or sLcO) superfamilies will be outlined.
1.3.3.1.       AtP binding cassette (Abc) transporters
AtP binding cassette (Abc) transporters are a superfamily of transmembrane proteins, 
capable of transporting a diverse array of compounds across cell membranes.  As a 
result, they play an important role in the absorption and elimination of both endogenous 
molecules and xenobiotics across biological membranes [Ford et al., 2009].  As 
such, Abc efflux transporters have been associated with reduced bioavailability of 
therapeutics or drug resistance, particularly in cancer chemotherapy [borst et al., 
2000; gottesman et al., 2002].  the group consists of seven distinct subclasses of 
Figure 1.6. Overview of transporter localisation and molecular trafficking
schematic of  epithelial cells (white rectangles) connected via tight junctions (grey rectangles). 
the tight junction provides the physiological divide between the apical membrane (closest 
to the lumen) and basolateral (bordering the tissues).  Efflux transporters extrude molecules 
from the membrane  out of the cell, whereas uptake transporters traffic molecules through 
the plasma membrane and into the cell.  therefore the net impact of both apical efflux and 
basolateral uptake transporters would be to traffic molecules to the apical surface and prevent 
permeability in to the cell.  conversely apical uptake and basolateral efflux transporters traffic 
molecules to the basolateral surface, and retain substances in the tissues.
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protein ranging from AbcA to Abcg.  the three most widely studied subclasses related 
to transport of therapeutic moieties include the multi-drug resistant proteins (MDr/
Abcb), multi-drug resistance-associated proteins (MrP/Abcc) and breast cancer 
resistance protein (bcrP/Abcg2) [choudhuri and klaassen, 2006].  It is currently 
accepted that virtually every cell in every species expresses Abc transporters and 
that they have a crucial role in cellular physiology [Linton, 2007].  
Until recently, no high resolution structural data was available for mammalian Abc 
transporters and hence information regarding their topology and functionality was 
based on prokaryotic Abc transporter homologues, in silico modelling and quantitative 
structure-activity estimation relationship (QsAr) experimentation [Vandevuer et al., 
2006].  the predicted topology of eukaryotic Abc proteins consists of 2 portions 
as outlined in Figure 1.7.  the intracellular portion of the transporter comprises 2 
nucleotide binding domains (NbD).  the amino acid motifs for the NbDs are conserved 
amongst the Abc transporters and mediate the binding and hydrolysis of AtP, which 
provides the energy required for transporter functionality [kast et al., 1996].  the 
PHPEUDQHERXQGSRUWLRQFRPSULVHVEHWZHHQWRWUDQVPHPEUDQH70ĮKHOLFHV
the transmembrane domains (tMD) provide a passage for substances to be extruded 
from the membrane and have more variability in their amino acid sequences which 
determines the specificity of the transporter [Ford et al., 2009].  Abc transporters 
are defined as either full transporters, made up of either one polypeptide chain or 
half transporters where the transporter is assembled from a homo- or heterodimer 
[tusnady et al., 2006].  
1.3.3.1.1. Abcb transporters
the Abcb subfamily contains 4 full transporters and 7 half transporters [Vasiliou 
et al., 2009].  Of these transporters, Abcb1 (MDr1), Abcb4 (MDr3) and Abcb11 
(bsEP) have been established to be involved in the translocation of therapeutic drug 
substances [smith et al., 2000; stieger, 2011].  MDr1 is the most researched and best 
characterised of the Abc transporters.  It is ubiquitously expressed, predominantly 
located on the apical surface of epithelial barriers and its key physiological function is 
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thought to be the defence against environmental insults from xenobiotics [Hamilton et 
al., 2002; kim, 2002].  
Until recently, structural predictions for MDr1 were based on low resolution eukaryote 
electron microscopy images and Fourier projection reconstructions [rosenburg 
et al., 2001].  In 2009, Aller and co-workers published the first mammalian x-
ray crystallography images of murine mdr1a, confirming the predicted topology of 
mammalian MDr1 [Aller et al., 2009].  MDr1 has two discrete but coupled functions, 
Figure 1.7. Membrane topology models for MDR1, MRP1 and BCRP
schematic outlining the predicted membrane topology of MDr1, MrP1 and bcrP.  Abc 
WUDQVSRUWHUVSRVVHVVWUDQVPHPEUDQHGRPDLQVFRPSULVLQJWUDQVPHPEUDQHĮKHOLFHV
and 2 intracellular nucleotide binding domains.  Abcb transporters such as MDr1 have two 
EXQGOHVRIĮKHOLFHVZKLFK IRUPDFHQWUDO FDYLW\$%&& WUDQVSRUWHUV FRQVLVWRIHLWKHU
or 3 transmembrane domains.  both MDr1 and MrP1 are full transporters containing at 
least 2 transmembrane domains and 2 nucleotide binding domains.  In contrast, the half 
transporter, bcrP contains just 1 transmembrane domain and 1 nucleotide binding domain 
and forms dimeric or oligomeric structures for functionality.   schematic taken from http://
www.sigmaaldrich.com/life-science/metabolomics/enzyme-explorer/cell-signaling-enzymes/
xenobiotics/drug-metabolism-tech-review.html
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namely AtP hydrolysis and substrate transport which are represented in its structure 
[sauna and Ambudkar, 2007].  the structure of MDr1, outlined in Figure 1.7 comprises 
70' HDFK FRQWDLQLQJ  K\GURSKRELF70 Į KHOLFDO UHJLRQV 7KH  EXQGOHV RI Į
helices form a large internal cavity which is open to both the cytoplasm and the inner 
leaflet of the membrane.  Within the tMD, 2 portals have been identified which are 
likely to transport moieties directly from the membrane.  the large binding pocket is 
likely to accommodate more than one substrate simultaneously [Loo et al., 2003] and 
comprises mostly hydrophobic and aromatic amino acid residues with only 15 out of 
73 residues being polar [Aller et al., 2009].  Upstream of each tMD lies a hydrophilic 
NbD containing the highly conserved AtP binding cassette motifs including Walker 
Figure 1.8.  3D representation of MDR1
MDr1 comprises 2 bundles of 6 transmembrane domains which form a substrate binding 
pocket.  two nucleotide binding domains (NbD) are present within the cytoplasm and mediate 
the binding of AtP to drive the energy dependent mechanism of the transporter.  the NbD are 
highly conserved with specific sequences, namely Walker A, Walker b and the linker peptide 
or c motif.  taken from bolhuis et al., 1997.  
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A, Walker b units and the linker peptide or c motif outlined in Figure 1.8.  [sauna and 
Ambudkar, 2007].  It has been demonstrated that for every molecule of substrate, 
2 AtP molecules are required, likely for the 2 conformational changes involved to 
transport the substrate and reset the transporter to the original conformation [sauna 
and Ambudkar, 2001; Hamilton et al., 2002].  
MDr1 is established to have the ability to extrude a diverse range of hydrophobic 
substrates from cells including many anti-cancer drugs.  several mechanisms for 
MDr1 functionality have been proposed as outlined in Figure 1.9.  these range from 
conventional models whereby the substrate binds to the transporter from the aqueous 
phase and is translocated across the lipid bilayer into the extracellular environment. 
However, transport of drugs from the cytosol now seems unlikely [bolhuis et al., 
1997].  It is now widely accepted that MDr1 acts to traffic hydrophobic substances 
that have diffused into the lipophilic cell membrane.  the ‘hydrophobic vacuum 
cleaner’ mechanism, describes the translocation of substances from either inner or 
outer leaflet of the lipid bilayer into the external environment [gottesman and Pastan, 
1993].  A variation of this mechanism termed the ‘flippase’ model, first proposed by 
Figure 1.9.  Proposed mechanisms for MDR1 functionality
several proposals for the mechanism of MDr1 outlining translocation of a substrate from the 
aqueous phase across the lipid bilayer into the extracellular environment.  However, transport 
of drug from the cytosol now seems unlikely and it is now widely accepted that MDr1 acts 
to traffic hydrophobic substances that have diffused into the lipophilic cell membrane.  the 
‘hydrophobic vacuum cleaner’ mechanism, describes the translocation of substances from 
either inner or outer leaflet of the lipid bilayer into the external environment.  A variation of this 
mechanism termed the ‘flippase’ model predicts the pumping of substances via a conformational 
change from the inner to the outer leaflets of the membrane where they then diffuse into the 
external medium. Figure taken from bolhuis et al., 1997.  
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Higgins and gottesman predicts pumping of substances via a conformational change 
from the inner to the outer leaflets of the membrane where they then diffuse into 
the external medium [Higgins and gottesman, 1992; bolhuis et al., 1997].  this 
mechanism may also explain the broad substrate specificity of MDr1 by the presence 
of multiple hydrophobic interactions with the lipid bilayer and the hydrophobic pocket 
of the transporter [Higgins and gottesman, 1992; Hamilton et al., 2002].  Whilst the 
structure of mdr1a has now been elucidated, the mechanism of substrate translocation 
by MDr1 on a molecular level is still in its infancy and the nature of multi-substrate 
specificity still not yet fully understood.  Nevertheless, the unidirectional lipid flippase 
model is now generally accepted and is outlined further in Figure 1.10 [Aller et al., 
2009].
1.3.3.1.2.       Abcc transporters
the Abcc subfamily contains multidrug resistance associated transporters MrP1-
9 (Abcc1-6, 10-12) as well as cFtr/Abcc7 and sUr1 and 2 (Abcc8/9) [toyoda 
Figure 1.10.  Model of substrate transport by MDR1
substrates (pink) that have partitioned into the bilayer can enter the internal drug-binding pocket 
(green) of MDr1 through an open portal. the substrate interacts with residues in the drug 
binding pocket in the inward facing conformation (A).  AtP (yellow) binds to the NbDs causing 
a conformational change in the transporter, presenting the substrate and drug-binding site(s) 
to the  extracellular space (b).   Exit of the substrate to the inner leaflet is sterically hindered 
providing unidirectional transport to the outside.  Image taken from Aller et al., 2009.
Lumen
tissues
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et al., 2008].  the MrP transporters have been established to transport therapeutic 
substances across the membrane [Zhou et al., 2008].  structurally, they comprise 
2 NbDs and 2 (MrP 4, 5, 8 and 9) or 3 (MrP1, 2, 3, 6, 7) tM regions (Figure 1.7). 
MrP1, 3 and 6 are typically located on the basolateral surfaces of polarised tissues 
whereas MrP 2 is found predominantly on apical epithelial surfaces.  In contrast, 
MrP4 and MrP5 have been reported to have both apical and basolateral locations 
depending on the organ system [keppler, 2011].  Only limited immunolocalisation 
experiments have been conducted for MrP7-9 and transporter localisation has not 
been confirmed in most epithelial barriers [keppler, 2011].  
In general, substrate molecules for MrP transporters comprise amphiphilic organic 
anions between 300-1000 Da.  However some organic cations (vincristine) can be 
transported by MrP transporters in the presence of reduced glutathione [Loe et al., 1998; 
keppler, 2011].  Endogenous substrates for the MrP transporters include glutathione, 
OHXNRWULHQH&DQGȕJOXFXURQRV\OHVWUDGLROZKLOVWPDMRUGUXJVXEVWUDWHVLQFOXGH
methotrexate, etoposide and vincristine.  A broad substrate specificity and significant 
overlap in substrate recognition exist between individual MrP transporters [van der 
Deen et al., 2005; Zhou et al., 2008; keppler et al., 2011].
1.3.3.1.3.       Other Abc transporters
the breast cancer resistance protein (bcrP/Abcg2) has also been demonstrated to 
impact the absorption of drug molecules across polarised epithelial barriers [Meyer 
zu schwabedissen and kroemer, 2011].  the half transporter contains 6 tM domains 
constituting one tMD and one NbD [Doyle et al., 1998; sakardi et al., 2004].  It 
is now widely accepted that an Abc transporter requires 2 tMDs and 2 NbDs for 
functionality [Ni et al., 2010a] and evidence suggests that bcrP half transporter can 
form a functional homodimer bridged by disulphide bonds [rosenberg et al., 1997; 
kage et al., 2002; Litman et al., 2002; bhatia et al., 2005].  More recent studies 
indicate bcrP may be able to form higher order oligomeric states [Ni et al., 2010b]. 
bcrP is located on the apical side of polarised cells and is capable of transporting 
both hydrophobic substrates as well as hydrophilic conjugated organic cations.  It has 
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a high degree of substrate overlap with MDr1 and due to the similar localisation on 
membranes, can lead to a synergistic effect, limiting drug penetration across epithelial 
barriers.  [schinkel et al., 2003; Matsson et al., 2009; Ni et al., 2010a].
1.3.3.2.       solute-Linked carrier (sLc) transporters
the sLc22A subgroup of transporter superfamily have demonstrated the translocation 
of therapeutic moieties.  this includes organic cation transporters (Oct1-3), carnitine 
organic cation transporters (OctN1,2) and organic anion transporters (OAt1-4). 
Oct and OctN transporters have been established to translocate both neutral but 
predominantly positively charged substrates (hormones, metabolites, neurotransmitters 
and drugs) [koepsell et al., 2007], whereas OAt transporters primarily mediate the 
transport of endogenous and exogenous organic anions [burckhardt and burckhardt, 
2011].  
Peptide transporters PEPt1 and 2 belong to the sLc15 family and form part of the 
proton-coupled oligopeptide transporter (POt) superfamily.  both transporters are 
located on the apical surfaces of membranes and have a wide substrate specificity 
[Daniel and kottra, 2004].  It has been demonstrated that PEPt1 and 2 transporters not 
only transport exogenous and endogenous peptides but can additionally translocate 
peptidomimetic drugs contributing to the high bioavailability of these molecules [Yang 
et al., 1999; Zhu et al., 2000].  
1.3.3.3.       solute-Linked carrier Organic Anion (sLcO) transporters
the organic anion transporting polypeptides (OAtP) superfamily (recently reclassified 
under the sLcO gene symbol) mediate the transport of a broad range of exogenous 
and endogenous amphipathic compounds in a sodium and AtP-independent manner 
[kim, 2003; Hagenbuch and Meier, 2003].  OAtP transporters are expressed on a 
wide variety of membranes and facilitate the influx of a number of therapeutic drugs 
[Niemi, 2007].  there are 11 established human OAtP transporters namely OAtP1A2, 
1b1, 1b3, 1c1, 2A1, 2b1, 3A1, 4A1, 4c1, 5A1 and 6A1 [Hagenbuch and Meier, 2004]. 
some, such as OAtP2A1, 3A1 and 4A1 are ubiquitously expressed whereas others 
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are thought to have organ-specific expression [Mikkaichi et al., 2004; Hagenbuch and 
gui, 2008].  the predicted structure of OAtP transporters comprises 12 tM regions 
with a large fifth extracellular loop [Hagenbuch and Meier, 2003; kalliokoski and Niemi, 
2009].  Although the exact transport mechanism of OAtP transporters has not been 
established [Mahagita et al., 2007] it has been postulated that translocation occurs 
through a central positively charged core in a rocker-switch mechanism [Meier-Abt et 
al., 2005].  this mechanism has been reported for other transporters and is based on the 
premise that the transport protein has both inward and outward possible conformations 
which can interconvert when a substrate is bound [Meier-Abt et al., 2005].  the majority 
of research characterising OAtP-mediated drug transport has concerned OAtP1b1, 
1A2, 1b3 and 2b1 whilst endogenous or exogenous substrates have not yet been 
identified for OAtP5A1 and 6A1 [kalliokoski and Niemi, 2009; könig, 2011]. 
1.4. bIOLOgIcAL MODELs FOr DrUg PErMEAbILItY AND  
 AbsOrPtION scrEENINg
An understanding of respiratory biopharmaceutics is key for successful regulatory 
approval of new inhaled drug moieties and for improving the targeting of inhaled 
therapeutics.  the safety and efficacy of new drug moieties must be demonstrated 
before administration to humans.  regarding absorption, candidate drugs are typically 
first screened for epithelial permeability using in vitro human cell assays, before 
absorption studies in various animals in vivo.  the use of animal models in research 
is steadily declining, driven by the 3 r’s (replacement, reduction and refinement) 
principle of animal research [Flecknell, 2002].  the impetus to move away from animal 
models was particularly evident in the pharmaceutical industry where permeability 
measurements from validated in vitro systems were approved for absorption predictions 
in vivo (guidance notes ucm070246) [http://www.fda.gov].  Whilst in vitro cultures of 
epithelial barriers in other organs are well defined and in vitro-in vivo correlations 
(IVIVc) established, respiratory biopharmaceutics is less well understood.  this is 
largely due to it being a much smaller, less established research area, made more 
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challenging by the greater physiological complexity of the lung and fewer developed 
inhaled therapeutic compounds [Forbes and Ehrhardt, 2005].
1.4.1.   In vivo models
In the 1970s and 1980s, schanker and colleagues published a succession of 
experiments regarding the absorption and disposition of a range of therapeutic moieties 
from animal lungs in vivo, predominantly in rat [schanker and burton, 1976; schanker, 
1983].  Of the animal models available, the rat is most commonly used given their size, 
which is small enough to achieve economical dosing but large enough to manipulate 
for multiple administrations and blood sampling.  several methodologies exist but in 
general the animal is first anaesthetised before typically undergoing a tracheotomy or 
orotracheal intubation.  the subject is kept in the supine position whilst either a drug 
solution (typically 10-200 µl) is instilled, or an aerosol formulation administered via 
the trachea.  In the first in vivo studies, destructive tissue sampling was undertaken 
for every data point, whereby the animal was sacrificed, lungs excised and drug 
content determined.  One significant modification was the surgical catheterisation 
of an appropriate vein which allowed multiple blood samples to be taken from the 
animal.  this method provided drug concentrations in the plasma which could be 
more accurately determined and reduced animal wastage [sakagami, 2006]. 
Whilst in vivo studies provide pharmacokinetic data regarding the fate of a drug and 
its metabolites in a whole animal system, there is a high degree of inter-laboratory 
variability, primarily caused by methodological variation and regional distribution within 
the lung [tronde et al., 2008].  Additionally, the ethics of animal testing and cost of 
in vivo experimentation are major factors for consideration.  Furthermore significant 
differences for drug handling between different species have been demonstrated, 
[sakagami, 2006] highlighting the need for confirmation of drug handling by the lung 
using ex vivo and in vitro methods.  
1.4.2.   Ex vivo models
Ex vivo animal models comprise freshly extracted whole or part lung tissue and are 
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commonly used in biopharmaceutical research when the mechanism of drug transport 
is not fully elucidated by in vitro and in vivo models.  similar to in vivo models, rat, 
guinea pig and rabbit constitute the majority of animals used, given the more difficult 
surgical procedures required for smaller animals such as mice [sakagami, 2006].  thin 
sections of lung tissue have been used to assess drug metabolism, pharmacology and 
toxicology [Wohlsen et al., 2003; ressmeyer et al., 2006].  tissue strips have also been 
used in tissue baths or Ussing chambers to assess drug permeability [Widdicombe, 
1997].  One major limitation of lung tissue slice preparations is that due to the size of 
the tissue, they are only available for the large airways [tronde et al., 2008]. 
Isolated perfused lung (IPL) models are a useful tool allowing the investigation of 
lung pharmacokinetics without the systemic effects of in vivo models.  In IPL models, 
animal lungs (commonly rat) are isolated from the systemic circulation and perfused 
via the pulmonary circulation [tronde et al., 2008].  this experimental set up has the 
advantage of maintaining tissue architecture (structure, permeability) and functionality 
(cell interactions, biochemical activity), being a closer representation of the in vivo state 
in comparison with in vitro modelling [sakagami, 2006].  Additionally ventilation and 
perfusion can be tightly controlled and sampling of the perfusate is easily accessible. 
However, the tissue only remains viable for 3 to 5 hours after isolation and these time 
restraints make it impossible for slower pharmacokinetic processes to be investigated. 
Furthermore, whilst the pulmonary circulation is maintained, the bronchial circulation 
is likely to be severed during the tissue isolation process.  therefore, absorption in the 
tracheo-bronchial region is unlikely to be represented in this model [Mehendale et al., 
1981; sakagami, 2006].
1.4.3.   In vitro models
respiratory epithelial in vitro models comprise homogeneous or heterogeneous 
populations of epithelial cells from either a primary or immortalised cell line source. 
the cells are cultured usually on suspended inserts, allowing differentiation of the 
cells at an air-liquid interface, and providing the opportunity to study the permeability 
of substances across the resulting polarised cell layers.  the use, development and 
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characterisation of in vitro airway epithelial cultures has increased, predominantly 
driven by the FDA recommendation (guidance notes ucm070246), to predict absorption 
of novel therapeutics based on apparent permeability coefficients (P
app
) from in vitro 
cell models [http://www.fda.gov].  In vitro cell culture tools allow a high throughput 
investigational approach to study the permeability of substances across the main 
barrier to absorption.  Herein, bronchial epithelial models will be considered in more 
detail.  Although alveolar models have also been developed, these are outside the 
scope of this work.
1.4.3.1. Primary cultures
there are several commercial sources and well defined methodologies describing 
the isolation and culture of primary tracheo-bronchial cells obtained directly from the 
lungs of humans and other animals [sporty et al., 2008].  Primary bronchial epithelial 
cultures contain mixed phenotypes and provide the closest native cultures of the 
airway epithelium in vitro.  Whilst they are particularly useful in the comparison of 
structural and functional differences between healthy and diseased epithelium, their 
limited functional lifespan (2-3 passages), lack of availability and donor variability are 
major limitations [Mathias et al., 1996; Forbes and Ehrhardt, 2005].  Despite being 
commercially available, primary human bronchial epithelial cell layers are generally 
less economical and convenient than other in vitro models.
1.4.3.2.    Immortalised cell lines
Immortalised bronchial epithelial cell lines are the in vitro models of choice given 
the significantly lower culture costs, less variability and longer functional passage 
window compared with primary culture.  Whereas the caco-2 cell line has become the 
gold standard for intestinal permeability modelling, no agreement has been reached 
for a single corresponding cell line for the bronchial epithelium.  A correlation has 
been established between apparent permeability in caco-2 cell monolayers and the 
apparent absorption rate constant in the isolated perfused rat lung (IPrL) model for 
a small number of compounds (r2 = 0.87).  However, whereas the bronchial and 
intestinal epithelium may have comparable paracellular and passive, unfacilitated 
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transcellular drug trafficking characteristics, transporter expression and functionality 
profiles vary considerably [Florea et al., 2003; bleasby et al., 2006].  In vitro cell culture 
models derived from lung tissues should provide a more representative model of 
airway epithelium permeability.  However, development and validation of a universally 
standardised model is challenging, and as such no consensus has been reached for 
in vitro bronchial epithelial models [sakagami, 2006].  this is likely to have a major 
impact on inter-laboratory variability for in vitro permeability data, making it difficult 
to compare published studies from different groups [sporty et al., 2008].  table 1.1 
summarises the physiological and biopharmaceutical properties of bronchial epithelial 
cells commonly used in literature.
1.4.3.2.1. 16HbE14o-
16HbE14o- cells are derived from bronchial epithelial cells from a 1-year old male 
heart-lung transplant patient and transformed via a sV40 large t antigen using the 
replication defective psVori- plasmid [cozens et al., 1994].  cells have a cuboidal 
morphology and form polarised, cell layers (1-5 cells thick) with functional tight 
junctions when cultured under submerged conditions.  It has been reported that the 
cells have similar morphology and display several properties (lectin binding patterns, 
IcAM-1 expression) resembling basal cells in vivo [Ehrhardt et al., 2002; Forbes et 
al., 2002].  However, the cells have a non-secretory phenotype and when cultured at 
the AL interface, produce multiple layers of cells, morphologically unrepresentative of 
the bronchial epithelium [Ehrhardt et al., 2002].  One main drawback with 16HbE14o- 
cells is that they are not commercially available and therefore have been less widely 
used than calu-3 cells [sporty et al., 2008].  
1.4.3.2.2. calu-3
the calu-3 cell line is a commercially available immortalised cell line derived from 
a bronchial adenocarcinoma from a 25-year old male [Fogh et al., 1977].  the cells 
exhibit properties found in serous cells and have been successfully differentiated 
at an AL interface to form polarised cell layers (1-3 cells thick) containing a mixed 
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population of ciliated and secretory cell phenotypes [shen et al., 1994; Foster et al., 
2000, grainger et al., 2006].  cells form functional tight junctions and have been 
employed in the study of drug transport [cavet et al., 1997; Hamilton et al., 2001a; 
Madlova et al., 2010] and metabolism [Florea et al., 2001]  as well as particle uptake 
[Fiegel et al., 2003; Amidi et al., 2006; Vllasaliu et al., 2010].
1.4.3.2.3. Other cell Lines
the commercially available bEAs-2b cell line is derived from normal bronchial 
epithelium obtained from non-cancerous individuals.  cells were immortalised by 
infection with a replication-defective sV40/adenovirus 12 hybrid and cloned.  this cell 
line is not as suitable as 16HbE14o- and calu-3 for drug permeability testing given 
that it does not form polarised cell layers [Noah et al., 1995].  However, it is commonly 
used to study the structure and function of airway epithelium as well as the expression 
and activity of drug metabolising enzymes [Eaton et al., 1996; Atsuta et al., 1997].  
Zabner and co-workers have developed immortalised normal and cystic fibrosis 
Table 1.1:  Summary of morphological and barrier intergrity characteristics of 
commonly used bronchial epithelial in vitro models
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human airway epithelial cell lines transformed by the reverse transcriptase component 
of telomerase and genes from the human papillomavirus type 16.  the normal 
transformed cell line (NuLi-1) formed tight, polarised cell layers with similar barrier 
properties to native bronchial epithelium past passage 30 in culture.  However, by 
passage 20 approximately only 5% of the cells were ciliated and ~12% secretory cells 
suggesting the cellular composition of NuLi-1 cells is not entirely representative of the 
bronchial epithelium [Zabner et al., 2003].
1.4.3.3. Disease model cell lines
several cystic fibrosis models from immortalised airway epithelial cell lines have been 
established.  these include NcF3 [scholte et al., 1989], cFt1 [Olsen et al., 1992], 
cuFi-3, cuFi-4 [Zabner et al., 2002] and cFbE41o- [Ehrhardt et al., 2006].  these 
tools have facilitated studies to understand cystic fibrosis pathophysiology, airway 
permeability and treatment development, providing a more reliable and accessible 
investigational platform than primary diseased tissues [sporty et al., 2008].  to date, 
no comparable models are available for the study of other airway diseases such as 
asthma, cOPD and bronchiectasis and the study of these airway diseases in vitro 
relies on primary cells and tissues from affected individuals.
1.4.4.  In silico models
the development of in silico models for the prediction of adsorption, distribution, 
metabolism and excretion of oral drug candidates (e.g. gastroPlustM) has spurred 
the interest in development of similar models to predict inhaled pharmacokinetics. 
As such in silico models have been developed to simulate and predict the deposition 
of inhaled drug particles in the lung via computational fluid dynamic [Longest and 
Holbrook, 2011] and imaging techniques [Martonen et al., 2005].  studies have shown 
that the physicochemical properties of drug molecules most influential on pulmonary 
absorption are lipophilicity, molecular polar surface area and hydrogen bonding 
potential [tronde et al., 2008].  In vitro-in vivo correlations have been established 
between in vivo inhaled drug absorption in the rat and in vitro cell culture permeability 
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of caco-2 cells [tronde et al., 2003a], calu-3 cells [Mathias et al., 2002] and 
16HbE14o- cells [Manford et al., 2005] allowing mathematical predictions for inhaled 
drug absorption.  recently, cooper and colleagues were able to predict efficacious 
lung doses in vivo from a quantitative structure-activity relationship model [cooper 
et al., 2010].  the establishment of such models will enhance the understanding of 
inhaled biopharmaceutics and may potentially minimise the use of extensive in vivo 
testing in the future.
1.5.             INHALED DrUg DELIVErY
the concept of drug delivery by inhalation has been established for centuries by the 
smoking of leaves and the addition of volatile therapeutic formulations to boiling water 
for inhalation [Fiel, 2001; barnes, 2006].  In contrast, modern inhaled therapeutic 
agents are typically aerosolised liquids or inhaled powders administered via nebuliser 
or inhaler devices.  Increasing interest in the lung as a site for drug delivery was spurred 
in the last century with the discovery of inhaled anaesthetics and the development of 
LQKDOHGȕ
2
-adrenoceptor antagonists for asthma [barnes et al., 2006].  the lung is 
often overlooked as a site for drug delivery but there is an increasing interest in the 
production of inhaled therapies for both local and systemic lung delivery.
1.5.1.  systemic inhaled drug delivery
Inhaled drug delivery for systemically absorbed therapeutics offers several advantages 
for therapeutic moieties that cannot be administered via the oral route.  the lung is a 
particularly attractive delivery route for proteins, peptides and antibodies that would 
be denatured by the acidity or by enzymatic digestion in the stomach.  Additionally 
the large respiratory epithelial surface in contact with pulmonary capillaries provides 
a huge target area for systemic absorption.  Furthermore, the thin epithelial airway 
mucosa and high vascularisation surrounding the alveoli promotes swift drug 
absorption into the systemic circulation and hence a rapid onset of action [taylor 
and kellaway, 2001].  Although the alveolar region is the obvious target for inhaled 
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systemic drug delivery, the trachea-bronchial region, with its leakier epithelium should 
not be overlooked [Ehrhardt et al., 2008].  
the FDA approval and product launch of the first inhaled insulin signified a huge 
leap in the advancement of systemically targeted inhaled drug delivery.  However, 
the withdrawal of Exubera® from the market in October 2007 symbolised a major 
blow for systemically inhaled therapeutics [Opar et al., 2008].  Importantly, the main 
the failures of Exubera® were not as a direct consequence of poor inhaled insulin 
biopharmaceutics, but related to a reduction in patient convenience, associated with 
the inhaler device and coupled with significant advancements for injectable insulin, 
as well as the price and poor marketing strategy [Opar et al., 2008].  However, 
with the trend of increasingly larger, more poorly soluble drug molecules and the 
development of proteins and antibodies for the treatment of disease, the lung still 
remains an attractive target for drug delivery [von Wichert et al., 2005].  Other inhaled 
therapies in development include gene therapy for the treatment of cystic fibrosis 
[Laube, 2005] and cancer [rao et al., 2003] and inhaled vaccines [bivas-benita et 
al., 2005].  More recently, inhaled loxapine has shown safety and efficacy in clinical 
trials for use in the treatment of agitation and migraine [Allen et al., 2011], inhaled 
dihydroergotamine (DHE) has been shown to be effective and safe in the treatment 
of migraine in phase 3 studies [Aurora et al., 2011] and inhaled fentanyl was being 
developed for breakthrough pain management for cancer patients [Overhoff et al., 
2008].  Despite these efforts, inhaled drug delivery for local targets in airway disease 
remains the mainstay of research and marketed inhaled therapeutics.
1.5.2. Local inhaled drug delivery
the majority of marketed inhaled therapeutics are currently targeted at the bronchi and 
large bronchiole regions of the conducting airways for the delivery of local treatments of 
asthma, cOPD, cystic fibrosis and bronchiectasis [West, 1996; ross, 2006].  Marketed 
GUXJFODVVHV LQFOXGHȕ
2
-agonists and long acting agonists (salbutamol, terbutaline, 
VDOPHWHURO DQG IRUPRWHURO ZKLFK ELQG WR ȕ
2
 adrenoceptors in the smooth airway 
muscle to stimulate bronchodilatation [Johnson, 2006].  similarly the anticholinergic 
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drugs (ipratropium, tiotropium) block muscarinic acetylcholine receptors in the airway 
smooth muscle, inhibiting bronchoconstriction and mucus secretion [baigelman and 
chodosh, 1977].  glucocorticoids (beclometasone, budesonide, fluticasone) bind 
to glucocorticoid receptors in cells where they have several actions to dampen the 
immune response [Lu et al., 2006].  It is now well established that cOPD patients 
have substantial remodelling of the respiratory airways [Hogg, 2004].  similarly it is 
becoming apparent that asthma, previously thought to be a disease of the conducting 
airways also impacts on the respiratory airways [Wagner et al., 1990; Nihlberg et al., 
2010].
Local inhaled drug delivery offers several advantages over oral therapy for respiratory 
diseases.  Firstly, it is possible to achieve a high local concentration of drug direct 
to the site of action.  this not only reduces the therapeutic dose required but also 
minimises the absorption into the systemic circulation, and hence reduces systemic 
side effects.  Delivering the drug directly to the site of action also results in a rapid 
onset of action unlike oral dosage forms, which have to undergo gastric emptying 
before absorption can commence and a therapeutic response can be elicited [taylor 
and kellaway, 2001].  
1.6. sUMMArY
In summary the lung provides a wealth of opportunities for both local and systemic 
drug delivery for the treatment of airway and systemic disease.  currently, marketed 
inhaled products are mainly aimed at delivering therapeutic compounds to the 
conducting airways for the treatment of local airway disease.  to date, the lung has 
not been fully exploited as an organ for systemic delivery of therapeutic moieties 
largely as a result of the complexity of the lung, requirement of device formulation 
for delivery of such compounds and less characterisation of lung pharmacokinetic 
and pharmacodynamics profiles in comparison with other organs.  gaining a better 
understanding of functional permeability mechanisms in the airway epithelium and 
32ŚĂƉƚĞƌ ? 琀 /ŶƚƌŽĚƵĐƟŽŶ
characterising these mechanisms in in vitro tools will aid the development of new 
inhaled therapeutic moieties, the understanding of drug bioavailability in the lung and 
may provide an insight to permeability alterations in diseased lung tissue.
1.7. AIMs AND ObJEctIVEs OF tHIs PhD
currently, medical and drug regulatory bodies advise screening the permeability of 
inhaled drug candidates using human in vitro epithelial models, before safely and 
absorption profiles are characterised for the rat in vivo (guidance notes ucm070246) 
[http://www.fda.gov].  More recently, the significance of drug transporter interactions, 
and the increasing awareness of the involvement of transporters for the permeability 
of substances through epithelial barriers has heightened, and has been reflected in 
regulatory guidance (guidance notes 05/Wc500090112) [http://www.ema.europa.eu]. 
However, the understanding of transporter expression and functionality in the lung 
and in airway epithelium is poorly understood [bosquillon, 2010; gumbleton et al., 
2011].  Furthermore, the in vitro tools available to study drug transporters are not 
sufficiently characterised to fully understand the role of transporters in inhaled drug 
absorption.  Additionally, the transition from human in vitro permeability screening to 
modelling absorption in rat in vivo is vast.  Interspecies differences in drug absorption, 
potentially caused by variations in transporter expression and functionality may arise 
between rat and human have been demonstrated for some compounds [Mathias et 
al., 2002; Madlova et al., 2010].  Although ex vivo rat models provide an intermediary 
model, a rat in vitro model would be better suited to understand specific difference in 
drug permeability and transporter functionality between rat and human.
this thesis focuses on bronchial epithelial in vitro cell culture modelling, addressing 
the need for development and characterisation of new in vitro predictive tools and 
providing further characterisation of existing in vitro models.  In this process the 
limitations of current techniques for permeability screening will be assessed alongside 
the current restrictions of transporter gene, protein and functional characterisation. 
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the first results chapter describes the development and optimisation of a rat bronchial 
epithelial cell line for in vitro permeability screening.  this in vitro model is characterised 
alongside existing human in vitro models (calu-3 cells and primary bronchial epithelial 
cell cultures) regarding morphological similarity to the bronchial epithelium and the 
possession of suitable barrier properties to make them relevant and operational 
for use as a permeability screening tool.  the next chapter characterises the gene 
and protein expression of selected Abc, sLc and sLcO transporters in these three 
models in comparison with expression in bronchial epithelium from human and rat. 
the final chapter assesses the functional transport mechanisms present in the in vitro 
bronchial epithelium models with a particular focus on the transporters involved in the 
net secretory transport of 3H-digoxin in calu-3 and primary normal human bronchial 
epithelial cells.  
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2. MAtErIALs AND MEtHODs
2.1. MAtErIALs
2.1.1. general chemicals
Unless otherwise specified all chemicals were obtained from sigma Aldrich (Poole, 
Dorset, Uk).  All water used was deionised (dH
2
O) unless stated otherwise.  All phosphate 
buffered saline (Pbs) was at pH 7.4 without calcium and magnesium salts.  All cell culture 
reagents were purchased sterilised or sterilised prior to use either by filtration through a 
0.22 µm Whatman sterile filter or autoclaving at 121°c at 1 bar for 20 min.
2.1.2. cell culture reagents
calu-3, caco-2, rL-65 and HEk293 cell lines were obtained from the American type 
culture collection (rockville, MD, UsA).  calu-3 cells were cultured using the same 
batch of foetal bovine serum (Fbs) non UsA origin from sigma, (Poole, Dorset, 
Uk).  Forskolin was obtained from calbiochem (beeston, Nottinghamshire, Uk) and 
insulin-transferrin-selenium obtained from Invitrogen (Paisley, renfrewshire, Uk). 
NHbE primary cells, (b-ALI certified batch 139014 from a 61 year old Hispanic male), 
proprietary b-ALItM and bgEMtM medium, singleQuottM supplements and growth 
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factors were all obtained from Lonza (slough, berkshire, Uk). transfected MDckII cells 
overexpressing human MDr1 (MDckII-MDr1) and the wild type parental cell control 
(MDckII-Wt) were purchased from the Netherlands cancer Institute (Amsterdam, 
Netherlands).  culture flasks (75 cm2) and polycarbonate transwells® 0.4 µm pore 
size, 12 well (1.12 cm2) and 24 well (0.33 cm2) were obtained from corning costar 
(Nottingham, Nottinghamshire, Uk).  collagen type I from rat tail was sourced from 
bD biosciences (Oxford, Oxfordshire, Uk).
2.1.3. Histology reagents
All histology and microtomy consumables including wax, cassettes and blades were 
purchased from tAAb (Aldermaston, berkshire, Uk).
2.1.4. Quantitative polymerase chain reaction (qPcr) reagents
mrNA was extracted using rNA stat-60tM purchased from tel-test Inc (Nordic biosite 
Ab, täby, sweden) and quality assessed using 1% w/v agarose gels run alongside 
DNA ladder from Life technologies from Invitrogen (Paisley, renfrewshire, Uk).  For 
preparation of gels, agarose was purchased from seakem science rockland Inc. 
(rockland, ME, UsA) and ethidium bromide from continental Lab Products Inc. (san 
Diego, california, UsA).  
the superscript™ First strand synthesis system for rt-Pcr from Invitrogen, (Paisley, 
renfrewshire, Uk) was used for cDNA synthesis.  Manual real-time Pcr was carried 
out in MicroAmp Optical 96-well plates using taqMan probes and reagents from 
Applied biosystems (Foster city, cA, UsA).  Automated Pcr was carried out on 
predesigned taqMan Low Density custom Array Micro Fluidics cards using taqMan 
reagents from Applied biosystems (Foster city, cA, UsA).
2.1.5. Western blot reagents
cells were lysed in the presence of protease inhibitor cocktail II obtained from 
calbiochem (beeston, Nottinghamshire, Uk).  the dual colour precision molecular 
weight markers and rcDc protein estimation kit were all obtained from biorad (Hemel 
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Hempstead, Hertfordshire, Uk).  Nitrocellulose Protran bA85 0.45 µm pore size was 
obtained from scientific Lab supplies (Nottingham, Nottinghamshire, Uk).  blots were 
probed using the anti-mouse Westernbreeze® chemiluminescent detection kit from 
Invitrogen (Paisley, renfrewshire, Uk) according to the manufacturer’s instructions. 
2.1.6. Immunochemicals
the c219 anti-Pgp mouse monoclonal antibody was obtained from calbiochem 
(beeston, Nottinghamshire, Uk) and the MrP2 mouse monoclonal antibody from 
Abcam (cambridge, cambridgeshire, Uk).  Mouse anti-human ZO-1 primary 
antibody was purchased from Invitrogen (Paisley, renfrewshire, Uk).  the mouse 
anti-human UIc2 antibody and mouse anti-human bsEP antibody were obtained from 
Enzo Life sciences (Exeter, Devon, Uk) and the mouse anti-human Mrk16 antibody 
from Abnova (Newmarket, suffolk, Uk).   the flow cytometry goat anti-mouse FItc 
labelled secondary antibody was obtained from beckman coulter (High Wycombe, 
buckinghamshire, Uk).  Further details of all antibodies used throughout this work can 
be found in table 2.1.
2.1.7. radiochemicals
3H-pravastatin (specific activity 5 ci/mmol) was obtained from American radiolabeled 
chemicals (st Louis, MO, UsA).  14c-Mannitol (specific activity 61 mci/mmol), 3H-
digoxin (specific activity 40 ci/mmol), 3H-taurocholic acid (specific activity 40 ci/
mmol), super polyethylene 20 ml scintillation vials and OptiPhase Hisafe 2 scintillation 
cocktail were all purchased from Perkin Elmer (cambridge, cambridgeshire, Uk).  
2.1.8. Permeability experiment consumables
Permeability studies were all performed in pH 7.4 standard buffer solution (sbs), comprising 
Hank’s balanced salt solution (Hbss) supplemented with 20 mM 4-(2-hydroxyethyl)-1-
piperazine-ethanesulfonic acid (HEPEs) and 1% v/v DMsO.  Psc833 (MDr1 inhibitor) 
was obtained from tebu-bio (Peterborough, cambridgeshire, Uk).  Mk571 (MrP inhibitor) 
was purchased from calbiochem (beeston, Nottinghamshire, Uk). 
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2.1.9. Equipment
cell samples for histology were prepared using a tissue processor tP 1020, wax 
embedder Eg 1160 and rotary microtome rM 2165 all from Leica (Milton keynes, 
buckinghamshire, Uk).  samples were imaged using an Eclipse E400 microscope 
fitted with coolPix 4500 camera both from Nikon (kingston, surrey, Uk).  For scanning 
electron microscopy samples were dried using a Leica EM cPD030 critical point 
dryer (Milton keynes, buckinghamshire, Uk).  Aerial cell morphology was analysed 
using scanning electron microscopy carried out on a variable pressure JOEL 6060LV 
unit (Welwyn, Hertfordshire, Uk).  Image analysis was carried out using the in-built 
sEM control User Interface software (version 6.57) and digital imaging system. 
samples were gold coated using a balzers Union scD030 sputter coater unit (Milton 
keynes, buckinghamshire, Uk).  the Hg_U133A, Hg_U133b and Hg_U133 2.0 
Plus microarray databases were from Affymetrix (High Wycombe, buckinghamshire, 
Uk).  Data from the Hg_U133 2.0 Plus microarray chip was in-house data generated 
by AstraZeneca (Loughborough, Leicestershire, Uk).  rNA gels were run using the 
Mini-sub cell gt system and protein samples run using the Mini-gel system both 
from biorad (Hemel Hempstead, Hertfordshire, Uk).  rNA was quantified using 
a Nanodrop ND-1000 UV-Vis spectrophotometer from NanoDrop technologies 
(Wilmington, Nc, UsA) and agarose gels containing mrNA visualised using a UV 
gene genius transluminator from syngene (cambridge, cambridgeshire, Uk).  cDNA 
synthesis was carried out on a MJ Mini Personal thermal cycler from biorad (Hemel 
Hempstead, Hertfordshire, Uk).  Manual Pcr was carried out on a 7500 real time 
Pcr sequence Detection system and automated Pcr on predesigned taqMan Low 
Density custom Array Micro Fluidics cards and processed using AbI Prism 7900Ht 
sequence Detection system all from Applied biosystems (Foster city, cA, UsA). 
sonication of cell lysate preparations was conducted on a Decon Fs100 ultrasonic 
bath (Hove, sussex Uk).  tris-acrylamide gels were cast using the biorad Mini 
gel system and gels were run and transferred to nitrocellulose using the Protean II 
Western blotting tank (Hemel Hempstead, Hertfordshire, Uk).  All fluorescent imaging 
for immunocytochemistry samples was conducted on the Zeiss confocal Microscope 
(Welwyn garden city, Hertfordshire, Uk) and all flow cytometry data on the beckman 
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coulter EPIcs Altra™ flow cytometer (High Wycombe, buckinghamshire, Uk). 
Fluorescent immunocytochemistry samples were viewed using the Zeiss Meta 510 
confocal microscope (Welwyn garden city, Hertfordshire, Uk).  the transepithelial 
electrical resistance (tEEr) was measured using an EVOM2 from World Precision 
Instruments (stevenage, Hertfordshire, Uk).  All scintillation counting for 3H and 
14c radiolabelled samples in functional studies was measured on a Wallac 1490 
liquid scintillation counter from Perkin Elmer (cambridge, cambridgeshire, Uk).  All 
fluorescent and luminescent samples were analysed using a tecan Infinite® M200 
PrO spectrophotometer (reading, berkshire, Uk).
2.2.  MEtHODs
2.2.1.  cell culture
2.2.1.1.  general cell culture
For routine cell culture, all cell types were maintained in a humidified incubator at 37°c 
and 5% v/v cO
2
, and medium was replaced three times per week.  cells were passaged 
when confluency reached 80-90% of the t-75 culture flask.  In brief, cells were rinsed 
with 10 ml of pre-warmed Pbs before incubation with 5 ml 0.25% v/v trypsin/EDtA 
solution until visual detachment of the cells occurred.  trypsin was neutralised with 
either 5 ml of fresh medium containing 10% v/v Fbs or trypsin neutralising solution for 
serum free media.  the cell suspension was collected and centrifuged at 250 g for 5 
min unless otherwise stated.  the resulting pellet was resuspended in fresh medium 
and a portion of this transferred to a new culture flask.
2.2.1.2. calu-3 cell culture
Immortalised, human, cancerous bronchial epithelial cells, calu-3 were used at low 
passage (25-30) and high passage (45-50) for all experiments.  cells were cultured 
in Dulbecco’s modified Eagle’s medium / Ham’s F12 nutrient mixture (DMEM:F12) 
1:1, containing 10% v/v Fbs and supplemented with 1% v/v penicillin-streptomycin 
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antibiotic solution, 2 mM L-glutamine and 1% v/v non-essential amino acids.  cells 
were passaged when 90% confluent using a 1:3 split ratio.
cells were seeded at a density of 1 x 105 cells/cm2 and cultured at an air-liquid 
(AL) interface on 12 well polycarbonate, 0.4 µm pore size, transwell® cell culture 
supports.  For seeding, cells were introduced to the apical compartment in 500 µl cell 
suspension and 1500 µl fresh medium was added to the basolateral chamber.  After 
24 h, cells were raised to the AL interface.  Medium was aspirated from both apical 
and basolateral chambers and 500 µl medium replaced in the basolateral chamber 
only.  Medium was subsequently changed three times a week from the basolateral 
compartment.  cells were maintained on transwell® inserts up to 21 days before 
experiments were conducted.
2.2.1.3. caco-2 cell culture
Immortalised, human, colonic epithelial cells, caco-2 were used between passages 
55 to 75.  cells were cultured in DMEM, containing 10% v/v Fbs and supplemented 
with 1% v/v penicillin-streptomycin antibiotic solution, 2 mM L-glutamine, 1% v/v non-
essential amino acids and 1 mM sodium pyruvate.  cells were passaged when 90% 
confluent using a 1:6 split ratio. 
cells were seeded at a density of 2 x 105 cells/cm2 on 12 well polycarbonate, 0.4 µm 
pore size, transwell®
 
cell culture supports as previously described and cultured in 
submerged or liquid-liquid (LL) conditions.  Medium was subsequently changed three 
times a week from both compartments.  cells were maintained on transwell® inserts 
for 21 days.
2.2.1.4. rL-65 cell culture
rodent bronchial epithelial cells were obtained at an unknown passage number and 
used for an additional 17 passages.  cells were cultured in a serum free medium 
(sFM) comprising DMEM:F12 (1:1), supplemented with 85 nM selenium, 2.5 µg/
ml bovine insulin, 5.4 µg/ml human transferrin, 30 µM ethanolamine, 0.1 mM 
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phosphoethanolamine, 500 nM hydrocortisone, 5 µM forskolin, 50 nM retinoic and 
0.15 mg/ml bovine pituitary extract (bPE).  cells were passaged when 90% confluent 
by centrifuging the cell suspension at 150 g for 5 min and using a 1:20 split ratio. 
cells were seeded on filters as outlined above in section 2.2.1.2 at 1 x 105 cells/cm2 
unless otherwise stated and cultured either in AL or LL conditions.  rL-65 cells were 
either cultured in the sFM described above with the addition of 1% v/v penicillin-
streptomycin antibiotic solution, in a serum containing medium (scM) comprising the 
calu-3 medium outlined in section 2.2.1.2 with 50 nM retinoic acid or in a primary 
supplemented medium (PsM) comprising DMEM:Ham F12 (1:1) supplemented with 
proprietary supplement and growth factor singleQuotstM (bovine pituitary extract 
(bPE), hydrocortisone, human epithelial growth factor (hEgF), epinephrine, insulin, 
triiodothyronine, transferrin, gentamicin, amphotericin b and retinoic acid).
2.2.1.5. NHbE cell culture
NHbE cells were cultured according to the supplier’s protocol.  In summary, cells 
were cultured between passage 1 and 4 to a maximum of 15 population doublings. 
cells were cultured in the proprietary bronchial air-liquid interface (b-ALI) basal 
medium supplemented with singleQuotstM as outlined above.  When cells reached 
~90% confluence they were harvested using the supplier’s subculture reagents and 
protocols for seeding onto 0.33 cm2 transwell® inserts previously coated with 30 µg/
ml rat tail type 1 collagen for 45 min at room temperature.  
cells were seeded onto the apical side of the polycarbonate, 0.4 µm pore size, collagen 
coated transwell® in a cell suspension containing 50 000 cells in 100 µl of basal 
medium per insert, and 500 µl basal medium added to the basolateral compartment. 
Medium was removed and replaced on the following day and on the third day after 
seeding, the cells were raised to the AL interface.  All medium was removed from 
both sides of the transwell®, and 500 µl of differentiation medium (containing the 
same supplements as the basal medium but with the addition of an inducer solution 
provided by the supplier) added to the basolateral side.  this differentiation medium 
was subsequently removed and replenished from the basolateral side of the transwell® 
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three times a week.  NHbE cells were cultured until 21 to 23 days after the air-lift and 
were then processed for experiments.
2.2.1.6. MDckII cell culture
Immortalised, Madin Darby canine kidney cells were purchased at an unknown 
passage number and used up to 20 passages from delivery.  cells were cultured in 
DMEM, containing 10% v/v Fbs and supplemented with 1% v/v penicillin-streptomycin 
antibiotic solution and 2 mM L-glutamine.  cells were passaged when 90% confluent 
using a 1:20 split ratio.
cells were seeded at a density of 5 x 105 cells/cm2 on 12 well polycarbonate, 0.4 µm 
pore size, transwell® cell culture supports as outlined in section 2.2.1.3 and cultured 
in submerged conditions for 5 days before being used in experiments.
2.2.1.7. HEk293 cell culture
Immortalised, human embryonic kidney cells were used between passages 35 to 
40.  cells were cultured in DMEM, containing 10% v/v Fbs and supplemented with 
1% v/v penicillin-streptomycin antibiotic solution and 2 mM L-glutamine.  cells were 
passaged when 90% confluent using a 1:6 split ratio.
cells were seeded at a density of 5 x 105 cells/cm2 on 12 well polycarbonate, 0.4 µm 
pore size, transwell® cell culture supports as outlined in section 2.2.1.3 and cultured 
in submerged conditions for 5 days before experimentation.
2.2.1.8. cryopreservation and cell revival
cells were removed from the culture vessel with 5 ml 0.25% v/v trypsin/EDtA, neutralised 
and centrifuged as outlined in 2.2.1.1.  the cell pellet was resuspended in 1 ml ‘freezing 
medium’ comprising DMsO and the specific culture medium for the cells at a 1:9 ratio. 
Approximately 3 x 106 cells/ml were transferred to cryogenic storage vials, placed in 
isopropanol containing cryo-container (Mr Frosty™) and stored in a -80°c freezer.  After 
24 h, vials were relocated to liquid nitrogen for long term storage.
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cells were removed from storage and placed directly into a 37°c waterbath until 
thawed.  Immediately, the cells were transferred into a culture flask containing 10 to 
15 ml pre-warmed medium.  Medium was exchanged the following day.
2.2.1.9. general assays
2.2.1.9.1. trypan blue exclusion assay
cell counts and viability estimations were performed using the trypan blue exclusion 
technique using 0.5% w/v trypan blue and a haemocytometer.  An equal volume of 
cell suspension and trypan blue were mixed and 10 µl applied to the haemocytometer. 
cells were counted in three of the outer squares and results averaged.  cells that had 
taken up the trypan blue stain were excluded from the cell count.
2.2.1.9.2. tEEr measurements
transepithelial electrical resistance (tEEr) was measured immediately before 
medium exchange.  cells cultured at the AL interface had media added to both 
compartments so the final volumes were 500 µl apical and 1500 µl basolateral or 100 
µl apical and 500 µl basolateral in 12 and 24 well transwells® respectively.  these 
were allowed to equilibrate in an incubator for 15 min before tEEr measurements 
were taken.  chopstick electrodes were first sterilised in 70% IMs before being used 
to measure tEEr.  An average reading from 12 blank transwell® inserts without cells 
was deducted from the raw tEEr values to account for the resistance produced by 
the membrane and/or collagen treatment.  tEEr values were adjusted for area of the 
transwell®LQVHUWDQGVWDWHGLQFP2.
2.2.2.  Morphological characterisation
2.2.2.1. Preparation of cytology samples
All medium was removed from the transwell® and cells rinsed twice with pre-warmed 
Pbs.  cells were fixed with 3.7% w/v paraformaldehyde in Pbs for 15 min at room 
temperature.  Fixing solution was removed and fixed cell layers stored submerged 
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in Pbs at 4°c until processed.  For histology preparation, filters were excised from 
the inserts and placed between two foam pads inside a histology cassette.  samples 
were subjected to 5 min incubations in increasing concentrations of ethanol in dH
2
O 
(25, 50, 75, 90, 95, 100% v/v), followed by two 5 min exposures to xylene and finally 
30 min in paraffin wax.  Dehydrated samples were embedded in wax and 6 µm thick 
cross-sections cut and mounted on poly-L-lysine impregnated histology slides.
2.2.2.2. cytological staining
slides containing cell layer cross-sections were incubated twice in xylene for 2 min 
and rehydrated in decreasing concentrations of ethanol in dH
2
O (100, 95, 90, 75, 
50, 25% v/v) for 2 min each.  slides were then immersed in 100% dH
2
O before 
histological staining.  All incubation steps for histological staining were performed at 
room temperature.
2.2.2.2.1. Haematoxylin and eosin staining
slides were immersed in Mayer’s haematoxylin stain for 10 min and excess stain 
removed by rinsing for 2 min in dH
2
O.  samples were then submerged for 2 min in 
scott’s tap water (3.5 g sodium bicarbonate, 20 g magnesium sulphate in 1 l dH
2
O) 
before incubation in 1% v/v eosin in dH
2
O for 5 min.  slides were rinsed in dH
2
O until 
the colour ran clear and mounted with glycerol and cover slip for imaging.
2.2.2.2.2. Alcian blue cytological staining
Wax embedded cell samples were submerged in a 1% w/v alcian blue in 3% v/v acetic 
acid pH 2.5 for 5 min.  Excess stain was removed in dH
2
O with a 2 min wash before 
incubation in neutral fast red for 5 min.  the sample was rinsed again in dH
2
O before 
mounting with glycerol for imaging.
For aerial images of mucus detection, after the paraformaldehyde fixation step, cell 
samples were incubated in 1% w/v alcian blue in acetic acid pH 2.5 for 20 min.  After 
this time, the sample was rinsed in dH
2
O until the colour ran clear, excised from the 
transwell® insert and mounted on a glass slide using glycerol before imaging.
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2.2.2.3. Immunocytochemistry of tight junction proteins
cells cultured on transwell® inserts were harvested for detection of tight junction 
protein, ZO-1.  All medium was aspirated from the transwell® and cells washed 
twice with Pbs pH 7.4.  samples were fixed for 15 min with 500 µl of 3.7% w/v 
paraformaldehyde in the apical chamber.  After the elapsed time, paraformaldehyde 
was removed and Pbs added to both chambers.  Fixed samples were stored up to 14 
days at 2-8°c prior to analysis.
For immunocytochemistry (Icc), all steps were carried out at room temperature unless 
otherwise stated.  cells were permeabilised with 0.1% v/v triton X-100 in Pbs for 5 
min and rinsed in Pbs.  samples were then blocked for 30 min with 1% w/v bovine 
serum albumin (bsA) in Pbs to prevent non-specific binding.  cells were incubated 
with the primary antibody, mouse anti-ZO-1 human monoclonal antibody for 60 min at 
37°c.  cells were washed in 1% w/v bsA in Pbs three times to remove any unbound 
primary antibody before incubation with FItc-labelled goat anti-mouse Igg (1:64) 
in Pbs for a further 30 min.  samples were washed twice with Pbs to remove any 
unbound secondary antibody and incubated for 30 s in propidium iodide (PI) 1 µg/ml in 
Pbs as a nuclear counter-stain.  Inserts were washed a further three times with Pbs 
before the filter was excised and mounted on a slide using DAbcO anti-fade mounting 
media.  samples were imaged by confocal microscopy fitted with a x63 objective and 
x1 optical zoom.  samples were excited at 485 nm and 543 nm wavelengths and 
emission observed at 519 nm and 617 nm for FItc and PI respectively.  An average of 
8 images were taken for each single cross-section image.
2.2.2.4. scanning electron microscopy
cells were fixed in a 1:1 mixture of medium and fixing solution (2.5% v/v glutaraldehyde 
in 0.1 M sodium cacodylate buffer, pH 7.2) which was added to both apical and 
basolateral chambers of the transwell®.  After 5 min, the solution was removed and 
replaced with 2.5% v/v gluteraldehyde fixing solution and samples were stored at 4°c 
for up to 2 weeks.  
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For scanning electron microscopy (sEM) processing, all fixing solution was aspirated 
from both chambers of the transwell® and 1% w/v osmium tetroxide in Pbs added to 
both compartments.  After 90 min, the solution was removed and rinsed five times with 
Pbs before dehydration in progressively increasing concentrations of ethanol in dH
2
O 
(25%, 50%, 75%, 95% and 100%).  samples were dried using cO
2 
critical point drying 
and inserts were removed and mounted on aluminium stubs with adhesive carbon 
tape.  the samples were gold coated for 5 min under an argon atmosphere and 
analysed with sEM at an accelerating voltage of 30 kV and stage height of 10 mm. 
2.2.3.  transporter gene expression analysis
2.2.3.1. gene catalogue data mining
gene expression profiling of Abc transporters in human samples was extracted from 
the Hg_U133A, Hg_U133b and Hg_U133 2.0 Plus Affymetrix microarray chipsets. 
Data was collated for transporter gene expression in different organs, lung regions, 
healthy individuals, pulmonary disease states and in smokers and non-smokers.  Data 
was analysed for the reliability of detection, expressed as % present and categorised 
as follows:
฀•฀฀ +++ ‘high’ 75-100 % present
฀•฀฀ ++ ‘moderate’ 50-75 % present
฀•฀฀ + ‘low’ 25-50 % present  
฀•฀฀ - ‘negligible’ 0-25 % present
More detailed explanations of Affymetrix microarray expression methodology and 
data analysis can be found in Appendix A.
2.2.3.2. Quantitative polymerase chain reaction (qPcr)
2.2.3.2.1. cell harvesting for rNA extraction
calu-3, NHbE and rL-65 cells cultured on transwell® inserts were harvested on the 
same day as functionality experiments.  Medium was removed from the transwell®, 
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cells were washed with Pbs and filters excised using sterile and rNAse free 
equipment.  Either 12 filters (12 well transwell® inserts) or 20 filters (24 well transwell® 
inserts) were transferred to two sterile rNAse free 1.5 ml cryovials.  samples were 
immediately frozen in liquid nitrogen and stored at -80°c until processing.
2.2.3.2.2. Preparation of rNA
total rNA was extracted from the cell samples using rNA-stAt 60™ according to 
the manufacturer’s instructions.  In summary, 1.2 ml rNA-stAt 60 was added to each 
frozen cryovial to fully immerse the excised filters.  the solution was incubated at room 
temperature for 5 min and transferred to a sterile microcentrifuge tube.  to this 240 µl 
chloroform was added, tubes vortexed and incubated for 3 min at room temperature 
before phase separation centrifugation at 12 000 g, 4°c for 15 min.  the resulting 
upper, clear, aqueous phase was transferred to a fresh sterile microcentrifuge tube 
and 600 µl isopropanol added.  the sample was stored at 4°c for 30 min before 
centrifugation at 12 000 g, 4°c for 10 min and supernatant decantation  the remaining 
pellet was washed in 1.2 ml ice cold 75% v/v ethanol, vortexed and centrifuged at 7400 
g, 4°c for 5 min.  the ethanol was decanted and pellet air dried at room temperature 
for 30 min before being resuspended with rNAse free water and stored at -80°c until 
required.  Preparations were assessed for rNA quantity using a Nanodrop ND-1000-
UV-Vis spectrophotometer and only samples with an absorbance ratio at 260-280 
greater than 1.82 were accepted.  Integrity of the rNA preparation was also assessed 
by the presence of distinct 18s and 28s bands on a 1% w/v agarose gel using a tbE 
buffer (90 mM tris-borate, 2 mM EDtA, pH 7.8).
2.2.3.2.3. cDNA synthesis
cDNA was prepared from 2 µg of total rNA using the superscripttM First-strand 
synthesis system with random hexamer primers according to the manufacturer’s 
protocol.  samples were incubated at 65°c for 5 min then held on ice for 1 min before 
the addition of superscript III reverse transcriptase.  samples were then incubated 
at 25°c for 10 min followed by exposure to 50°c for 50 min before the reaction was 
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terminated by heating to 85°c for 5 min.  cDNA samples were then chilled on ice, 
diluted to 25 ng/µl with rNAse free water and stored at -80°c until required. 
2.2.3.2.4. Manual taqMan® Pcr
taqMan® analysis was performed in a 25 µl reaction mixture containing 30 ng cDNA, 
taqMan® Universal Pcr Master Mix (containing Amplitaq gold DNA polymerase, 
dNtPs with dUtP, passive reference and optimised buffer) and Assay-on-demand™ 
gene expression assay mix (containing 18 µM random hexamer primers).  sample 
preparation was carried out according to the manufacturer’s instruction.  the Pcr 
conditions comprised a 2 min incubation at 50°c followed by a 10 min polymerase 
activation at 95°c.  this was followed by 40 cycles alternating between 95°c for 15 s 
and 60°c for 1 min each.
2.2.3.2.5. Automated taqman® Pcr low density array 
samples of 100 µl containing 20 ng cDNA and taqMan® Universal Pcr Mastermix 
were ejected into the loading wells of the taqMan® low density custom array card. 
samples were briefly centrifuged to allow the sample to access the preloaded reaction 
wells and sealed according to the manufacturer’s instructions.  the Pcr conditions 
were identical to those outlined above in section 2.2.3.2.4. 
2.2.3.2.6. relative expression analysis
Normalisation of cDNA amplification to a passive reference dye included in the taqMan® 
Universal Pcr Master Mix was carried out in the reaction cycle.  All thresholds for 
generation of c
t
 data were calculated automatically by the software.  target genes 
were compared with house-keeping genes (rPLP0 and MVP for human samples; 
JDSGKDQGPYSIRUUDWVDPSOHVWRJHQHUDWHǻ&
t
 as follows:
ǻ&
t  
=  c
t target gene
  -  c
t control
relative expression level of the normalised target gene was calculated by:
2ǻ&t
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2.2.3.3. Data analysis
Data are presented as mean values from three samples.  genes were assigned 
arbitrary categories for relative gene expression levels as follows:
฀•฀฀ +++ ‘high’ > 0.5
฀•฀฀ ++ ‘moderate’ 0.02 – 0.5
฀•฀฀ + ‘low’ 0.001 – 0.02
฀•฀฀ - ‘negligible’ < 0.001
2.2.4.  transporter protein expression analysis
2.2.4.1. Western blotting
2.2.4.1.1. Preparation of total cell lysates
calu-3, rL-65, caco-2, MDckII Wt, MDckII MDr1 and HEk293 cells cultured on 
transwell® inserts were rinsed in Pbs and detached from the surface by the addition of 
500 µl non-enzymatic cell dissociation buffer (prepared in Hbss without calcium and 
magnesium salts) to the apical compartment.  cells were counted and resuspended 
in rIPA cell lysis buffer containing 1 µl of protease inhibitor cocktail set II per 200 µl, 
(20 million cells per 1 ml buffer solution).  cells were vortexed, sonicated for 30 s and 
agitated at 700 rpm at 4°c for 30 min.  cell debris was pelleted at room temperature 
via centrifugation at 12 000 g for 20 min and the resulting supernatant was decanted. 
the protein concentration was quantified using the rcDc protein assay according to 
the manufacture’s protocol, using bsA as the protein standard.  the cell lysate was 
divided into aliquots and stored at -20°c until needed.
2.2.4.1.2. sodium dodecyl sulphate polyacrylamide gel electrophoresis  
  (sDs-PAgE)
Protein samples were resolved using 7 or 12% tris-acrylamide gels according to the 
method previously described [Laemmli et al., 1970] with minor modifications.  In short, 
10 to 100 µg of protein sample in 10 µl was diluted 1:1 with reducing buffer (containing 
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2 ml of 0.5 M tris-Hcl pH 6.8, 2 ml glycerol, 4 ml of 10% sDs, 0.2% bromophenol 
blue, 100 mM dithiothreitol, and 2 ml dH
2
O).  samples were mixed on the vortex and 
maintained at 37°c for 10 min before loading into gels alongside 5 µl protein standards. 
Proteins were resolved at 0.04 amps / 200 volts in running buffer containing 30 g 
tris, 144 g glycine, 10 g sDs made up to 10 l with dH
2
O and electrophoresis was 
terminated just before the blue dye front reached the bottom of the gel.  
2.2.4.1.3. Western blotting of sDs-PAgE separated proteins
the proteins were then transferred to a nitrocellulose membrane as previously 
described [towbin et al., 1979].  transfer was conducted in transfer buffer (containing 
14.41 g glycine, 3.025 g tris, 1 g sDs and 200 ml methanol to 1 l with dH
2
O) for 60 
min at 100 volts / 2.0 amps at 4°c.  
Proteins transferred onto Western blots were visualised by staining with copper 
phthalocyanine 3, 4’, 4’’, 4’’’-tetrasulphonic acid tetrasodium salt (cPtA) as previously 
described [bickar and reid, 1992].  Western blots were immersed into 0.05 % w/v 
cPtA solution in 12 mM Hcl for 1 min.  Excess cPtA was removed with dH
2
O in 
order to visualise bound protein.  Prior to immunoprobing cPtA was removed from 
the nitrocellulose by washing with 12 mM sodium hydroxide.
2.2.4.1.4. Immunoprobing of blots
samples were probed for MDr1, bsEP and MPr2 membrane transporters using 
a chemiluminescence detection kit according to the manufacturer’s instructions.  In 
summary, nitrocellulose was rinsed twice with dH
2
O before a 30 min incubation in 
blocking solution.  blots were submerged in 20 ml blocking solution containing primary 
antibodies (5 µg/ml mouse anti-P-glycoprotein human (c219), and 1:50 mouse anti-
human MrP2) and incubated overnight at 4°c on an oscillating platform rotating at 
60 rpm.  cells were rinsed three times in antibody wash solution and incubated for 
30 min in 10 ml goat-anti mouse Igg secondary antibody solution.  Nitrocellulose 
was rinsed again three times in wash solution and twice in dH
2
O before addition of 
the chemiluminescent substrate for 5 min.  Excess substrate was removed using lint-
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free tissue and the membrane sandwiched between two sheets of cling-film.  Light 
emission was detected by exposure to kodak X-Omat chemiluminescent detection 
film for 1 to 5 min depending on the intensity of the signal.  the film was developed 
using 20% v/v LX-24 developer, fixed in 20% v/v FX-40 fixer and rinsed with dH
2
O 
before being air dried.
2.2.4.2. Immunocytochemistry of transporter proteins
Immunocytochemistry (Icc) was conducted as outlined in section 2.2.2.3.  the mouse 
anti-human MDr1 antibodies Mrk16 (15 µg/ml) or UIc2 (20 µg/ml) were used as 
the primary antibody.  Z-stack reconstructions of samples were the average of four 
images for every 0.5 µm slice through the sample.  MDckII-MDr1 cells were used 
as the positive MDr1 control and MDckII-Wt used as the negative wild type control 
for MDr1.  However, due to the expression of canine mdr1 in the MDckII-Wt cells, 
HEk293 cells were also used as a negative MDr1/mdr1 control.
2.2.4.3. Flow cytometry
cells were harvested from transwell® inserts by the addition of 500 µl or 100 µl trypsin 
to the apical compartment of each 12 and 24 well transwell®, respectively.  When 
detached, cells were collected and mixed with an equal volume of 0.5% v/v Fbs in 
Pbs and pelleted at 250 g for 5 min.  the solution was decanted and cells resuspended 
in fresh 0.5% v/v Fbs in Pbs solution.  cells were counted, concentration adjusted to 
1 million cells/ml and 100 µl (100 000 cells) transferred to clean flow cytometry tubes. 
Primary anti-MDr1 antibodies, Mrk16 (1 µg) and UIc2 (0.2 µg) were added in 10 µl 
volumes and samples, briefly vortexed and incubated at 37°c for 30 min.  samples 
were washed by the addition of 2 ml cold ‘stop solution’ (0.5% v/v Fbs and 15 mM 
sodium azide in Pbs), vortexed and centrifuged at 400 g for 5 min.  the solution was 
decanted and samples were resuspended in 100 µl ‘stop solution’ containing FItc-
labelled goat anti-mouse Igg (1:1000) and incubated at 4°c for 30 min.  samples 
were rinsed again with 2 ml stop solution, centrifuged at 400 g for 5 min and solution 
decanted.  Labelled samples were fixed by the addition of 500 µl fixing solution (0.5% 
v/v formaldehyde in Pbs) and stored at 4°c in the dark for up to one week before 
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analysis.  An unstained sample and the appropriate isotype controls were included in 
each analysis to address autofluorescence and non-specific binding, respectively.  
For data analysis, each sample population was gated to only include cells of interest 
based on either their forward scatter (cell size) and/or side scatter (cell granularity) 
profiles.  Dead cells were identified from optimisation experiments with PI and 
excluded from the analysis.  A total of 30 000 events were collected for each sample. 
raw data was analysed using WinMDI 2.9 software (build #2, 6-19-2000; scripps 
research Institute. http://facs.scripps.edu/software.html) and the absolute mean 
fluorescence intensity (MFI) value for each marker was determined. Absolute MFI 
value is defined as: [absolute MFI] = [MFI value of sample] – [MFI value of isotype/
unstained sample].  
2.2.4.3.1. UIc2 shift assay
samples were treated as outline above in 2.2.4.3 but first incubated at room 
temperature for 10 min either alone in 0.5% v/v Fbs in Pbs or with the addition of 
chemical inhibitor compounds; 1 µM Psc833, 30 µM verapamil, 30 µM Mk571, 30 
µM indometacin or 1 mM probenecid.  the primary antibody UIc2 was then added as 
outlined above in 2.2.4.3.  
2.2.5.  transport studies
2.2.5.1. general set up
After 21 days in culture on filters, all medium was aspirated from the transwell® rinsed 
once with standard buffer solution (sbs).  sbs was added to both compartments.  For 
12 well transwell® inserts, 500 µl was added to the apical side and 1500 µl added 
to the basolateral compartment.  the 24 transwell® format had 200 µl and 800 µl 
added to apical and basolateral compartments respectively.  cells were allowed to 
equilibrate at 37°c for 60 min before tEEr measurements were taken.  Only inserts 
ZLWKDUHVLVWDQFH!ȍFP2&DOXFHOOVDQG1+%(FHOOVDQG!ȍFP2 (rL-65 
cells) were used for experiments.  All buffer solution was aspirated from the transwell® 
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prior to commencing permeability studies.  cells were maintained at 37°c in between 
sampling unless otherwise stated.
2.2.5.2. radioactive substrate transport studies
For absorption (Ab) experiments, the apical (donor) compartment was filled with 510 
µl (12 well) or 210 µl (24 well) of sbs containing the substrate (25 nM 3H-digoxin, 
100 nM 3H-pravastatin or 217 nM 3H-taurocholic acid) and 6.55 µM 14c-mannitol as a 
paracellular marker.  the basolateral (receiver) compartment was filled with 1500 µl 
(12 well) or 800 µl (24 well) of sbs.  Immediately 10 µl was sampled from the donor 
compartment and transferred to a scintillation vial containing 2 ml scintillation fluid. 
After 30, 60 and 90 min, 300 µl (12 well) or 200 µl (24 well) samples were taken 
from the receiver chamber for analysis of radioactive content and replaced with an 
equivalent volume of sbs.  At 120 min a 300 µl (12 well) or 200 µl (24 well) sample 
was taken from the receiver chamber and a 10 µl sample from the donor chamber.  
For secretory (bA) experiments, the apical (receiver) chamber was filled with 500 µl 
(12 well) or 200 µl (24 well) of sbs and basolateral (donor) chamber with 1510 µl (12 
well) or 810 µl (24 well) of sbs containing the radioactive substrate (25 nM 3H-digoxin, 
100 nM 3H-pravastatin or 217 nM 3H-taurocholic acid) and 6.55 µM 14c-mannitol as 
a paracellular marker.  Immediately 10 µl was sampled from the donor compartment 
and transferred to a scintillation vial containing 2 ml scintillation fluid.  After 30, 60 
and 90 min, 100 µl (12 well) or 50 µl (24 well) samples were taken from the receiver 
chamber for analysis of radioactive content and replaced with an equivalent volume 
of sbs.  At 120 min a 100 µl (12 well) or 50 µl (24 well) sample was taken from the 
receiver chamber and a 10 µl sample from the donor chamber.  
tEEr measurements were taken at the end of the experiment to check integrity of 
the cell layers was not compromised.  cell layers that had tEEr values below the 
boundaries stated above or a decrease in tEEr by more than 50% were excluded from 
the analysis to rule out mechanical injury to the monolayers during the experiment. 
All samples were transferred to scintillation vials containing 2 ml scintillation fluid and 
mixed thoroughly on the vortex before analysis by liquid scintillation counting.  
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the concentration of tritiated substrate and 14c-mannitol in each sample was calculated 
relative to the number of radioactive counts in the donor compartment at t
0
 where the 
substrate concentration was known.  the apparent permeability (P
app
) of each tritiated 
substrate and 14c-mannitol through the cell monolayer was then calculated using the 
following equation:
P
app    
=             J      
                          A x c
0
Where:
฀•฀฀ J = dJ/dt is the flux (the amount of substrate permeating through the cell layers 
 during the time of experiment in g.s-1)
฀•฀฀ A is the surface area of the transwell® insert surface in cm2
฀•฀฀ c
0
 is the initial concentration of the substrate the donor solution in g.ml-1
cell layers where 14c-mannitol P
app
 > 1.5 x 10-6 cm/s (calu-3 and NHbE) > 2 x 10-6 
cm/s (MDckII), > 3.0 x 10-6 cm/s (rL-65) or 14c-mannitol flux r2 value was below 
0.95 were rejected.  chemical structures of the substrate compounds can be found in 
Appendix b.
2.2.5.3. chemical inhibition studies
Ab and bA transport experiments were performed with the 3H-digoxin substrate as 
outlined above in section 2.2.5.2.  cells were first incubated for 60 min in receiver 
solution containing the chemical inhibitor compounds (1 µM Psc833, 30 µM 
verapamil, 30 µM Mk571, 10 µM indomethacin or 1 mM probenecid) in sbs.  Donor 
solutions contained the corresponding chemical inhibitor, 25 nM 3H-digoxin and 
6.55 µM 14c-mannitol in sbs containing.  the concentration of the inhibitor was 
maintained constant throughout the duration of the experiment.  chemical structures 
of the inhibitor compounds can be found in Appendix c.
2.2.5.4. biological inhibition studies
the UIc2 and Mrk16 MDr1 functional antibody inhibitors were carried out alongside 
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3H-digoxin substrate transport experiments.  before the assay, cells were incubated 
in sbs containing, UIc2 (20 µg/ml), Mrk16 (15 µg/ml) or c219 (10 µg/ml; antibody 
control) for 60 min at 37°c.  After the elapsed time, solutions were removed and 
transport assay carried out as outlined above in section 2.2.5.2.  
As a control for antibody attachment during the experiment, a non-radiolabelled 
sample was processed for immunocytochemical detection of the antibodies.  samples 
were incubated for 1 h in either, UIc2 (20 µg/ml) or Mrk16 (15 µg/ml) and then for a 
further 2 h in Pbs.  cells were then incubated in secondary goat anti-mouse Igg-FItc 
tagged secondary antibody (1:64) in Pbs for 30 min before two washes in Pbs and 
fixation in 3.7% w/v paraformaldehyde for 15 min at room temperature.  cells were 
permeabilised for 5 min with 0.1% v/v triton X-100 and nuclei counterstained with 
1 µg propidium iodide in Pbs for 30 s.  samples were washed twice more with Pbs, 
inserts excised and mounted with DAbcO on glass slides for confocal imaging.
2.2.5.5. Metabolic inhibition assays
calu-3 cells at low and high passage ranges were incubated for 1 h, 3 h and 6 h in 
either sbs alone, 1.5 mM, 15 mM or 150 mM sodium azide (inhibitor of oxidative 
phosphorylation) in sbs and assayed for AtP content using the AtP-lite® kit according 
to the manufacturer’s instructions.  In brief, one well (12 well for calu-3, MDckII; 24 
well for NHbE) was incubated with 50 µl cell lysis buffer at room temperature on 
an orbital shaker set at 700 rpm.  After 5 min, 100 µl luminescent substrate buffer 
was added and samples incubated for a further 5 min at 700 rpm.  samples were 
then transferred to a black 96 well plate, dark adapted for 10 min and analysed for 
luminescence.  AtP content was expressed as the % of AtP relative to the control 
(sbs alone) on an average of 3 samples for calu-3 and MDckII cells and for a single 
NHbE transwell® insert. 
Ab and bA transport studies using 3H-digoxin and 3H-pravastatin were conducted in 
the presence of 15 mM sodium azide.  cells were incubated for 60 min in receiver 
solution (sbs containing 15 mM sodium azide) 500 µl (12 well) or 200 µl (24 well) in 
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the apical compartment and 1500 µl (12 well) or 800 µl (24 well) in the basolateral 
compartment.  Donor solutions comprised sbs containing 15 mM sodium azide, 25 
nM 3H-digoxin and 6.55 µM 14c-mannitol in sbs.  the concentration of sodium azide 
was maintained constant during the experiment and assay was conducted as outlined 
in section 2.2.5.2.
2.2.5.6. Fluorescent substrate transport experiments
rhodamine 123 (rh123) was used as a general Abc transporter substrate in rL-65 
transport experiments.  Assays were performed in 12 well plates as outlined in section 
2.2.5.2 but using 5 µM rh123 as the substrate and conducted in reduced lighting.  the 
10 µl samples taken from the donor compartment were diluted 1 in 100 in sbs before 
analysis and 100 µl samples taken from the receiver compartment analysed neat.  All 
samples were transferred to a black 96 well plate and analysed using a fluorescent 
plate reader.  samples were excited at 488 nm and emission observed at 543 nm.  
2.2.6.  statistical analysis
For all tEEr and permeability data generated, results were expressed as mean ± 
VG'DWDVHWVZKHUHQZHUHDVVHVVHGIRUQRUPDOLW\DQGWKHGDWDZDVIRXQGWRILW
a normal (gaussian) distribution.  therefore, normality was assumed for all datasets 
where n < 5.   Data were compared using a two-tailed, unpaired student’s t test with 
Welch correction applied (to consider unequal variance between datasets).  statistical 
significance was evaluated at the 95% and 99% confidence levels and data considered 
to be statistically significant to control conditions represented with an asterix (* p<0.05 
or ** p<0.01) above the data.  All statistical tests were performed using graphPad 
Instat® version 3.06.
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3. cHArActErIsAtION OF cELL MOrPHOLOgY AND bArrIEr   
 INtEgrItY
3.1. INtrODUctION
several immortalised human bronchial epithelial cell lines have been established as 
in vitro models for permeability screening [Forbes, 2000; sakagami, 2006].  calu-3 
was selected for these investigations due to the greater abundance of information 
in literature regarding model characterisation and transporter expression and 
functionality.  cells were cultured at the AL interface as this has been shown to play 
an important role in differentiation of the epithelial barrier both in primary tracheocytes 
[Adler et al., 1990; sakagami, 2006] and in calu-3 cells [Fiegel et al., 2003; grainger 
et al., 2006].  In addition to the well established and optimised culture conditions, 
characterisation of tight junction formation, tEEr profile and paracellular permeability 
markers is also well documented for calu-3 cells [Forbes and Ehrhardt, 2005; 
sakagami, 2006].  However, there is disparity in the literature regarding the trafficking 
of actively transported substrates across the cell layers [Forbes and Ehrhardt , 2005; 
bosquillon, 2010].  One potential explanation may be the changing expression and 
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functionality of transporter proteins with increasing passage number.  to date, the 
impact of passage number on the morphology and permeability characteristics of 
calu-3 cells has not been reported.
Primary NHbE cells have also been established as a suitable model for permeability 
screening [Lin et al., 2007].  comparison of calu-3 with NHbE cells may help clarify 
differences in morphology and para- and transcellular permeability attributable 
to the cancerous origin of calu-3.  As a foundation for future chapters and to aid 
characterisation of transcellular drug trafficking in the models, it is essential to 
understand any differences in morphology, barrier properties and paracellular 
permeability between calu-3 cells cultured at low and high passage and NHbE cells.
In vitro permeability modelling has become an essential tool to predict absorption 
of inhaled drug candidates [tronde et al., 2008].  In silico, in vitro, and animal ex 
vivo and in vivo models are key tools to enhance understanding of drug permeability 
and absorption in the lung, given absorption data from the human lung in vivo is 
limited.  In vitro - ex vivo / in vivo correlations have been established for a limited 
number of compounds between caco-2 permeability and IPrL absorption [tronde 
et al., 2003a; tronde et al., 2003b], 16HbE14o- permeability and IPrL absorption 
[Manford et al., 2005] and calu-3 cell permeability with rat in vivo absorption data 
[Mathias et al., 2002].  However it has also been reported that for some compounds, 
in vitro permeability does not correlate to either ex vivo or in vivo absorption in the rat 
[Mathias et al., 2002; Madlova et al., 2009].  Potential explanations for these differences 
may be due to altered morphology, barrier characteristics, paracellular permeability 
or a different transporter functionality profile in the rat airway in comparison with 
human airway epithelium.  Primary cultures of rat tracheal in vitro models have been 
described [kaartinen et al., 1993; clark et al., 1995; Davenport and Nettesheim, 1996] 
however, there is currently no established rat bronchial epithelium in vitro cell line 
available suitable for permeability testing.  such a model would aid the understanding 
of interspecies variations and differences in model complexity between human in vitro 
permeability screening and rat ex vivo / in vivo drug absorption studies for inhaled 
drug candidates.
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rL-65 is a rat airway (bronchial/bronchiolar) epithelial cell line previously isolated 
from 5 day old sprague-Dawley rats [roberts et al., 1990].  Published work on this cell 
line includes the investigation of pathways associated with the induction of cytosolic 
phospholipase A
2
, [Van Putten et al., 2001; blaine et al., 2001; Wick et al., 2005] 
WKHLPSDFWRISHUR[LVRPHSUROLIHUDWRUDFWLYDWHGUHFHSWRUȖRQWXPRURLJHQHVLV>%UHQ
Mattison et al., 2005; Nemenoff et al., 2008] and oxidative stress/apoptotic effects of 
carbon nanotubules [sharma et al., 2007; rarichandran et al., 2009].  More recently, 
work has been published regarding the disruption of adherens junctions between rL-
65 cells with genetic transfections of k-ras [Wang et al., 2008] and chemical insult 
with immunosuppressive drugs [Felton et al., 2011].  However, to date the potential of 
rL-65 as an in vitro model for permeability screening has not been reported.  
3.2. AIMs
this chapter focuses on the development and characterisation of the rat cell line 
(rL-65) as a tool for in vitro permeability screening and its comparison with existing 
human bronchial epithelial cell culture models.  specifically, the objectives were to:
 Evaluate the established human bronchial epithelial cell culture models   
 cultured in our laboratory and using our methodology against the literature
 Investigate the impact of passage number on calu-3 cell morphology, barrier  
 function and paracellular permeability 
 Optimise the culture conditions for the rL-65 cell line to achieve tEEr and  
 paracellular marker permeability suitable for use in permeability studies
 characterise the morphology of the rL-65 cell line cultured under different  
 conditions and to assess how culture conditions can impact cell morphology
 compare and contrast the morphology and permeability characteristics in  
 rL-65 cells against established human bronchial epithelial cell culture 
  models.
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3.3. rEsULts
3.3.1. Assessment of suitability for permeability modelling
tEEr profiles for human bronchial epithelial in vitro models calu-3 and NHbE cells 
are shown in Figure 3.1.  calu-3 cells at high passage were confluent by day 7 in 
FXOWXUH SURGXFLQJ 7((5 YDOXHV RI    FP2.  In comparison, calu-3 cells 
cultured at low passage only became confluent after 9 days in culture generating 
7((5YDOXHVRIFP2 12 days after seeding.  Low passage calu-3 cells had 
a significantly (p<KLJKHU7((5DIWHUGD\VFP2) in comparison 
ZLWK KLJK SDVVDJH &DOX FHOOV    FP2).  both passage ranges tested 
maintained suitable tEEr at 21 days in culture for use as a permeability screening 
tool.  Furthermore, replicable tEEr values at 21 days in culture were measured for 
multiple passages in the low and high passage groups.  A sample of 68 calu-3 cell 
OD\HUVEHWZHHQSDVVDJHVSURGXFHG7((5YDOXHVRIFP2 whilst 
SDVVDJHFHOOOD\HUVJHQHUDWHG7((5YDOXHVRIFP2. 
similarly to high passage calu-3 cells, NHbE cells were 100% confluent early on in 
FXOWXUHSURGXFLQJ7((5YDOXHVRIFP2 4 days after air-lift.  NHbE tEEr 
YDOXHVDIWHUGD\VLQFXOWXUHFP2IRUSDVVDJHDQGFP2 
for passage 3 cells) were not significantly different (p>0.01) between passage and 
were in a more comparable range with low passage calu-3 cells.
rL-65 cells cultured in serum free medium (sFM) in both AL and LL conditions had 
very similar tEEr profiles until day 8 in culture (Figure 3.2A).  the tEEr value peaked 
DWGD\VLQFXOWXUHFP2) for cells cultured under submerged conditions 
whereas those cultured at the AL interface had the highest tEEr at day 10 (823 ± 
FP2).  the tEEr decreased steadily after these time points for both AL and LL 
interface culture, and by 21 days cells cultured at the AL interface were no longer 
attached to the filters.  
rL-65 cells cultured in serum containing medium (scM) at AL interface had a more 
desirable tEEr profile for use as a permeability model than in submerged conditions 
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Figure 3.1.  TEER profiles for human bronchial epithelial cell culture models
the tEEr profiles for (A) calu-3 cells seeded at a density of 1 x 105 cells/cm2 cultured on 12 
well  transwell®LQVHUWVIRUGD\VDWDQDLUOLTXLGLQWHUIDFHDWżORZSDVVDJHDQGŶ
high passage (45-50) and (b) NHbE cells seeded on 24 well transwell® inserts at a density of 
5 x 104 cells/cm2 at passage 2 (ŸDQGSDVVDJHƇFXOWXUHGIRUGD\VSRVWDLUOLIW5HVXOWV
were adjusted for the resistance of the filter and normalised to the area of the insert.  Data are 
represented as mean ± sd of 12 cell layers. ** indicates a significant difference (p<0.01) in the 
tEEr value of calu-3 cells cultured at low and high passage at 21 days.
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Figure 3.2.  TEER profiles for the rat lung cell line (RL-65) cultured with different types 
of growth media
tEEr profiles for rL-65 cells at passage 3 grown on 12 well transwell® inserts up to 21 days 
and cultured in (A) serum free medium (sFM) (b) serum containing medium (scM) and (c) 
primary supplemented medium (PsM).  cells were seeded at a density of 1 x 105 cell/cm2 and 
FXOWXUHGLQHLWKHUVXEPHUJHGFRQGLWLRQV//ŶRUDWWKHDLUOLTXLGLQWHUIDFH$/ż5HVXOWV
were adjusted for the resistance of the filter and normalised to the area of the insert.  Data 
are represented as mean ± sd of 4-6 cell layers. ** indicates a significant difference (p<0.01) 
in the tEEr value of rL-65 cells cultured in PsM in AL and LL culture conditions after day 6 
in culture.
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)LJXUH%7KH7((5IRUVXEPHUJHGFXOWXUHVSHDNHGDWGD\FP2) 
DQGGURSSHGWREHORZFP2 after day 12 until the end of the time course.  In 
comparison, cells cultured in scM at the AL interface produced tEEr values above 
FP2 after day 8 in culture and this was maintained up until the end of the 21 
day monitoring period.
rL-65 cells cultured in the primary supplemented medium (PsM) produced significantly 
higher (p<0.01) tEEr values after day 7 when cultured under submerged conditions 
)LJXUH&+RZHYHUQHLWKHUFRQGLWLRQSURGXFHG7((5YDOXHV!FP2 for 
the duration of the experiment deeming the cell layers less suitable for use as a 
permeability screening tool.  reduction of the seeding density did not significantly 
(p>0.01) increase the tEEr for rL-65 cultured in PsM (Figure 3.3c).  For this reason, 
rL-65 cells cultured in this medium were not characterised further.
reduction of the seeding density for rL-65 cells cultured in sFM delayed the maximum 
tEEr value from 8 days with cells seeded at 1 x 105 cells/cm2, to 10 days for cells 
seeded at 5 x 104 and 1 x 104 cells/cm2 (Figure 3.3A).  Altering the seeding density did 
not significantly increase (p>0.01) the maximum tEEr values reached by the cells 
cultured in sFM.  In contrast, rL-65 cells cultured in scM seeded at 1 x 105 cells/cm2 
had significantly higher (p<0.01) tEEr values after day 6 in culture than cells seeded 
at 1 x 104 cells/cm2, and after day 12 when compared to cells seeded at 5 x 104 cells/
cm2 (Figure 3.3b).  
the following culture conditions were selected due to their proven ability to produce 
7((5YDOXHV!FP2, in line with tEEr for existing cell layers used as permeability 
screening tools:  
 rL-65 cultured in sFM for 8 days at an AL interface
 rL-65 cultured in scM for 8 days at an AL interface
 rL-65 cultured in scM for 21 days at an AL interface
Additionally, as reducing the seeding density did not increase the tEEr values for rL-
65 cells all experiments hereafter all rL-65 cells were seeded on transwell® inserts 
using the seeding density 1 x 105 cells/cm2. 
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Figure 3.3.  Impact of seeding density on TEER profiles on RL-65 cells 
tEEr profiles for rL65 cells at passage 6 grown on 12 well transwell® inserts up to 21 days 
and cultured in (A) serum free medium (sFM), (b) serum containing medium (scM) and (c) 
SULPDU\VXSSOHPHQWHGPHGLXP360&HOOVZHUHVHHGHGDWGHQVLWLHVRIż[5 cell/cm2, 
(Ɣ) 5 x 104 cell/cm2RUƔ[4 cell/cm2. 
 
results were adjusted for the resistance of the filter 
and normalised to the area of the insert.  Data are represented as mean ± sd of 4-6 cell layers. 
** indicates a significant difference (p<0.01) between the tEEr value of rL-65 cells cultured 
at 1 x 105 cells/cm2 and 1 x 104 seeding densities from day 6, and between 1 x 105 and 5 x 104 
cell/cm2 seeding densities after 14 days.
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Apparent paracellular permeability (P
app
) values for the established paracellular marker 
14c-mannitol for all human and rat models are shown in table 3.1.  In all models 
tested, the P
app
 was in the range expected for a confluent cell layer with functional tight 
junctions.  there was no significant difference (p>0.01) between absorptive (Ab) and 
secretory (bA) paracellular transport of 14c-mannitol for any of the models tested.
With regards to the human models, there was no significant impact (p>0.01) of 
passage number on 14c-mannitol P
app
 for either calu-3 or NHbE cells.  Moreover, 
there was no significant difference (p>0.01) in paracellular permeability between the 
two different human cell models.  14c-mannitol P
app
 values for rL-65 cells cultured for 
21 days at an AL interface in scM were not significantly different (p>0.01) from either 
calu-3 or NHbE cell values.  rL-65 cells cultured in scM for 8 days generated 14c-
mannitol P
app
 values approximately 3 times greater than at 21 days and cells cultured 
in sFM produced 14c-mannitol P
app
 values in the order of 2 times greater magnitude 
than their scM cultured counterpart.
An inverse correlation (r2 = 0.9658) was observed between post-experimental tEEr 
value and 14c-mannitol P
app
 in rL-65 cells cultured at the AL interface in scM and 
sFM (Figure 3.4).  therefore, tEEr may be used as an indicator of paracellular 
permeability in the rL-65 cell model.  Furthermore, from this correlation, rL-65 tEEr 
YDOXHV!FP2 would be predicted to generate 14c-mannitol P
app
 < 1 x 10-6 cm/s 
in line with observed values for calu-3 and NHbE cells.
All in vitro models stained positive for protein expression of the tight junction protein 
zona occludens protein-1 (ZO-1) (Figure 3.5A-E).  the location of the ZO-1 protein 
was identical to that of the positive control MDckII cells (Figure 3.5F) where nuclei 
were counterstained in red and the tight junction protein ZO-1 shown in green forming 
a continuous stain around the perimeter of each cell.  regions where the ZO-1 appears 
discontinuous in the bronchial epithelial samples are indicative of areas where cells 
have a less uniform height and hence the tight junction proteins do not appear in the 
same plane.  
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Figure 3.4.  Relationship between post-experimental TEER value and 14C-mannitol 
apparent permeability (P
app
) for RL-65 cell culture models
the tEEr values for rL-65 cells harvested after either 8 or 21 days and cultured at the 
AL interface in either scM or sFM were plotted against their 14c-mannitol P
app
 value. tEEr 
values were adjusted for the resistance of the filter and normalised to the area of the insert.  A 
strong inverse correlation (r = 0.9658) with power regression was found between tEEr value 
and 14c-mannitol P
app
. 
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Figure 3.5. Immunocytochemical detection of the tight junction protein zona  
occludens 1 (ZO-1) 
Immunocytochemical (Icc) staining of 3.7% w/v paraformaldehyde fixed (A) low passage 
calu-3 cells, (b) high passage calu-3 cells, (c) NHbE cells at passage 2, all cultured for 21 
days and (D) rL-65 cells cultured in sFM for 8 days, (E) rL-65 cells cultured in scM for 8 
days and (F) MDckII cells cultured for 5 days (positive control) on transwell® inserts at the 
AL interface.  the tight junction protein, ZO-1 is labelled with a FItc-secondary antibody tag 
shown in green and nuclear components are counter stained with propidium iodide and shown 
in red.  Images represent a  1 µm transverse section of cell layer(s).  Images taken with x 63 
oil objective and 1 x optical zoom with an average of 8 frames per image.
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the intensity and degree of ZO-1 staining was comparable between calu-3 cells 
cultured at low and high passage indicating the tightness of the junctions and 
permeability of the cell layer was unaffected by passage.  In the rL-65 samples, tight 
junctions between cells in the layer adjacent to the filter was observed.  the intensity 
and degree of staining was similar between cells cultured in scM and sFM for 8 
days.  this is in line with the tEEr values which were similar for the models at this 
time point.
3.3.2. Morphological characterisation
Haematoxylin and eosin histological staining of wax embedded 6 µm thick cross-
sections of calu-3 cells showed a 1-2 cell thick layer of columnar shaped cells 
(pseudostratified epithelium) for both low and high passage (Figure 3.6A and b).  In 
contrast NHbE cells cultured at passage 2 formed layers 2-3 cells thick (Figure 3.6c) 
and were more cuboidal in shape with oval nuclei.  NHbE cells cultured at passage 
3 adopted a multilayered epithelium (~8-10 layers) with flatter, more elongated, 
squamous morphology and thin, elongated nuclei.  rL-65 cells cultured in sFM for 8 
days had similar morphology and organisation to passage 2 NHbE cells.  In contrast, 
rL-65 cells cultured in scM for 8 days formed a viable cell layer 1-3 cells thick 
adjacent to the filter, below a ~5 µm thick layer of pink/purple eosin stained material 
containing no viable cells.  After 21 days cultured in scM the non-viable apical layers 
had extended to a multilayer ~30 µm thick and viable rL-65 cells formed a flatter 
single layer of cells, ~3 µm in height, adjacent to the filter.
small cylindrical appendages <0.5 µm diameter protruding from the apical surface 
were observed for calu-3 cells cultured at the AL interface for 21 days at both low and 
high passage from sEM images (Figure 3.7 A-b).  NHbE cells also had a similarly 
but more densely textured apical cell surface as calu-3 cells but the presence of 
apical appendages was less obvious (Figure 3.7 c).  rL-65 cells cultured in both 
sFM and scM showed a heterogenous cell population where approximately 50% 
of the cells appeared to have a textured apical surface and the other half a darker, 
flatter appearance (Figure 3.7 D-E).  Higher magification images revealed thin, apical 
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Figure 3.6. Haematoxylin and eosin histological cell staining
Histological staining of wax embedded perpendicular 6 µm sections of (A) low passage calu-
3 cells, (b) high passage calu-3 cells, (c) NHbE cells at passage 2 and (D) NHbE cells at 
passage 3 all cultured for 21 days at the AL interface.  right hand images show (E) rL-65 cells 
cultured in sFM for 8 days, (F) rL-65 cells cultured in scM for 8 days and (g) rL-65 cells 
cultured in scM for 21 days, all grown at the AL interface.  Haematoxylin stained nuclei are 
shown in blue and eosin stained cytoplasmic components shown in purple/pink.  samples are 
orientated with the uppermost surface the apical side at the AL interface and the lowest side 
closest to the filter.
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Figure 3.7. Scanning electron microscopy images of Calu-3, NHBE and RL-65 cell 
layers
sEM images of calu-3 and NHbE cell layers cultured for 21 days, and rL-65 cells layer 
cultured for 8 days at the AL interface on 12 well transwell® inserts.  Human cell lines on the 
left are (A) calu-3 cells at low passage, (b) calu-3 cells at high passage and (c) NHbE cells 
passage 2.  rL-65 images on the right are (D,F) rL-65 cells cultured in sFM and (E,g) rL-65 
cells cultured in scM.  All images were taken at 30 kV with stage height of 10 mm with a x 
8000 magnification for images A-c, F and g and x 250 magnification for D-E.
72ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨĞůůDŽƌƉŚŽůŽŐǇĂŶĚĂƌƌŝĞƌ/ŶƚĞŐƌŝƚǇ
Figure 3.8:  Mucus staining using Alcian blue
Histological staining of wax embedded perpendicular 6 µm sections of (A) low passage calu-
3 cultured for 21 days, (b) high passage calu-3 cells cultured for 21 days, (c) NHbE cells at 
passage 2 cultured for 21 days, (D) rL-65 cells cultured in sFM for 8 days, (E) rL-65 cells 
cultured in scM for 8 days and (F) rL-65 cells cultured in scM for 21 days, all grown at the 
AL interface.  Alcian blue stained mucopolysaccharides are shown in blue and nuclei stained 
red with nuclear fast red.  samples are orientated with the uppermost surface the apical side 
at the AL interface and the lowest side closest to the filter.  Images g-L as A-F from an aerial 
view of the apical surface stained with alcian blue for mucopolysaccharide detection.
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appendages projecting from the apical cell surface.  In cells cultured in sFM (Figure 
3.7 F) the apical appendages were similar to those found in calu-3 cells.  In contrast 
the cells cultured in scM had spherical, more discrete structures on the surface 
(Figure 3.7 g), more sparse but similar in morphology to NHbE cells.
Alcian blue histological staining of wax embedded 6 µm thick cell cross-sections 
highlighted the presence of acidic mucopolysaccharides localised to the apical surface 
of all the human cell models tested (Figure 3.8A-c, g-I).  In comparison, no staining 
was observed on the apical surface of the rL-65 cross sectioned samples (Figure 3.8 
D-F) and only sparse staining less than 5% was observed on the apical surface when 
intact inserts were stained.
3.4. DIscUssION
3.4.1. calu-3 cell layers
In vivo, the upper airway epithelium is pseudostratified and predominantly comprises 
columnar shaped ciliated cells interspersed with goblet cells [McDowell et al., 1978; 
Mathias et al., 1996].  culture of calu-3 cells at the AL interface has been shown to 
generate a model which is more morphologically representative of the in vivo airway 
epithelium in comparison with submerged culture [grainger et al., 2006].  Furthermore, 
AL interface culture has been reported to produce calu-3 cell layers with a greater 
abundance of acidic mucopolysaccharides (mucin) and apical projections (microvilli 
or immature cilia) [Fiegel et al., 2003; grainger et al., 2006; sakagami, 2006].  cells 
have also been reported to form a thicker (20-45 µm), more pseudostratified layer 
and possess a more columnar morphology in comparison with submerged culture 
[grainger et al., 2006].  these morphological features were demonstrated in both low 
and high passage calu-3 cells, indicating a good morphological correlation with both 
established in vitro calu-3 cell culture and in vivo bronchial epithelial cells.  
calu-3 cells demonstrate the closest morphological resemblance to in vivo bronchial 
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epithelium than other bronchial epithelial cell lines (16HbE14o- and bEAs cells) and NHbE 
cells.  this is important in permeability modelling as the barriers to permeability (mucus 
layer, number of plasma membranes, epithelium thickness) will be a closer representation 
of the in vivo environment potentially providing a more accurate in vitro model.  Furthermore 
the morphological properties of the cell line do not appear to alter substantially between low 
and high passage cells, indicating calu-3 cell layers can be reliably used to morphologically 
model the bronchial epithelium over a wide passage range (25-50).
tEEr is a measure of the resistance to the movement of an applied electric current 
across cell layers, and as such can be used to give an indication of confluency and 
formation of functional tight junctions between cells in polarised cell layers in vitro. 
A range of tEEr values for calu-3 cells cultured at the AL interface have been 
UHSRUWHG>6DNDJDPL@7((5YDOXHVEHWZHHQFP2 were reported for 
passages 38-53 between 11 and 21 days in culture [grainger et al., 2006; Madlova 
et al., @ZKHUHDVKLJKHU7((5YDOXHVFP2) have been published for 
calu-3 cells between passages 38-56 measured at days 8-10 [Ehrhardt et al., 2002; 
borchard et al., 2002; Fiegel et al., @+LJKHU7((5YDOXHVRIFP2 
have also been documented for calu-3 cells at a lower passage range (20-40) after 
8-16 days in culture [Mathias et al., 2002]. the calu-3 tEEr values measured after 
GD\VLQ$/LQWHUIDFHFXOWXUHLQWKHVHVWXGLHVZHUHFP2 and 722 ± 121 
FP2 for low and high passage calu-3 cells respectively.  these are in line with the 
published findings discussed above for AL interface culture at comparable passage 
numbers.  tEEr is likely to decrease with passage number given the biological ageing 
of calu-3 cells with multiple passaging.  senescence of calu-3 cells occurs after 
~55 passages in culture, thereafter cell layers lose the ability to form functional tight 
MXQFWLRQVDFFRPSDQLHGE\DUHGXFWLRQLQ7((5WRFP2 (personal observation). 
Additionally, the plateau in tEEr observed after day 6 - 10 in culture was in agreement 
with published work indicating the cells have become confluent with functional tight 
junctions at this time point [Foster et al., 2000; Ehrhardt et al., 2002; Fiegel et al., 
2003; grainger et al., 2006].  the presence of tight junctions was confirmed in both 
passage ranges of calu-3 cells tested and localisation was also in agreement with 
published literature [grainger et al., 2006].  
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there are several established marker compounds used to determine paracellular 
transport in in vitro cell culture models.  Examples of these include 14c-mannitol, 
Lucifer yellow and fluorescein sodium which all possess suitable physico-chemical 
properties (low molecular weight, hydrophilicity) to be predominantly transported via 
the paracellular pathway.  14c-mannitol was selected due to the ease of sampling, high 
degree of analytical accuracy and ease of analysis alongside other radiation transport 
experiments described in future chapters.  Paracellular P
app
 for calu-3 cells was in a 
similar range to other published studies, which have reported 14c-mannitol P
app
 for 
cells between passage 20-40 after 8-16 days in culture as 0.14 x 10-6 cm/s [Mathias et 
al., 2002], 0.28 x 10-6 cm/s after 21 days in culture [Madlova et al., 2010] and sodium 
fluorescein P
app
 at passage 38-56 after 8 days as 0.22 x 10-6 cm/s [Fiegel et al., 2003]. 
this indicates calu-3 cells cultured by our methodology produce suitably polarised 
cell layers on which to conduct permeability experiments and are comparable with the 
calu-3 cell model described in literature.  
Despite the variation in tEEr for calu-3 cells at different passage number, the 
permeability of paracellular marker 14c-mannitol was not statistically different (p>0.05) 
between low (0.35 ± 0.18 x 10-6 cm/s) and high passage (0.49 ± 0.24 x 10-6 cm/s) calu-
3 cell layers.  this is in accordance with literature where no significant difference in 
the flux of the paracellular marker Lucifer yellow was observed once resistance of the 
&DOXPRQROD\HUZDV!FP2 [Foster et al., 2000] and similarly for fluorescein 
VRGLXPDIWHU7((5!FP2 [Moebius et al., 2001].  this suggests that cell layers 
ZLWK 7((5 ! FP2 have reached 100% confluency, forming polarised layers 
with functional tight junctions between adjacent cells.  As passage number had no 
significant (p>0.05) impact on paracellular transport across calu-3 cell layers in these 
studies, any differences observed in substrate permeability between low and high 
passage cells may largely be attributed to the differences in transcellular transport 
mechanisms.  However, given the range of 14c-mannitol P
app
 observed, paracellular 
permeability of Ab and bA datasets for each transport condition should still be carefully 
considered to ensure differences in substrate trafficking are not caused by variations 
in cell layer integrity.  
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However, although no statistical difference (p>0.05) was observed for 14c-mannitol 
P
app
 at different passage number, the range at low passage (0.13 – 0.75 x 10-6 cm/s) 
and high passage (0.26 – 1.33 x 10-6 cm/s), together with the statistical difference in 
tEEr indicates a reduction in cell layer integrity with increasing passage.  similarly, 
FRQVLGHUDEOHLQWHUODERUDWRU\YDULDWLRQLQ7((5a±FP2) and 14c-mannitol 
P
app
 (0.09 – 0.61 x 10-6 cm/s) was reported for calu-3 cells cultured at the AL interface 
[Forbes and Ehrhardt., 2005; sakagami, 2006].  this disparity in the literature may be 
partly due to the different passage ranges used and time in culture when tEEr was 
reported.  Furthermore, differences in seeding density, coating of the culture surface, 
medium composition, batch variation of serum and modifications of general culture 
procedures are also likely to play a role in the variability of tEEr and paracellular 
P
app
 in calu-3 cells.  this interlaboratory variation in markers for barrier formation 
makes it difficult to reliably and meaningfully compare permeability data in calu-3 
from different laboratories.  If calu-3 cells are to be employed as the ‘gold standard’ 
in vitro model for the bronchial epithelium then a drive towards a standardised in vitro 
culture methodology is required.
3.4.2. NHbE cell layers
NHbE primary cells were cultured in the Lonza proprietary serum free medium b-ALItM 
designed to promote full differentiation of the airway epithelium indicated by barrier 
function (tEEr), secretory phenotype (mucin production) and ciliogenesis [https://
shop.lonza.com/shop/prd/b-ali-bronchial-air-liquid-interface-me/].  this growth factor 
and hormone supplemented medium composition is based on the defined medium 
developed for primary bronchial epithelial cells and first described by Lechner and co-
workers [Lechner et al., 1982] and is similar in composition to the majority of media 
reported to be used in the culture of primary bronchial epithelial cells [Mathias et al., 
1996].  A defined, serum-free medium is used to culture NHbE cells as serum has 
been found to inhibit cell growth [Wu et al., 1982] and affect the electrical properties 
of the cell layers [Yamaya et al., 1992].  
culturing primary bronchial epithelial cells on a collagen substratum at the AL interface 
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has also been shown to elevate the bioelectrical properties of cell layers [robinson 
et al., 1993; Johnson et al., 1993].  collagen provides a 3D scaffold that possesses 
several physical and biological characteristics to allow improved cell growth and 
differentiation in comparison with 2D tissue culture plastic.  It provides biological motifs 
for cell interaction, a flexible fibrous network of fibres offering a degree of movement in 
the system and the 3D environment allows more effective nutrient exchange [Ingber 
and Folkman, 1989a].  Published tEEr values for passage 2 NHbE cells cultured in 
bronchial epithelial cell basal medium (bEbM):DMEM/F12 (50:50) were 1117 ± 293 
FP2 after 21 days in culture [Madlova et al., @DQGFP2 after day 
8 when cultured in bEgM:DMEM/F12 (50:50) [Lin et al., 2007] compared with 1146 ± 
FP2 after 21 days in these studies.  In agreement with literature, a plateau for 
tEEr was reached after day 6-8 in culture indicating the formation of functional tight 
junctions between cells that had reached 100% confluency on the inserts [Lin et al., 
2007].  
Paracellular P
app
 for the marker 14c-mannitol in NHbE cells at passage 2 produced P
app
 
values of 0.55 ± 0.21 x 10-6 cm/s in these studies in line with an acceptable paracellular 
permeability range published from 0.35 ± 0.09 x 10-6 cm/s to 1.16 ± 0.38 x 10-6 cm/s 
for passage 2, 21 day old NHbE cells [Madlova et al., 2009].  the tEEr and 14c-
mannitol P
app
 data obtained for NHbE cultured in b-ALItM medium were comparable 
to those reported for NHbE cells cultured in different media types, indicating that the 
model has suitable barrier properties for use as a permeability screening tool.  
Inter-laboratory variability in tEEr values reported for NHbE cell layers was less 
than for calu-3 cell layers, albeit fewer reports are available in the literature.  similar 
problems regarding medium supplementation as described for calu-3 cells also apply 
to NHbE cell culture, although the availability of standardised culture kits from NHbE 
cell suppliers may alleviate this problem.  Although the 14c-mannitol P
app
 did not vary 
considerably between NHbE samples in this study, other investigations have reported 
a 3-fold difference in paracellular P
app
 for NHbE cell layers from the same donor 
[Madlova et al., 2009].  this suggests the barrier properties of NHbE cell layers are 
innately variable even when cultured at the same passage with identical methodology. 
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this range in paracellular P
app
 would be likely to impact permeability screening of 
compounds in NHbE cells, making the model less desirable.
culturing NHbE cells at the AL interface has also been reported to stimulate 
differentiation to a more in vivo like phenotype [Mathias et al., 1996].  NHbE cells require 
an AL interface for the formation of more columnar cell morphology and ciliogenesis 
[de Jong et al., 1994] which has also been replicated in rabbit and rat tracheal epithelial 
in vitro models [kaartinen et al., 1993; Mathias et al.,1995].  However, in other studies, 
NHbE cells have been shown to display secretory and ciliated phenotypes without 
the presence of a collagen substratum [stewart et al., 2011].  Passage 2 NHbE cells 
cultured for 21 days at the AL interface in these studies produced 2-3 layers of cuboidal 
shaped cells in agreement with published literature [kampf et al., 1999; ketterer et al., 
1999; Lehmann et al., 2009].  cilia were not identified clearly, but this may be due to 
either a thicker layer of mucus or more dense clusters of apical appendages on the 
apical cell surface of NHbE cells in comparison with calu-3 cells.  the production 
of mucopolysaccharides in primary tracheobronchial epithelial cells has been well 
established [Jetten et al., 1982; Wu et al., 1990] which when analysed from human 
tracheobronchial epithelial cell cultures was found to have a similar composition to 
sputum [Wu et al., 1990]  
In contrast with passage 2, the flattened, elongated, multi-layered (8-10 layers) 
appearance of NHbE cells at passage 3 was not morphologically representative of 
the bronchial epithelium and not in line with literature.  Potential causes may include 
differentiation of the cells away from bronchial epithelial phenotype or, more likely due 
to the cells reaching early senescence as a result of primary cell origin.  
the cuboidal morphology of NHbE cells is not morphologically representative of the 
columnar ciliated and goblet cells found in the bronchial epithelium in vivo and in calu-
3 cell layers.  the decreased height of NHbE cell layers may not provide as accurate 
a barrier to mimic bronchial epithelial permeability as other models.  Additionally, as 
a consequence of the altered morphology observed for passage 3, NHbE cells could 
only reliably be used up to passage 2, despite unchanged tEEr and paracellular P
app 
79ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨĞůůDŽƌƉŚŽůŽŐǇĂŶĚĂƌƌŝĞƌ/ŶƚĞŐƌŝƚǇ
at passage 3.  this would suggest that tEEr and 14c-mannitol permeability data may 
be unreliable controls for NHbE cell layers, and may explain the variability of the model 
reported in literature [Madlova et al., 2009].  this data also suggests that NHbE cells 
provide a window of only one passage in which they maintain physiological relevance 
and are suitable for functional studies, limiting the number of experiments per donor 
and making them less economically viable than other in vitro models.  Additionally 
variability between donor NHbE cells is likely, making the interpretation of functional 
studies more complex between different batches.
3.4.3.  rL-65 cell layers
In agreement with published findings the PsM supplemented with growth factors and 
hormones optimised for human bronchial epithelial cells was found to be suboptimal 
for rL-65 growth and development for the production of polarised cell layers [roberts 
et al., 1990], reflected by the tEEr profile.
Published tEEr values for rL-65 cells cultured in submerged conditions on 24 well 
transwell®LQVHUWVZHUHaFP2 after 6 days in culture [Wang et al., 2009] in line 
ZLWKWKH7((5YDOXHVFP2) measured at the same time point for rL-65 
cells cultured in sFM under submerged conditions in these studies.  the tEEr range 
IRU5/FXOWXUHGDWWKH$/LQWHUIDFHIRUGD\VLQ6)0±FP2) and for 
6&0FP2) is lower than the tEEr values obtained for calu-3 and NHbE 
cells found in these studies but in line with calu-3 cells [grainger et al., 2006; Madlova 
et al., 2009] and NHbE cells [Lin et al., 2007] cultured at the AL interface in other 
published work.
rL-65 is a normal immortalised rat airway cell line and comparison with a human 
normal immortalised bronchial epithelial cell line such as 16HbE14o- may be more 
appropriate than with cancerous (calu-3) or primary cell (NHbE) in vitro models. 
similarly to calu-3, a range of tEEr values have also been reported for 16HbE14o- 
FHOOVFXOWXUHGDWWKH$/LQWHUIDFH$7((5RIFP2 after 17 days in culture 
of cells between passage 47-78 [Ehrhardt et al., @DQGFP2 for cells 
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between passage 15-48 after 6 days in culture [Forbes et al., 2003] have been 
reported.  these values are in a similar range to tEEr values recorded for the rL-
65 cell line.  Paracellular P
app
 values for 14c-mannitol reported in 16HbE14o- cell 
layers (3.20 x 10-6 cm/s [Forbes 2000], 2.36 x 10-6 cm/s [Forbes et al., 2003]) are also 
comparable to the values generated by rL-65 cells cultured in sFM (3.09 ± 0.36 x 
10-6 cm/s) and scM (1.85 ± 0.35 x 10-6 cm/s) for 8 days.  this suggests that although 
rL-65 cell layers possess a more permeable epithelial barrier than calu-3 and NHbE 
cells, barrier properties are similar to the transformed human bronchial epithelial cell 
line 16HbE14o-.  As 16HbE14o- cell layers have been shown to possess suitable 
barrier characteristics to model bronchial epithelial permeability, this also indicates 
the suitability of rL-65 cell layers as an in vitro model for permeability screening.
An inverse correlation between 14c-mannitol P
app
 and tEEr values has been observed 
for both calu-3 and 16HbE14o- [sakagami, 2006].  However, this correlation is 
absent in some cell lines including the widely used canine kidney epithelial cell line 
MDckII, which demonstrates paracellular P
app
 <1.5 x 10-6 cm/s (in agreement with the 
formation of confluent cell layers with functional tight junctions) despite tEEr values 
RIaFP2 [Hansson et al., 1986; Wan et al., 2000].  studies have also shown 
that equivalent amounts of tight junction protein per unit area of monolayer were 
produced in comparison with the MDckI cell line which generates tEEr readings of 
aFP2 [Hansson et al., 1986; stevenson et al., 1988].  Additionally, overall tight 
junction organisation and the number and density of junctional fibrils and ZO-1 protein 
were shown to be similar between the MDckI and MDckII cell lines [stevenson et al., 
1988].  It has been postulated that MDckII cells, which possess more proximal tubule 
epithelial characteristics are likely to have more numerous and different ion channel 
characteristics to those present in MDckI cells (thought to be of distal tubule origin) 
and other epithelial cell lines [stevenson et al., 1988; svennevig et al., 1995].  the 
presence of ion channels, able to traffic Na+, k+, cl- and other organic cations may 
account for the low tEEr readings despite the presence of functional cell junctions 
[stevenson et al., 1988].  In contrast, rL-65 cell layers cultured at the AL interface 
follow a similar trend as other bronchial epithelial cell models, permitting tEEr to 
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be used as an indicator of barrier integrity, formation of functional tight junctions and 
paracellular permeability.
Although intra-passage variability in tEEr for rL-65 cells layers is low, the variability 
in tEEr values for rL-65 cell layers at different passage numbers is more apparent. 
the range for tEEr for rL-65 cells cultured at the AL interface in sFM for 8 days 
±FP2) corresponds to a 14c-mannitol P
app
 ~1 – 2 x 10-6 cm/s.  similar 
to other in vitro models, this variability may be problematic if using the model as a 
permeability screening tool with numerous substrates across multiple passages and 
the permeability of the paracellular marker control compounds should be carefully 
considered when interpreting the data. 
the presence of tight junction proteins, particularly ZO-1 and occludin has been well 
established for calu-3 cell layers [Foster et al., 2000; Wan et al., 2000; Ehrhardt et 
al., 2002; grainger et al., 2006].  the formation of tight junctions in the rL-65 cell line 
however is less well established.  research by Wang and co-workers focussed on the 
impact of specific oncogenes on the cell junctions between rL-65 cells.  this work 
highlighted the presence of adherens junctions between rL-65 cells and suggested 
WKHIRUPDWLRQRIWLJKWMXQFWLRQVZLWKPHDVXUHDEOH7((5aFP2 and the presence 
of ZO-1 protein [Wang et al., 2009].  this work also supports the presence of tight 
junctions in rL-65 with the addition of visual confirmation with Icc images detecting 
the ZO-1 protein localised around the circumference of cells where the tight junctions 
would be anticipated.  
culturing rL-65 cells in a serum based medium (scM) has previously demonstrated 
an overgrowth of fibroblastic cell types [roberts et al., 1990].  rL-65 cells cultured at 
the AL interface for 8 days produced cuboidal basal cells covered by 2-3 layers of non-
viable, squamous cells.  by 21 days in scM culture at the AL interface the epithelium 
had become more stratified (10-15 layers) resembling a stratified squamous epithelium 
with the only viable cells being the layer closest to the basal side.  this structure also 
resembles reports in literature which demonstrated that rL-65 cells cultured in scM 
for >8 days become more stratified and so highly keratinised that the apical cells 
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die [roberts et al., 1990].  Furthermore, studies by Ehrhardt and colleagues also 
demonstrated a multi-layered morphology (10-16 layers of cells displaying squamous 
metaplasia) for 16HbE14o- cell layers when cultured at an AL interface for 18 days 
[Ehrhardt et al., 2002].  However, the apical cell layers of 16HbE14o- contained viable 
cells, in contrast to the non-viable apical cell layers of rL-65 cells cultured at an AL 
interface.  these studies confirm that scM is not suitable for optimal morphological 
development of rL-65 into polarised cell layers for a bronchial epithelial cell model. 
this is likely due to the presence of key hormones, growth factors or proteins present 
in the serum that direct the cells towards a fibroblast differentiation pathway.
rL-65 cells cultured in sFM have been shown to produce non-keratinised, densely 
packed colonies representative of squamous epithelium with cuboidal shaped basal 
cells and more squamous shaped apical cells [roberts et al., 1990].  When cultured 
in sFM at the AL interface up to 8 days, the rL-65 cell line appears to retain these 
morphological features which are also in agreement with primary rat tracheal epithelial 
cultures [kaartinen et al., 1993; clark et al., 1995].  
No staining of acidic mucopolysaccharides was observed for rL-65 cells in any 
culture conditions tested indicating no cells with a mucous secreting phenotype were 
present in the cell population.  Airway epithelial cells in vivo are protected by a layer 
of mucus [Fahy and Dickey, 2010].  similarly a protective apical barrier is likely to be 
required for in vitro cultures at the AL interface to maintain cell viability and to prevent 
cellular dehydration.  With the exception of rL-65 cells grown in scM, cells cultured 
at the AL interface after 21 days were non-viable and had detached from the filters 
whereas viable cell layers were present in submerged culture.  It has been reported 
that both rabbit and human tracheobronchial primary cells only express a mucocilliary 
function (ciliogenesis and mucin secretion) when cultured on a collagen substratum 
[Wu et al., 1990; kim, 1985].  the impact of a collagen substratum on epithelial cell 
growth was outlined previously in section 3.4.1.2 and the same factors apply for the 
culture of rL-65 cells.  this could provide a potential explanation for the absence of a 
mucous secreting phenotype in rL-65 cells cultured in these studies.  However, other 
studies have shown primary human bronchial cell layers produce mucin and express 
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on transwell® inserts in absence of collagen coating [stewart et al., 2011].  
Although rL-65 cells cultured for 8 days in sFM do not provide a model of the 
bronchial epithelium as morphologically as accurate calu-3 cells, they are no more 
inferior than other established human bronchial epithelial cell lines (16HbE14o- and 
bEAs-2b).  similarly to 16HbE14o- cells, rL-65 cells do not produce any secretory 
component and may have basal cell origin, but further studies are required to confirm 
this.  rL-65 cells can be cultured at an AL interface to form polarised cell layers with 
functional tight junctions and exhibit tEEr and paracellular permeability values in 
line with established human bronchial epithelial cell models.  In terms of the epithelial 
barrier characteristics, rL-65 cells are suitable to be used as a rat bronchial epithelial 
in vitro model for permeability screening of inhaled therapeutics.  
3.5. cONcLUsION
the development and characterisation of in vitro tools is crucial for understanding 
mechanisms of drug trafficking across epithelial barriers.  A rat bronchial epithelial in 
vitro screening tool may aid the understanding of differences between species and 
model complexity for in vitro human permeability testing and absorption studies in rat 
in vivo.  the overall impact would be to refine inhaled pharmacokinetic studies and 
prevent the attrition of candidate compounds that could potentially be of therapeutic 
use in humans.
this chapter has demonstrated that the culture conditions employed in these studies 
are suitable to generate operational human and rat airway epithelial cell layers for 
permeability modelling.  specifically, calu-3 and NHbE cells have been cultured up 
to 21 days producing confluent, polarised cell layers with morphological and barrier 
properties in agreement with the literature, and which mimic the bronchial epithelium 
in vivo.  No significant difference in cellular structure or barrier integrity was observed 
between calu-3 at low and high passage.  In contrast, although no significant difference 
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(p>0.05) was observed for barrier integrity of NHbE cell layers at passage 2 and 
passage 3, their morphological structure varied considerably and passage 3 cells 
were not representative of the bronchial epithelium in vivo, likely due to senescence. 
Different culture conditions for rL-65 cells were investigated and cells cultured at 
the AL interface for 8 days in sFM were found not to be inferior to existing human 
bronchial epithelial cell models (16HbE14o-, bEAs-2b).  rL-65 cell layers present 
a potential in vitro tool to aid the understanding of interspecies differences in 
bronchial epithelial permeability between rat and human.  Further characterisation 
of transporter mediated drug trafficking is required to assess whether rL-65 cells 
possess appropriate transcellular drug trafficking mechanisms to be used as an in 
vitro permeability screening tool.
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4. cHArActErIsAtION OF AtP-bINDINg cAssEttE (Abc)  
 trANsPOrtEr gENE AND PrOtEIN EXPrEssION
4.1. INtrODUctION
In chapter three, AL interface cultures of calu-3, NHbE and rL-65 cell models 
demonstrated the expression of functional tight junction proteins and paracellular 
permeability, comparable with that of native bronchial epithelium.  However, the 
majority of drug molecules delivered to the lung are either too hydrophobic or have 
an unsuitably large molecular weight for paracellular transport.  Hence the majority 
of drug molecules delivered to the lung are transported across epithelial barriers 
via transcellular pathways, namely passive diffusion, carrier mediated transport, 
endocytic processes or transport through pores [Hillery, 2001].  In the past decade, an 
increasing number of drug compounds have been shown to be trafficked across cell 
membranes via transporter mediated processes [Fromm and kim, 2011].  Additionally, 
recent reviews have postulated that the extent of carrier mediated drug trafficking has 
been underestimated and may play a more significant role in drug absorption than 
previously thought [Dobson and kell, 2008].  Whilst transporter expression is well 
characterised in other organs including the kidney, liver and gI tract, transporters in 
the lung and in particular the bronchial epithelium, which provides one of the major 
barriers to inhaled drug delivery, remains poorly characterised [bosquillon, 2010].
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gene expression of transporters may be used as a predictive tool for transporter 
expression [Hilgendorf et al., 2007].  DNA microarray [bleasby et al., 2006] and qPcr 
techniques [Langmann et al., 2003; Nishimura and Naito, 2005] have been used to 
determine gene expression profiles for Abc, sLc and sLcO transporters in a range 
of organ systems including airway tissue.  the bronchial epithelium constitutes less 
than 10% of all the cell types present in whole lung tissue [Hillery, 2001] and thus 
gene expression in whole lung tissue is unlikely to be representative of the bronchial 
epithelium.  to date no similar extensive profiling of transporter expression has been 
conducted on human bronchial epithelial tissue.  However, there are some studies 
that have investigated the gene expression of individual transporters in the bronchial 
epithelium [Lechapt-Zalcman et al., 1997; bréchot et al., 1998].
gene expression of Abc, sLc and sLcO for undifferentiated bronchial epithelial in vitro 
models (including calu-3, 16HbE14o- and NHbE cells) has been investigated using semi-
quantitative rt-Pcr [Endter et al., 2009].  the impact of culture conditions, length in culture 
and passage number have been shown to impact cell layer integrity and morphology of 
calu-3 [grainger et al., 2006], 16HbE14o- [Ehrhardt et al., 2002] and NHbE [Lin et al., 
2007] as highlighted in chapter three.  However, to date, no extensive gene profiling 
studies for Abc, sLc or sLcO transporters in bronchial epithelial cell cultures differentiated 
at an AL interface have been reported.  Additionally the impact of passage or length of the 
culture period on transporter gene expression has not been widely considered.  
Protein expression of individually investigated Abc transporters has been reported in 
human bronchial epithelial tissue samples [van der Valk et al., 1990; cordon-cardo 
et al., 1990; Lechapt-Zalcman et al., 1997; bréchot et al., 1998; scheffer et al., 2002;] 
primarily using immunohistochemistry.  the majority of this work has been focussed 
on cFtr with fewer studies also considering MDr1, MrP1-3 and bcrP expression 
and localisation.  However, the protein expression of other Abc transporters (MDr3, 
bsEP, MrP4-9) in human airway epithelial cells remains unknown.  Protein expression 
of Abc transporters (primarily MDr1) has also been investigated in bronchial epithelial 
in vitro models, namely calu-3 [Florea et al., 2001; Hamilton et al., 2001a; Patel et 
al., 2002; brillault et al., 2009], 16HbE14o- [Ehrhardt et al., 2003;] and NHbE cells 
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[Lehmann et al., 2001; Lehmann et al., 2005; torky et al., 2005].  However, conflicting 
reports concerning transporter expression and localisation are present in the literature 
and similarly to the work in chapter three, may be explained by differences in cell 
culture conditions including the length of culture period, medium composition and 
supplementation, and passage effects.
Information regarding the protein expression of sLc and sLcO transporters in tissues 
and in vitro cell models of the bronchial epithelium is even more limited.  However, 
apical localisation of Oct1-3 has been reported in ciliated airway epithelial cells [Lips 
et al., 2005] and OctN1 and OctN2 apical expression has been characterised in 
human tracheal epithelia and human primary upper airway epithelium differentiated 
at the AL interface [Horvath et al., 2007].  to date, limited reports exist regarding the 
protein expression, particularly of sLcO transporters for in vitro bronchial epithelial 
cell models [bosquillon, 2010].
4.2. AIMs
this chapter focuses on understanding gene expression of Abc, sLc and sLcO 
transporters in whole lung, airway epithelial tissue, and in vitro bronchial epithelial 
models.  based on this data, transporters were selected for protein expression 
characterisation.  specifically, the objectives were to:
 create a comprehensive portfolio of transporter gene expression in human lung 
tissues, and to consider the impact of smoking, chronic airway disease and 
regional tissue effects on expression levels
 characterise gene expression of selected Abc, sLc and sLcO transporters in 
bronchial epithelial cell models from chapter three and to compare and contrast 
expression levels between models and with literature
 Identify interspecies differences between rat and human gene expression of 
transporters in lung tissues and in vitro models
 characterise protein expression and localisation of selected transporters in 
bronchial epithelial in vitro models and compare with published literature.
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4.3. rEsULts
4.3.1. characterisation of transporter gene expression in the lung using Affymetrix 
microarray data
Affymetrix microarray chipset data were used to investigate gene expression profiles 
of Abc, sLc and sLcO transporters in various human lung tissue samples.  to 
enable data comparison between multiple probe sets, expression data was described 
in % quartiles, dependent on the number of probes determined as present within 
each probe set (see Appendix A), providing a confidence level of gene expression 
in each sample.  gene expression of Abc transporters in human tissue samples 
from healthy patients and those with airway disease are outlined in table 4.1.  In 
normal healthy lung, expression of Abcb4, Abcb11, Abcc2 and Abcc11 were 
negligible (0-25% present) whereas Abcc4, Abcc5, Abcc10 and Abcg2 were 
highly expressed (75-100% present).  Expression of Abcb1, Abcc1, Abcc3 and 
Abcc6 were inconsistent given conflicting gene expression data from multiple probe 
sets for the same transporter.  However, on average, Abcb1, Abcc3 and Abcc6 
had low expression (25-50% present) and Abcc1 was moderately expressed 
(50-75% present) in healthy lung.  
several variations for Abc transporter gene expression were observed with airway 
disease state.  In emphysema, both Abcc5 and Abcc10 had reduced expression. 
similarly, chronic inflammation (an associated symptom of emphysema) also had 
reduced expression for the same transporters, but additionally Abcc1 and Abcc3 
levels were elevated.  Furthermore, Abcc5, Abcc10 and Abcg2 expression levels 
were reduced in cystic fibrosis lungs, whereas Abcb1, Abcb4 and Abcc3 gene 
expression levels were enhanced.  conversely in asthmatic lung samples, Abcb1, 
Abcb4, Abcc1 and Abcc10 gene expression was reduced but Abcc3 levels 
elevated in one out of three probe sets, in comparison with healthy lung tissue.  
gene expression profiles for sLc and sLcO transporters in human samples of healthy 
and diseased lung tissue are shown in table 4.2.  Negligible gene expression (0-
25% present) for sLc21A1, sLcO21A2 and sLc21A6-9 transporters was observed 
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for normal, healthy lung samples.  In contrast, sLc22A3 was moderately expressed 
(50-75% present) and sLc22A4 and sLc22A5 were highly expressed (75-100% 
present).  Whilst sLcO1A2 and sLcO1b1 had negligible expression (0-25% present) 
sLcO1c1, sLcO2b1, sLcO3A1 and sLcO4A1 were all moderately expressed (50-
75% present) although the multiple probe sets analysed for sLcO3A1 and sLcO4A1 
generated variability in expression levels. 
the impact of smoking and emphysema on Abc, sLc and sLcO transporter gene 
expression is assessed in more detail in tables 4.3 and 4.4.  sLcO1c1 expression was 
reduced in both smoker subgroups but levels returned to those found in healthy non-
smokers in both the ex-smoker subgroups.  similarly Abcc10 was also reduced in smoker 
subgroups but expression returned to normal levels only in the emphysema ex-smoker 
subgroup.  conversely, sLcO4A1 expression was increased in smoking and further 
enhanced in emphysema.  In general, reduced sLcO2b1 and sLcO3A1 expression 
was associated with current smokers and ex-smokers.  An increase in gene expression 
was observed in Abcb1 for current smokers with emphysema whereas Abcc5 levels 
were reduced.  both Abcc1 and Abcc3 expression were enhanced in the lungs of ex-
smoker emphysema patients relative to normal healthy lung tissue of non-smokers.  
A comparison of Abc transporter gene expression levels in different lung regions is 
outlined in table 4.5.  In agreement with data for whole lung, expression levels for 
Abcb4, Abcb11, Abcc2 and Abcc11 were negligible (0-25% present).  similarly, 
the 2 probe sets for Abcc6 that detected negligible expression (0-25% present) in 
whole lung detected the same levels in tissues from the bronchus and larynx.  Abcb1, 
Abcc1, Abcc5, Abcc10 and Abcg2 had lower expression in the bronchus compared 
with whole lung whilst no difference in expression level was observed for Abcc3 and 
Abcc4.  the larynx had similar expression levels to the whole lung and bronchus 
with the exception of Abcc4 and Abcg2 which had lower expression levels.  Abc 
transporter expression for bronchus shared some similarity with expression levels in 
large airway epithelium (table 4.6).  However, gene expression of Abcb1, Abcc1 and 
Abcg2 was lower in large airway epithelial tissue whereas Abcc3, Abcc5, Abcc6 
and Abcc10 levels were higher in comparison with expression in the bronchus.
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1
ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdƌĂŶƐƉŽƌƚĞƌ'ĞŶĞĂŶĚWƌŽƚĞŝŶǆƉƌĞƐƐŝŽŶ
'ĞŶĞŽĚĞ dƌĂŶƐƉŽƌƚĞƌ WƌŽďĞ/ EŽƌŵĂů ŵƉŚĂƐĞŵĂ ƐƚŚŵĂ ŚƌŽŶŝĐ/ŶŇĂŵŵĂƟŽŶ
ǇƐƟĐ
&ŝďƌŽƐŝƐ
^> ? ? ? Kd ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ?
^> ? ? ? Kd ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
^> ? ? ? Kd ?  ? ? ? ? ? ? YĂƚ A?A? A?A? A? A?A? A?A?
^> ? ? ? KdE ?  ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
^> ? ? ? KdE ?  ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
^> ? ? ? Kd ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ? ? ? ? ? ? ? Yǆ YĂƚ  ?  ?  ?  ?  ?
^> ? ? ? Kd ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ?
^> ? ? ? ? Kd ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ? ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YĂƚ A?A? A?A? A?A? A?A? A?A?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YƐ YĂƚ A?A? A?A?  ? A? A?A? ? ? ? ? ? ? YƐ YĂƚ A?A? A?A? A? A?A?A?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YƐ YĂƚ A?A? A?A? A?A? A?A? A?A? ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A? A?A? A?A?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YƐ YĂƚ A? A?A?  ? A? A?A?A? ? ? ? ? ? ? YƐ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
dĂďůĞ ? ? ? ?/ŵƉĂĐƚŽĨůƵŶŐĚŝƐĞĂƐĞŽŶŐĞŶĞ
ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ ŽĨ ƐŽůƵƚĞ ůŝŶŬĞĚ ĐĂƌƌŝĞƌ
ƚƌĂŶƐƉŽƌƚĞƌƐ ?^>ĂŶĚ^>K ?
'ĞŶĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ ƐĞůĞĐƚĞĚ ^> ĂŶĚ
^>KƚƌĂŶƐƉŽƌƚĞƌƐŝŶŶŽƌŵĂůĂŶĚĚŝƐĞĂƐĞĚ
ŚƵŵĂŶǁŚŽůĞůƵŶŐƟƐƐƵĞ ?ĂƚĂǁĂƐŵŝŶĞĚ
ĨƌŽŵīǇŵĞƚƌŝǆŐĞŶĞĐŚŝƉh ? ? ?ĂŶĚŐĞŶĞ
ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ ŐƌŽƵƉĞĚ ŝŶƚŽ ƋƵĂƌƟůĞƐ
ĚĞƐĐƌŝďŝŶŐA?ƉƌĞƐĞŶƚ ?ƉĞƌĐĞŶƚĂŐĞŽĨƉƌŽďĞƐ
ƚŚĂƚǁĞƌĞŝĚĞŶƟĮĞĚĂƐƉƌĞƐĞŶƚŝŶƚŚĞƉƌŽďĞ
ƐĞƚ ?ƐĞĞƉƉĞŶĚŝǆ ZĂƐĨŽůůŽǁƐ P R ? ? ? ? ? ?A?
 ?ŶĞŐůŝŐŝďůĞ Z ?  RA㴃?  ? ? ? ? ?A?  ?ůŽǁ Z ?  RA?A㴃?  ? ? ? ? ?A?
 ?ŵŽĚĞƌĂƚĞ Z ? RA?A?A㴃? ? ? ? ? ? ?A? ?ŚŝŐŚ Z ?^ĂŵƉůĞ
ƉŽƉƵůĂƟŽŶƐŝǌĞƐǁĞƌĞ  ? ?ŶŽƌŵĂů ůƵŶŐ ?  ? ?
ĞŵƉŚǇƐĞŵĂ ůƵŶŐ ?  ? ĂƐƚŚŵĂ ?  ? ? ĐŚƌŽŶŝĐ
ŝŶŇĂŵŵĂƟŽŶĂŶĚ ?ĐǇƐƟĐĮďƌŽƐŝƐ ?
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2
ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdƌĂŶƐƉŽƌƚĞƌ'ĞŶĞĂŶĚWƌŽƚĞŝŶǆƉƌĞƐƐŝŽŶ
ŵƉŚǇƐĞŵĂ>ƵŶŐ dĂďůĞ   ? ? ? ?  /ŵƉĂĐƚ ŽĨ ƐŵŽŬŝŶŐ ŽŶ ŐĞŶĞĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ ŽĨ dW ďŝŶĚŝŶŐ ĐĂƐƐĞƩĞ
 ? ?ƚƌĂŶƐƉŽƌƚĞƌƐ
'ĞŶĞĞǆƉƌĞƐƐŝŽŶŽĨƐĞůĞĐƚĞĚƚƌĂŶƐƉŽƌƚĞƌƐ
ŝŶŶŽƌŵĂůĂŶĚĚŝƐĞĂƐĞĚŚƵŵĂŶǁŚŽůĞ ůƵŶŐ
ƟƐƐƵĞ ?  ĂƚĂ ǁĂƐ ŵŝŶĞĚ ĨƌŽŵ īǇŵĞƚƌŝǆ
ŐĞŶĞĐŚŝƉh ? ? ?ĂŶĚŐĞŶĞĞǆƉƌĞƐƐŝŽŶůĞǀĞůƐ
ŐƌŽƵƉĞĚŝŶƚŽƋƵĂƌƟůĞƐĚĞƐĐƌŝďŝŶŐA?ƉƌĞƐĞŶƚ
 ?ƉĞƌĐĞŶƚĂŐĞŽĨƉƌŽďĞƐ ƚŚĂƚǁĞƌĞ ŝĚĞŶƟĮĞĚ
ĂƐƉƌĞƐĞŶƚ ŝŶƚŚĞƉƌŽďĞƐĞƚ  ?ƐĞĞƉƉĞŶĚŝǆ
 Z ĂƐ ĨŽůůŽǁƐ P  R ? ?  ? ? ? ?A?  ?ŶĞŐůŝŐŝďůĞ Z ?  RA㴃?  ? ? ?
 ? ?A?  ?ůŽǁ Z ?  RA?A㴃?  ? ? ? ? ?A?  ?ŵŽĚĞƌĂƚĞ Z ?  RA?A?A㴃?
 ? ? ? ? ? ?A?  ?ŚŝŐŚ Z ?  ^ĂŵƉůĞ ƉŽƉƵůĂƟŽŶ ƐŝǌĞƐ
ĨŽƌ ŚĞĂůƚŚǇ ůƵŶŐ ǁĞƌĞ  ? ? ŶŽŶ ?ƐŵŽŬĞƌ ?  ? ?
ƐŵŽŬĞƌ ?  ? ? Ğǆ ?ƐŵŽŬĞƌ ĂŶĚ ĨŽƌ ĞŵƉŚǇƐĞŵĂ
ůƵŶŐ ? ?Ğǆ ?ƐŵŽŬĞƌĂŶĚ ? ?ƐŵŽŬĞƌƐ ?
'ĞŶĞŽĚĞ dƌĂŶƐƉŽƌƚĞƌ WƌŽďĞ/ ,ĞĂůƚŚǇ>ƵŶŐEŽŶ ?ƐŵŽŬĞƌ ^ŵŽŬĞƌ ǆ ?ƐŵŽŬĞƌ ^ŵŽŬĞƌ ǆ ?ƐŵŽŬĞƌ
 ? DZ ?  ? ? ? ? ? ? YĂƚ A? A? A? A?A? A? ? ? ? ? ? ? YƐ YĂƚ A?  ?  ?  ?  ?
 ? DZ ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ? ? ? ? ? ? ? YƐ YĂƚ A?  ?  ?  ?  ?
 ? ? ^W  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ? ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
 ? DZW ?  ? ? ? ? ? ? YƐ YĂƚ A?A? A?A? A?A? A?A? A?A?A? ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
 ? DZW ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
 ? DZW ?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ?
 ? ? ? ? ? ? YƐ YĂƚ A? A? A? A? A?A?A?
 ? ? ? ? ? ? Yǆ YĂƚ  ?  ?  ?  ?  ?
 ? DZW ?  ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
 ? DZW ?  ? ? ? ? ? ? YƐ YĂƚ A?A? A?A? A?A? A? A?A?
 ? DZW ?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ?
 ? ? ? ? ? ? YĂƚ  ?  ?  ?  ? A?
 ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? DZW ?  ? ? ? ? ? ? Yǆ YĂƚ A?A?A? A?A? A?A? A?A? A?A?A? ? ? ? ? ? ? YƐ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? DZW ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ?
' ? ZW  ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
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ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdƌĂŶƐƉŽƌƚĞƌ'ĞŶĞĂŶĚWƌŽƚĞŝŶǆƉƌĞƐƐŝŽŶ
dĂďůĞ   ? ? ? ?  /ŵƉĂĐƚ ŽĨ ƐŵŽŬŝŶŐ ŽŶ ŐĞŶĞ
ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ ŽŶ ƐŽůƵƚĞ ůŝŶŬĞĚ ĐĂƌƌŝĞƌ
ƚƌĂŶƐƉŽƌƚĞƌƐ ?^>ĂŶĚ^>K ?
'ĞŶĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ ƐĞůĞĐƚĞĚ ^> ĂŶĚ
^>K ƚƌĂŶƐƉŽƌƚĞƌƐ ŝŶ ŶŽƌŵĂů ĂŶĚ ĚŝƐĞĂƐĞĚ
ŚƵŵĂŶǁŚŽůĞ ůƵŶŐƟƐƐƵĞ ? ĂƚĂǁĂƐŵŝŶĞĚ
ĨƌŽŵ īǇŵĞƚƌŝǆ ŐĞŶĞ ĐŚŝƉ h ? ? ? ĂŶĚ ŐĞŶĞ
ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ ŐƌŽƵƉĞĚ ŝŶƚŽ ƋƵĂƌƟůĞƐ
ĚĞƐĐƌŝďŝŶŐA?ƉƌĞƐĞŶƚ ?ƉĞƌĐĞŶƚĂŐĞŽĨƉƌŽďĞƐ
ƚŚĂƚǁĞƌĞŝĚĞŶƟĮĞĚĂƐƉƌĞƐĞŶƚŝŶƚŚĞƉƌŽďĞ
ƐĞƚ  ? ƐĞĞ ƉƉĞŶĚŝǆ  Z ĂƐ ĨŽůůŽǁƐ P  R ? ?  ? ? ? ?A?
 ?ŶĞŐůŝŐŝďůĞ Z ?  RA㴃?  ? ? ? ? ?A?  ?ůŽǁ Z ?  RA?A㴃?  ? ? ? ? ?A?
 ?ŵŽĚĞƌĂƚĞ Z ?  RA?A?A㴃?  ? ? ? ? ? ?A?  ?ŚŝŐŚ Z ?  ^ĂŵƉůĞ
ƉŽƉƵůĂƟŽŶ ƐŝǌĞƐ ĨŽƌ ŚĞĂůƚŚǇ ůƵŶŐ ǁĞƌĞ  ? ?
ŶŽŶ ?ƐŵŽŬĞƌ ?  ? ? ƐŵŽŬĞƌ ?  ? ? Ğǆ ?ƐŵŽŬĞƌ ĂŶĚ
ĨŽƌ ĞŵƉŚǇƐĞŵĂ ůƵŶŐ  ? ? Ğǆ ?ƐŵŽŬĞƌ ĂŶĚ  ? ?
ƐŵŽŬĞƌƐ ?
'ĞŶĞŽĚĞ dƌĂŶƐƉŽƌƚĞƌ WƌŽďĞ/ ,ĞĂůƚŚǇ>ƵŶŐEŽŶ ?ƐŵŽŬĞƌ ^ŵŽŬĞƌ ǆ ?ƐŵŽŬĞƌ ^ŵŽŬĞƌ ǆ ?ƐŵŽŬĞƌ
^> ? ? ? Kd ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ?
^> ? ? ? Kd ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
^> ? ? ? Kd ?  ? ? ? ? ? ? YĂƚ A?A? A?A? A? A?A?A? A?A?
^> ? ? ? KdE ?  ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
^> ? ? ? KdE ?  ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
^> ? ? ? Kd ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ? ? ? ? ? ? ? Yǆ YĂƚ  ?  ?  ?  ?  ?
^> ? ? ? Kd ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ?
^> ? ? ? ? Kd ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?  ? ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YĂƚ A?A? A? A?A? A? A?A?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YƐ YĂƚ A?A? A?A? A?A? A? A? ? ? ? ? ? ? YƐ YĂƚ A?A? A? A? A?A?A? A?A?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YƐ YĂƚ A?A?A? A?A? A?A? A?A?A? A?A? ? ? ? ? ? ? YĂƚ A?A?A? A?A? A?A? A?A?A? A?A?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YƐ YĂƚ  ? A? A? A?A? A?A? ? ? ? ? ? ? YƐ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
ŵƉŚǇƐĞŵĂ>ƵŶŐ
 ? ?ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdƌĂŶƐƉŽƌƚĞƌ'ĞŶĞĂŶĚWƌŽƚĞŝŶǆƉƌĞƐƐŝŽŶ
'ĞŶĞŽĚĞ dƌĂŶƐƉŽƌƚĞƌ WƌŽďĞ/ ƌŽŶĐŚƵƐ >ĂƌǇŶǆ >ƵŶŐ
 ? DZ ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ? ? ? ? ? ? ? YĂƚ A? A? A?A?
 ? DZ ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ? ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?
 ? ? ^W  ? ? ? ? ? ? YĂƚ  ?  ?  ? ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?
 ? DZW ?
 ? ? ? ? ? ? YƐ YĂƚ A? A?A?A? A?A?
 ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?
 ? DZW ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?
 ? DZW ?
 ? ? ? ? ? ? YƐ YĂƚ A?  ? A?
 ? ? ? ? ? ? Yǆ YĂƚ  ?  ?  ?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?
 ? DZW ?  ? ? ? ? ? ? YĂƚ A?A?A?  ? A?A?A?
 ? DZW ?  ? ? ? ? ? ? YƐ YĂƚ A? A?A?A? A?A?A? ? ? ? ? ? ? YĂƚ A?A? A?A?A? A?A?A?
 ? DZW ?  ? ? ? ? ? ? YĂƚ  ?  ?  ? ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?
 ? ? DZW ?  ? ? ? ? ? ? YƐ YĂƚ A?A? A?A?A? A?A?A?Ɛ ? ? ? ? ? ? Yǆ YĂƚ A?  ? A?A?A?
 ? ? DZW ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?
' ? ZW  ? ? ? ? ? ? YĂƚ A?A? A? A?A?A?
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ŝŶ ƚŚĞ ƉƌŽďĞ ƐĞƚ  ? ƐĞĞ ƉƉĞŶĚŝǆ  Z ĂƐ ĨŽůůŽǁƐ P  R ? ?  ? ? ? ?A? ŶĞŐůŝŐŝďůĞ Z ?  RA㴃?  ? ? ? ? ?A?  ?ůŽǁ Z ?  RA?A㴃?  ? ? ? ? ?A?
 ?ŵŽĚĞƌĂƚĞ Z ? RA?A?A㴃? ? ? ? ? ? ?A? ?ŚŝŐŚ Z ?^ĂŵƉůĞƉŽƉƵůĂƟŽŶƐŝǌĞƐĨŽƌŚĞĂůƚŚǇůƵŶŐǁĞƌĞ ?ďƌŽŶĐŚƵƐ ? ?ůĂƌǇŶǆ
ĂŶĚ ? ?ǁŚŽůĞůƵŶŐ ?
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transporter gene expression from Affymetrix DNA microarray of airway epithelial 
tissue samples from cOPD patients, generated in house at AstraZeneca was also 
analysed.  samples were categorised into large and small airway epithelia and cOPD 
severity according to the gOLD classification.  Differences in Abc transporter gene 
expression between whole lung and large airway epithelial tissue, gOLD stage 0 (at 
risk but with normal spirometry) were similar to the variations in expression observed 
between the bronchus and large airway epithelium.  Direct comparison of data in 
tables 4.1-4.2 and tables 4.6-4.7 with the same probes sets revealed that whilst 
Abcb1 and Abcc1 showed moderate expression (50-75% present) in the lung, they 
were negligibly expressed (0-25% present) in airway epithelia.  similarly Abcg2, that 
was highly expressed (75-100% present) in lung samples, was also found to have 
negligible expression levels (0-25% present) in airway epithelia.  gene expression of 
other Abc transporters was comparable between whole lung and bronchial epithelial 
tissue where Abcb4, Abcb11, Abcc2 and Abcc8 were negligibly expressed (0-
25% present) and Abcc4, Abcc5 and Abcc10 were highly expressed (75-100% 
present) in both sample sets.  the comparison of expression levels between lung and 
airway epithelia for Abcc6 was less clear given one probe set (214033_at) which 
was highly expressed (75-100% present) in the lung was only moderately expressed 
(50-75% present) in the airway epithelial, and another probe set (215559_at) that had 
negligible expression (0-25% present) in the lung was moderately expressed (50-75% 
present) in the airway epithelia.  
there was also some variability regarding the expression of sLc and sLcO transporters 
in large airway epithelial samples for gOLD stage 0 patients in comparison with 
lung tissue (table 4.7).  Moderate expression (50-75% present) of sLc22A3 and 
sLcO1c1 was observed in lung tissue samples whereas expression was negligible 
(0-25% present) in airway epithelia.  sLcO4A1 also had lower expression in the 
airway epithelial samples than in whole lung.  However, there was agreement between 
lung and airway epithelial expression with negligible expression (0-25% present) of 
sLc22A1, sLc22A2, sLc22A11, sLcO1A2 and sLcO1b1 and high expression 
(75-100% present) of sLc22A4, sLc22A5 and sLcO3A1 in whole lung and airway 
epithelial tissues.  sLcO1b3 and 6A1 which were not characterised in lung tissue 
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'ĞŶĞŽĚĞ dƌĂŶƐƉŽƌƚĞƌ WƌŽďĞ/ >ĂƌŐĞŝƌǁĂǇ WĞƌŝƉŚĞƌĂůŝƌǁĂǇ'K> ? 'K> ? 'K> ? 'K> ?
 ? DZ ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ? ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
 ? DZ ?
 ? ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ? A?  ?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?
 ? ? ^W  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ? ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?
 ? DZW ?  ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ? ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? DZW ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
 ? DZW ?
 ? ? ? ? ? ? YƐ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? ? ? ? ? Yǆ YĂƚ  ?  ?  ?  ?
 ? ? ? ? ? ? Yǆ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? ? ? ? ? YƐ YĂƚ A?A? A? A?A? A?A?A?
 ? DZW ?
 ? ? ? ? ? ? ? YĂ YĂƚ  ?  ?  ?  ?
 ? ? ? ? ? ? ? YĂ YĂƚ  ?  ?  ?  ?
 ? ? ? ? ? ? YĂƚ A?A? A?A?A? A?A?A? A?A?A?
 ? DZW ?
 ? ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
 ? ? ? ? ? ? YƐ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? DZW ?
 ? ? ? ? ? ? YĂƚ A?A? A?A?A? A?A? A?A?A?
 ? ? ? ? ? ? YĂƚ A?A? A?A?A? A? A?A?A?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?
 ? ? DZW ?  ? ? ? ? ? ? YƐ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?Ɛ ? ? ? ? ? ? Yǆ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? DZW ?  ? ? ? ? ? ? ? YĂƚ  ? A?A?  ? A?A? ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?
 ? ? DZW ?  ? ? ? ? ? ? ? YĂ YĂƚ  ?  ?  ?  ? ? ? ? ? ? ? ? YĂ YĂƚ  ?  ?  ?  ?
' ? ZW  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
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 ? ?ƚƌĂŶƐƉŽƌƚĞƌƐŝŶĂŝƌǁĂǇĞƉŝƚŚĞůŝĂ
'ĞŶĞ ĞǆƉƌĞƐƐŝŽŶ ĚĂƚĂ ŵŝŶĞĚ ĨƌŽŵ īǇŵĞƚƌŝǆ ŐĞŶĞ ĐŚŝƉ h ? ? ? ƉůƵƐ  ? ? ? ŝŶ ?ŚŽƵƐĞ ĚĂƚĂ ŐĞŶĞƌĂƚĞĚ ďǇ
ƐƚƌĂĞŶĞĐĂ Z ? ĨŽƌ ĂŝƌǁĂǇ ĞƉŝƚŚĞůŝĂů ĞǆƉƌĞƐƐŝŽŶ ŽĨ  ƚƌĂŶƐƉŽƌƚĞƌƐ ŝŶ KW 'K>  ? ĂŶĚ 'K>
 ?ƉĂƟĞŶƚƐ ? ĂƚĂǁĂƐŐƌŽƵƉĞĚ ŝŶƚŽƋƵĂƌƟůĞƐĚĞƐĐƌŝďŝŶŐA?ƉƌĞƐĞŶƚ  ?ƉĞƌĐĞŶƚĂŐĞŽĨƉƌŽďĞƐƚŚĂƚǁĞƌĞ
ŝĚĞŶƟĮĞĚĂƐƉƌĞƐĞŶƚŝŶƚŚĞƉƌŽďĞƐĞƚ ?ƐĞĞƉƉĞŶĚŝǆ ZĂƐĨŽůůŽǁƐ P R ? ? ? ? ? ?A? ?ŶĞŐůŝŐŝďůĞ Z ? RA㴃? ? ? ? ? ?A?
 ?ůŽǁ Z ? RA?A㴃? ? ? ? ? ?A? ?ŵŽĚĞƌĂƚĞ Z ? RA?A?A㴃? ? ? ? ? ? ?A? ?ŚŝŐŚ Z ?^ĂŵƉůĞƉŽƉƵůĂƟŽŶ ƐŝǌĞƐĨŽƌůĂƌŐĞĂŝƌǁĂǇǁĞƌĞ ?
 ?'K> ? Z ? ? ?'K> ? ZĂŶĚĨŽƌƉĞƌŝƉŚĞƌĂůĂŝƌǁĂǇǁĞƌĞ ? ?'K> ? ZĂŶĚ ? ?'K> ? Z ?
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showed negligible expression (0-25% present) in both airway epithelia tested.  
some differences in gene expression were also observed between large and small 
airway epithelium for some transporters.  In general, sLc22A6, sLc22A8 and 
sLcO2A1 and OAtP2b1 all had lower expression levels in large airway epithelium in 
comparison with peripheral airway epithelium.  Additionally, variations in transporter 
gene expression were also apparent with advancing stages of cOPD (assessed at 
gOLD stage 2 – moderate disease with FEV1 50-79% of predicted).  In both large and 
peripheral airway epithelia, the expression levels for Abcc6, Abcc8 and OAt1 were 
elevated with worsening cOPD.  
given the variation in Abcb1 expression levels in human lung samples, abcb1a and 
1b expression levels were characterised in the rat in different organs and compared 
with human lung Abcb1 expression levels (table 4.8).  In both human and rat, 
Abcb1 and abcb1a/1b respectively were highly expressed (75-100% present) in 
the brain, intestine, colon, kidney, liver and uterus, moderately expressed (50-75% 
present) in the heart whilst negligible expression (0-25% present) was observed in 
stomach, pancreas and skin tissues.  However, different levels of gene expression 
were observed for the adrenal glands, prostate and lung.  the expression of Abcb1 
in the human lung samples was negligible to low (0-50% present), depending on the 
probe set used.  In contrast, expression of abcb1a/1b was unanimously high between 
all 3 probe sets available in the rat, highlighting a potential interspecies difference 
between Abcb1 and abcb1a/1b expression in rat and human lungs.  
4.3.2. qPcr of transporter expression in bronchial epithelial cell models
Automated and manual qPcr was employed to characterise transporter gene 
expression for NHbE and calu-3 cells at low and high passage.  Data was expressed 
relative to 2 selected house-keeping genes (MVP and rPLP0) and assigned into 
four categories from ‘negligible’ to ‘high’ expression dependant on the 2ǻ&
t 
value as 
outlined in 2.2.3.2.6.
Abc transporter gene expression for NHbE and calu-3 bronchial epithelial cell layers 
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^> ? ? ? Kd ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
^> ? ? ? KdE ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ? ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
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^> ? ? ? ? Kd ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
^>K ? ? KdW ? ?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?
 ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
 ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YĂƚ  ?  ?  ?  ?
^>K ? ? KdW ? ?  ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A?
^>K ? ? KdW ? ?
 ? ? ? ? ? ? YĂƚ A?A?  ? A?A?A? A?
 ? ? ? ? ? ? YƐ YĂƚ  ? A?A?A? A?A?A? A?A?A?
 ? ? ? ? ? ? YƐ YĂƚ  ?  ?  ?  ?
^>K ? ? KdW ? ?
 ? ? ? ? ? ? YƐ YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? ? ? ? ? YĂƚ A?A?A? A?A?A? A?A?A? A?A?A?
 ? ? ? ? ? ? YĂƚ A?A? A?A?A? A?A?A? A?A?A?
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dĂďůĞ ? ? ? ?/ŵƉĂĐƚŽĨKWĚŝƐĞĂƐĞƉƌŽŐƌĞƐƐŝŽŶŽŶŐĞŶĞĞǆƉƌĞƐƐŝŽŶůĞǀĞůƐŽĨƐŽůƵƚĞůŝŶŬĞĚĐĂƌƌŝĞƌ
ƚƌĂŶƐƉŽƌƚĞƌƐ ?^>ĂŶĚ^>K ?ŝŶĂŝƌǁĂǇĞƉŝƚŚĞůŝĂ
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KƌŐĂŶ ?ZĞŐŝŽŶ ,ƵŵĂŶdŝƐƐƵĞƐ ? ? ? ? ? ? YƐ YĂƚ  ? ? ? ? ? ? YĂƚ  ? ? ? ? ? ? ? YĂƚ  ? ? ? ? ? ? ? YĂƚ  ? ? ? ? ? ? ? YƐ YĂƚ
ĚƌĞŶĂů  ?  ?  ? A?A?A? A?A?A?
ƌĂŝŶ A?A? A?A?A? A?A?A? A?A?A? A?A?A?
^ƚŽŵĂĐŚ  ?  ?  ?  ?  ?
/ŶƚĞƐƟŶĞ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
ŽůŽŶ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
Heart A?A? A?A? A?A? A?A? A?A?
<ŝĚŶĞǇ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
>ŝǀĞƌ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
>ƵŶŐ  ? A? A?A?A? A?A?A? A?A?A?
WĂŶĐƌĞĂƐ  ?  ?  ?  ?  ?
WƌŽƐƚĂƚĞ A? A?A?  ?  ?  ?
hƚĞƌƵƐ A?A?A? A?A?A? A?A?A? A?A?A? A?A?A?
^ŬŝŶ  ?  ?  ?  ?  ?
ZĂƚdŝƐƐƵĞƐ dĂďůĞ ? ? ? ?ZĞŐŝŽŶĂůŐĞŶĞĞǆƉƌĞƐƐŝŽŶŽĨ  ? ŝŶ ŚƵŵĂŶ ƟƐƐƵĞƐ ĂŶĚ
ĂďĐď ?Ă ? ?ďŝŶƌĂƚƟƐƐƵĞƐĂŵƉůĞƐ
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ĂŶĚ h ? ? ĨŽƌ ĞǆƉƌĞƐƐŝŽŶ ŽĨ  ? ?
ĂďĐď ?ĂĂŶĚĂďĐď ?ďŝŶŚƵŵĂŶĂŶĚƌĂƚ
ƟƐƐƵĞ ƐĂŵƉůĞƐ ?  ĂƚĂ ǁĂƐ ŐƌŽƵƉĞĚ
ŝŶƚŽ ƋƵĂƌƟůĞƐ ĚĞƐĐƌŝďŝŶŐ A? ƉƌĞƐĞŶƚ
 ?ƉĞƌĐĞŶƚĂŐĞ ŽĨ ƉƌŽďĞƐ ƚŚĂƚ ǁĞƌĞ
ŝĚĞŶƟĮĞĚĂƐƉƌĞƐĞŶƚ ŝŶ ƚŚĞƉƌŽďĞƐĞƚ
 ?ƐĞĞƉƉĞŶĚŝǆ ZĂƐĨŽůůŽǁƐ P R ? ? ? ? ? ?A?
 ?ŶĞŐůŝŐŝďůĞ Z ?  RA㴃?  ? ? ? ? ?A?  ?ůŽǁ Z ?  RA?A㴃?  ? ? ?
 ? ?A? ?ŵŽĚĞƌĂƚĞ Z ? RA?A?A㴃? ? ? ? ? ? ?A? ?ŚŝŐŚ Z ?
,ƵŵĂŶ ƐĂŵƉůĞ ƉŽƉƵůĂƟŽŶ ƐŝǌĞƐ ǁĞƌĞ
 ? ? ĂĚƌĞŶĂů ?  ? ? ? ? ďƌĂŝŶ ?  ? ? ƐƚŽŵĂĐŚ ?
 ? ? ?ŝŶƚĞƐƟŶĞ ? ? ? ?ĐŽůŽŶ ? ? ? ?ŚĞĂƌƚ ? ? ? ?
ŬŝĚŶĞǇ ?  ? ? ůŝǀĞƌ ?  ? ? ůƵŶŐ ?  ? ?ƉĂŶĐƌĞ Ɛ ?
 ? ?ƉƌŽƐƚĂƚĞ ? ? ?ƵƚĞƌƵƐĂŶĚ ? ?ƐŬŝŶ ?ZĂƚ
ƐĂŵƉůĞŶƵŵďĞƌƐǁĞƌĞ ? ? ? ?ƉĞƌŽƌŐĂŶ
ĂŶĚ ?ĞĂĐŚĨŽƌƉƌŽƚƐƚĂƚĞĂŶĚƵƚĞƌƵƐ ?
 ? ? ?ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdƌĂŶƐƉŽƌƚĞƌ'ĞŶĞĂŶĚWƌŽƚĞŝŶ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is outlined in table 4.9.  Abcb4, Abcc11 and Abcc12 expression was negligible 
(<0.001) for all cells tested.  In comparison, Abcc2, Abcc4 and Abcc6 were 
expressed at a low level (0.001-0.02) and Abcc1, Abcc3, Abcc5 and Abcc10 were 
found moderately expressed (0.02-0.5) in all in vitro models.  Abcg2 had negligible 
expression (<0.001) in calu-3 cell layers but was expressed at a low level (0.001-0.02) 
in NHbE cells.  Abcb11 expression was low (0.001-0.02) for both calu-3 low passage 
and NHbE cell layers but the expression level was negligible (<0.001) for calu-3 high 
passage cells.  Abcc10 was expressed at a moderate level (0.02-0.5) in calu-3 cells 
but had low expression (0.001-0.02) in NHbE cells.  Abcb1 expression was moderate 
(0.02-0.5) in low passage calu-3 cells, low (0.001-0.02) in high passage calu-3 cells 
and negligible (<0.001) in NHbE cells.  
gene expression for sLc and sLcO transporters in NHbE and calu-3 in vitro models 
is outlined in table 4.10.  sLc22A2, sLc22A4, sLc22A6-A9, sLcO1A2, sLcO1b1, 
sLcO1c1 and sLcO2b1 expression was negligible (<0.001) in all cell models.  In 
contrast, sLcO3A1 and sLcO4A1 were both moderately expressed (0.02-0.5) in all 
in vitro models examined.  sLc22A1, sLc22A3, sLc22A5, sLcO1b3 and sLcO4A1 
all ranged between low to moderate (0.001-0.5) expression in the in vitro models. 
Peptide transporters sLc15A1/A2 had highest expression in NHbE cell layers (0.02-
0.5), but were expressed at low (0.001-0.2) and negligible (<0.001) levels in calu-3 
cells at low and high passage respectively.  In general, there was a high level of 
consistency in sLc and scLO expression in all 3 in vitro models tested with only 
4 of the genes tested varying between low (0.001-0.02) and moderate (0.02-0.5) 
expression between the models. 
No significant differences in gene expression of the Abc and sLc transporters 
investigated was observed for rL-65 cells cultured in either sFM or scM for 8 days. 
Expression levels of all transporters tested were negligible with the exceptions of 
abcb1b (mdr1b) and slc22a5 (octn2) which were expressed at low and moderate 
levels, respectively (table 4.11).
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DsW >ZW A?A? A?A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
ZW>W ? ZW>W ? A?A?A? A?A?A? A?A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? DZ ? A?A? A?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? DZ ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? ? ^W A?  ? A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? DZW ? A?A? A?A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? DZW ? A? A? A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? DZW ? A?A? A?A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? DZW ? A? A? A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? DZW ? A?A? A?A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? DZW ? A? A?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? ? DZW ? A?A? A?A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? ? DZW ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? ? DZW ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
 ? &dZ A?A? A?A? A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
' ? ZW  ?  ? A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
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ŽŶ    ǁĞůů dƌĂŶƐǁĞůů ? ŝŶƐĞƌƚƐ Ăƚ ĂŶ Ăŝƌ ?ůŝƋƵŝĚ
ŝŶƚĞƌĨĂĐĞ ? E,ĐĞůů ůĂǇĞƌƐ  ?ƉĂƐƐĂŐĞ  ? ZǁĞƌĞ
ĐƵůƚƵƌĞĚ ŽŶ  ? ?  ǁĞůů ƉƌĞ ?ĐŽůůĂŐĞŶ ĐŽĂƚĞĚ
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AM ? ? ? ? ?  ?ŶĞŐůŝŐŝďůĞ Z ?  RA㴃?  ? ? ? ? ? ? ? ? ? ?  ?ůŽǁ Z ?  RA?A㴃?
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^> ? ? ? WWd ? A?  ? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? WWd ? A?  ? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? Kd ? A?A? A? A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? Kd ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? Kd ? A? A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? KdE ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? KdE ? A?A? A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? Kd ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? Kd ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? Kd ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^> ? ? ? Kd ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^>K ? ? KdW ? ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^>K ? ? KdW ? ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^>K ? ? KdW ? ? A?A? A?A? A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^>K ? ? KdW ? ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^>K ? ? KdW ? ?  ?  ?  ? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^>K ? ? KdW ? ? A?A? A?A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^>K ? ? KdW ? ? A?A? A?A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
^>K ? ? KdW ? ? A?A? A? A?A? ,Ɛ ? ? ? ? ? ? ? ? Yŵ ? ED Y ? ? ? ? ? ?
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ƐĞƌƵŵĨƌĞĞŵĞĚŝƵŵ ?^&D ZďĞĨŽƌĞŚĂƌǀĞƐƟŶŐ ?
ǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ ǁĞƌĞ ŶŽƌŵĂůŝƐĞĚ ƚŽ Ă
ƉĂƐƐŝǀĞƌĞĨĞƌĞŶĐĞĚǇĞĂŶĚƌĞůĂƟǀĞĞǆƉƌĞƐƐŝŽŶ
ƚŽ ƚŚĞ ŚŽƵƐĞŬĞĞƉŝŶŐ ŐĞŶĞƐ  ?ŐĂƉĚŚ ĂŶĚ
ŵǀƉ Z ĐĂůĐƵůĂƚĞĚ ?  ĂƚĂ ǁĞƌĞ ŐƌŽƵƉĞĚ ŝŶƚŽ
ďƌŽĂĚ ĐĂƚĞŐŽƌŝĞƐ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞŝƌ ƌĞůĂƟǀĞ
ĞǆƉƌĞƐƐŝŽŶ ǀĂůƵĞƐ ĂƐ ĨŽůůŽǁƐ P   R ? ? AM ? ? ? ? ?
 ?ŶĞŐůŝŐŝďůĞ Z ? RA㴃? ? ? ? ? ? ? ? ? ? ? ?ůŽǁ Z ? RA?A㴃? ? ? ? ? ? ? ? ?
 ?ŵŽĚĞƌĂƚĞ Z ? RA?A?A㴃?AN ? ? ? ?ŚŝŐŚ Z ?
Gene Protein RL-65 SFM RL-65 SCM Assay ID
Sequence 
Accession ID
mvp lrp +++ +++ rn00575634_m1 NM_022715
gapdh gapdh +++ +++ rn01775763_m1 NM_017008
abcb1a mdr1a - - rn01639253_m1 NM_133401
abcb1b mdr1b + + rn00561753_m1 NM_012623
abcc2 mrp2 - - rn00563231_m1 NM_012833
slc22a1 oct1 - - rn00562250_m1 NM_012697
slc22a2 oct2 - - rn00580893_m1 NM_031584
slc22a3 oct3 - - rn00570264_m1 NM_062183
slc22a5 octn2 ++ ++ rn00570533_m1 NM_019269
slc22a6 oat1 - - rn00568143_m1 NM_017224
slc22a7 oat2 - - rn00585513_m1 NM_053537
slc22a8 oat3 - - rn00580082_m1 NM_031332
slco1a1 oatp1a1 - - rn00755148_m1 NM_017111
slco1a3 oatp1a3 - - rn00755673_m1 NM_110464
slco1a4 oatp1a4 - - rn00756233_m1 NM_131906
slco1b2 oatp1b2 - - rn00581304_m1 NM_031650
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4.3.3.  characterisation of protein expression for selected Abc transporters  
  in in vitro cell models
based on the varying gene expression levels of Abcb1 reported in the literature and 
highlighted from Affymetrix DNA microarray data and gene expression in the in vitro 
bronchial epithelial models tested, MDr1 was selected as one of the transporters to 
take forward to characterise protein expression in the in vitro models.  Additionally, 
there are also conflicting reports regarding MrP2 expression and functionality, 
particularly in calu-3 cell layers. Due to the same apical location on epithelia, overlap 
in substrate specificity and identical direction of substrate trafficking as MDr1, MrP2 
was also characterised for protein expression.
4.3.3.1. Western blotting
the c219 (mouse anti-human P-gp) antibody detected a band of protein ~170 kDa in 
caco-2 and MDckII-MDr1 cell lysates (Figure 4.1A and b).  No protein of any size 
was detected in the control lane (lysis buffer alone) or with the negative cell lysate 
controls, HEk293 and MDckII-Wt.  A protein band ~ 150 kDa was detected for calu-
3 cell lysates at both passages and for all culture conditions tested.  For low passage 
calu-3 cells the intensity of the detected protein band was comparable for all culture 
conditions.  High passage calu-3 cells harvested after culture in t-75 flasks for 7 days 
had comparable expression intensity to their low passage counterpart.  However, high 
passage cells cultured at the AL interface showed increased MDr1 protein expression 
after 14 days and further still after 21 days in culture.  
In contrast with human samples, the c219 antibody detected two strong protein bands 
at ~140 kDa and ~100 kDa and a weaker band ~60 kDa in rat duodenal cell lysate 
(Figure 4.2).  However, no distinct bands could be identified for rL-65 cell lysates 
cultured in either sFM or scM.  
the mouse anti-human MrP2 antibody detected a protein band ~180 kDa in sf21-
MrP2 vesicles (positive control) which was absent in the control lane (lysis buffer 
only) and in calu-3 cells at low or high passage irrespective of passage number and 
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Figure 4.1  Western blot for MDR1 in human cell samples
Western blot detection for MDr1 using c219 (mouse anti-human P-gp) antibody 100 µg/
20ml.  Equal proportions of cells were lysed by identical methodology, and 10µl (calu-3, 
HEk293, MDckII cells) or 5 µl (caco-2 cells) of cell lysate containing 20-30 µg of total protein 
was electrophoresed on a 7% sDs-PAgE gel at  40 mA for 90 minutes and transferred to 
nitrocellulose at 100 V for 60 min.  blots were probed overnight using c219 (mouse anti-human 
P-gp) antibody 100 µg/20ml and detected by chemiluminescence. (A) Lane identification: (1) 
molecular weight markers, (2) caco-2 P54, (3) blank lysis buffer only, (4) calu-3 low passage 
cultured in t75 flask, (5) calu-3 low passage cultured on transwell® inserts for 14 days at AL 
interface and (6) calu-3 low passage cells cultured on transwell® inserts for 21 days at AL 
interface.  Lanes (7-9) as (4-6) but high passage calu-3 cell lysates.  (b) Lane identification: 
(1) blank lysis buffer only, (2 and 6) molecular weight standards, (3) HEk293 lysates, (4) 
MDckII Wt cell lysates, (5) MDck-MDr1 cell lysates.
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Figure 4.2  Western blot for mdr1 in rat cell samples
Western blot detection for mdr1 using c219 (mouse anti-human P-gp) antibody 100 µg/20ml. 
For rL-65 cell lysates 20-30 µg total protein and for rat duodenal lysates 1 µg total protein 
were electrophoresed on a 7% sDs-PAgE gel at  40 mA for 90 minutes and transferred to 
nitrocellulose at 100 V for 60 min.  blots were probed overnight using c219 (mouse anti-human 
P-gp) antibody 100 µg/20ml and detected by chemilluminescence. (A) Lane identification: (1) 
blank lysis buffer only (negative control), (2) rat duodenal lysate (positive control) (3 and 7) 
molecular weight markers, (4) rL-65 cell lysates cultured at an AL interface for 8 days in sFM, 
(5) rL-65 cells cultured at the AL interface in scM for 8 days. 
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Figure 4.3  Western blot for MRP2 in human cell samples
Western blot detection for MrP2 using mouse anti-human MrP2 antibody 100 µg/20ml. 
between 20-30 µg total protein from calu-3 and caco-2 cell lysates were electrophoresed on 
a 7% sDs-PAgE gel at  40 mA for 90 minutes and transferred to nitrocellulose at 100 V for 
60 minutes.  blots were probed overnight using MrP2 antibody 100 µg/20ml and detected by 
chemilluminescence.  Lane identification: (1) lysis buffer only (negative control), (2) molecular 
weight markers, (3) sf21 human MrP2 vesicles, (4) calu-3 low passage cultured in t75 flask, 
(5) calu-3 low passage cultured on transwell® inserts for 14 days at AL interface and (6) calu-
3 low passage cells cultured on transwell® inserts for 21 days at AL interface.  Lanes (7-9) as 
(4-6) but high passage calu-3 cell lysates.
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length in culture (Figure 4.3).  As no MrP2 was detected via western blotting, MrP2 
expression was not characterised further with other techniques.  
4.3.3.2. Immunocytochemistry
Immunocytochemistry using the UIc2 (mouse anti-human MDr1) antibody generated 
positive staining for MDr1 on the apical membranes of all calu-3, NHbE and MDckII 
cells (Figure 4.4A-E).  More abundant apical staining was observed for high passage 
calu-3 cells in comparison with low passage calu-3 cells.  Although both MDckII-
Wt and MDckII-MDr1 cell layers stained positively on the apical side (likely due to 
interaction of UIc2 with canine mdr1 expressed in the wild type control), the degree 
and intensity of staining observed with UIc2 was greater for MDckII-MDr1 cells. 
HEk293 cells were used as a negative control cell line and displayed minimal staining 
on the apical cell surface and to a much lesser degree than in the positive control cell 
samples (Figure 4.4F).  
A similar staining pattern was observed with the Mrk16 (mouse anti-human MDr1) 
antibody as for UIc2.  Minimal staining was observed on the apical surface of calu-3 
cell layers cultured at low passage whereas profuse staining was demonstrated on 
the apical surface of the majority of cells at high passage (Figure 4.5A and b).  NHbE 
cell layers had a more intermediate expression level between calu-3 low and high 
passages (Figure 4.5c).  both MDckII-Wt cells and MDckII-MDr1 cells exhibited 
staining on the apical side but the degree and intensity of staining was greater for 
MDckII-MDr1 likely due to the same interaction with native canine mdr1 transporters 
present in MDckII cells as outlined above (Figure 4.5D and E).  For confirmation 
of selectivity, no staining was detected by Mrk16 for the negative control cell line, 
HEk293 (Figure 4.5F).  All secondary control samples (primary antibody incubation 
step omitted) were measured with identical settings to the sample and no FItc signal 
was observed in any cell line tested (Appendix D).  
both UIc2 and Mrk16 antibodies for human MDr1 were used to detect mdr1a/1b 
in rL-65 cells cultured in sFM and scM, given cross-reactivity with rat mdr1a/b has 
been reported [Jakob et al., 1997]  (Figure 4.6).  In both types of medium, positive 
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Figure 4.4 UIC2 immunological human cell staining for MDR1
Immunocytochemical staining for 3.7% w/v paraformaldehyde fixed (A) low passage calu-3 
cells; (b) high passage calu-3 cells and (c) NHbE cells passage 2 all cultured on 12 well 
transwell® inserts at the AL interface for 21 days.  (D) MDckII Wt (wild type MDckII control) 
and (E) MDckII-MDr1 (positive control) both cultured on 12 well tranwell® inserts for 5 days 
under submerged conditions and (F) HEk293 (negative control) cells cultured on glass slides 
for 2 days.  the UIc2 (mouse anti-human MDr1) antibody is labelled with a FItc-secondary 
antibody tag shown in green and nuclear components are counter stained with propidium 
iodide and shown in red.  Images are a z-stack of assembled 0.5 µm transverse section of cell 
layer(s).  Images taken with x63 oil objective and x1 optical zoom with an average of 4 frames 
per image.
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Figure 4.5 MRK16 immunological human cell staining for MDR1
Immunocytochemical staining for 3.7% w/v paraformaldehyde fixed (A) low passage calu-3 
cells; (b) high passage calu-3 cells and (c) NHbE cells passage 2 all cultured on 12 well 
transwell® inserts at the AL interface fore 21 days.  (D) MDckII Wt (wild type MDckII control) 
and (E) MDckII-MDr1 (positive control) both cultured on 12 well tranwell® inserts for 5 days 
under submerged conditions and (F) HEk293 (negative control) cells cultured on glass slides 
for 2 days.  the Mrk16 (mouse anti-human MDr1) antibody is labelled with a FItc-secondary 
antibody tag shown in green and nuclear components are counter stained with propidium 
iodide and shown in red.  Images are a z-stack of assembled 0.5 µm transverse section of cell 
layer(s).  Images taken with x63 oil objective and x1 optical zoom with an average of 4 frames 
per image.
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Figure 4.6 UIC2 and MRK16 immunological rat cell staining for MDR1
Immunocytochemical staining for 3.7% w/v paraformaldehyde fixed rL-65 cells cultured in 
(A-c) sFM and (D-F) scM on 12 well transwell® inserts at the AL interface for 8 days.  (A and 
D) secondary control, (b and E) UIc2 primary antibody 20 µg/ml, (c and F) Mrk16 primary 
antibody 15 µg/ml.  the primary antibodies were labelled with a FItc-secondary antibody tag 
shown in green and nuclear components are counter stained with propidium iodide and shown 
in red.  Images are a z-stack of assembled 0.5 µm transverse section of cell layer(s).  Images 
taken with x63 oil objective and x1 optical zoom with an average of 4 frames per image.
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staining was observed on the apical surface of the cell layers and UIc2 produced a 
stronger signal than with Mrk16.   staining was detected on the apical cell surface of 
rL-65 cells cultured in sFM.  similarly positive staining was observed apical surface 
of the layer furthest from the filter for rL-65 cells cultured in scM.  No FItc signal was 
observed for secondary control samples (secondary antibody alone) in cells cultured 
in either medium.  
4.3.3.3. Flow cytometry
Flow cytometry using the UIc2 antibody suggested 36% calu-3 cells at low passage 
expressed the MDr1 transporter in comparison with 70% for high passage calu-3 
cells, resulting in a relative mean intensity of fluorescence (MFI, i.e. sample MFI / 
control MFI) of 5.2 and 15.0 respectively (Figure 4.7A and b).  Only 6% of NHbE 
cells at passage 2 expressed MDr1 generating a relative MFI of 1.3 in comparison 
with 81% of cells at passage 3 with relative MFI of 27.7 (Figure 4.7c and D).  the 
Mrk16 antibody also indicated that approximately double the number of cells in the 
high passage calu-3 population (10%) expressed MDr1 in comparison with low 
passage cells (4%) although these values were less than achieved with the UIc2 
antibody, possibly due to different affinities of the antibody to MDr1 (Figure 4.8A and 
b).  conversely, only 1-3% of the NHbE cell populations at passage 2 and passage 3 
were detected by the Mrk16 antibody and no difference was observed in the relative 
MFI values (1.2) at either passage (Figure 4.8c and D).  
the negative controls HEk293 and MDckII-Wt cells indicated that 19% and 23% 
of cells bound UIc2 respectively, whilst binding occurred for only 3% and 5% cell 
population with Mrk16 resulting in a relative MFI value of 1.3.  In contrast, a shift in 
fluorescence was observed in 54% and 63% for the positive control, MDckII-MDr1 
cells incubated with Mrk16 and UIc2 antibodies respectively producing relative MFI 
values of 4.5 and 7.5 (Figure 4.9 and 4.10). 
113ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdƌĂŶƐƉŽƌƚĞƌ'ĞŶĞĂŶĚWƌŽƚĞŝŶǆƉƌĞƐƐŝŽŶ
Figure 4.7 UIC2 flow cytometry for MDR1 transporter expression in human bronchial 
epithelial cell models
Flow cytometry for 1 x 105 cells of (A) low passage calu-3 cells; (b) high passage calu-3 cells; 
(c) NHbE cells passage 2 and (D) NHbE cells passage 3 all cultured on 12 well (A and b) or 
24  well (c and D) transwell® inserts at the AL interface for 21 days.  Insets (i) and (ii) show 
density plots for the secondary control and sample respectively; (iii) depicts histogram, black 
line secondary control, red line sample.  relative MFI (sample MFI/control MFI) stated on (iii). 
samples incubated with 0.2 µg / 100 µl UIc2 (mouse anti-human MDr1) antibody and labelled 
with goat anti-mouse Igg FItc-tagged secondary antibody (1:1000).  results are from a total 
of 3 x 104 events.  All viable cells were gated and dead cells ruled out by size and granularity 
from previous optimisation experiments with propidium iodide. 
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Figure 4.8 MRK16 flow cytometry for MDR1 transporter expression in human bronchial 
epithelial cell models
Flow cytometry for 1 x 105 cells of (A) low passage calu-3 cells; (b) high passage calu-3 cells; 
(c) NHbE cells passage 2 and (D) NHbE cells passage 3 all cultured on 12 well (A and b) or 
24  well (c and D) transwell® inserts at the AL interface for 21 days.  Insets (i) and (ii) show 
density plots for the secondary control and sample respectively; (iii) depicts histogram, black 
line secondary control, red line sample.  relative MFI (sample MFI/control MFI) stated on 
(iii).  samples incubated with 1 µg / 100 µl Mrk16 (mouse anti-human MDr1) antibody and 
labelled with goat anti-mouse Igg FItc-tagged secondary antibody (1:1000).  results are 
from a total of 3 x 104 events.  All viable cells were gated and dead cells ruled out by size and 
granularity from previous optimisation experiments with propidium iodide. 
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Figure 4.9 UIC2 flow cytometry for MDR1 transporter expression in MDR1 positive and 
negative control cell lines
Flow cytometry for 1 x 105 cells of (A) HEk293 cells; (b) MDckII-Wt cells and (c) MDckII-
MDr1 cells all cultured on 12 well transwell® inserts under submerged conditions for 5 days. 
Insets (i) and (ii) show density plots for the secondary control and sample respectively; (iii) 
depicts histogram, black line secondary control, red line sample.  relative MFI (sample MFI/
control MFI) stated on (iii).  samples incubated with 0.2 µg / 100 µl UIc2 (mouse anti-human 
MDr1) antibody and labelled with goat anti-mouse Igg FItc-tagged secondary antibody 
(1:1000).  results are from a total of 3 x 104 events.  All viable cells were gated and dead 
cells ruled out by size and granularity from previous optimisation experiments with propidium 
iodide. 
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Figure 4.10 MRK16 flow cytometry for MDR1 transporter expression in MDR1 positive 
and negative control cell lines
Flow cytometry for 1 x 105 cells of (A) HEk293 cells; (b) MDckII-Wt cells and (c) MDckII-
MDr1 cells all cultured on 12 well transwell® inserts under submerged conditions for 5 days. 
Insets (i) and (ii) show density plots for the secondary control and sample respectively; (iii) 
depicts histogram, black line secondary control, red line sample.  relative MFI (sample MFI/
control MFI) stated on (iii).  samples incubated with 1 µg / 100 µl Mrk16 (mouse anti-human 
MDr1) antibody and labelled with goat anti-mouse Igg FItc-tagged secondary antibody 
(1:1000).  results are from a total of 3 x 104 events.  All viable cells were gated and dead 
cells ruled out by size and granularity from previous optimisation experiments with propidium 
iodide. 
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4.4. DIscUssION
4.4.1. transporter gene expression 
there have been several published studies detailing the gene expression of Abc, 
sLc and sLcO transporters in different human tissues, including the lung.  bleasby 
and colleagues published gene expression profiles for over 50 transporters in 40 
different tissues obtained by commercial DNA microarray and expressed in gross 
quartiles as a rough measure of absolute signal intensity (AsI) [bleasby et al., 2006]. 
Additionally, qPcr studies investigating transporter gene expression in human 
tissues have been published [Langman et al., 2003; Nishimura and Naito 2006]. 
smaller rt-Pcr studies have also been published detailing gene expression of Abc 
transporters in cancer cell lines, including the lung [kool et al., 1997].  Whilst there 
are several studies investigating transporter gene expression in human lung tissue, 
there is only one published study by Endter and co-workers which investigated gene 
expression of Abc, sLc and sLcO transporters in several airway epithelial in vitro 
cells in submerged cultures on well plates [Endter et al., 2009].  A few individual 
reports of transporter gene expression for differentiated bronchial epithelial cell layers 
exist, but to date, no screen for gene expression of multiple drug transporters has 
been published in such models.  
Affymetrix arrays enable fast and accurate high throughput screening for thousands 
of transcripts in tissue or cell samples.  Unlike other DNA microarrays (such as those 
employed in the studies by bleasby and co-workers) where each gene of interest has 
one probe ~60 base pairs long, Affymetrix is based on a probe set design (outlined 
in Appendix A).  In essence, the probe set contains 11-20 probes, each ~25 base 
pairs long, designed to perform more specific and reliable gene detection.  this data 
can be added to a database, allowing data mining from a vast number of different 
genes in different species, tissues, disease states and environmental impacts.  there 
are several commercially available gene catalogue systems where DNA microarray 
companies have compiled gene expression data from their systems.  these sources 
can be a useful starting point for understanding transporter gene expression in the 
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lung.  However, purchased DNA microarray expression data and published literature 
for gene expression of drug transporters often does not provide details on the region 
of the lung tissue analysed.  It is therefore assumed that this data relates to whole 
lung tissue, and given that there is in abundance of 40 different cell types present 
in lung tissue [sorokin, 1970], this may not be representative of transporter gene 
expression in the bronchial epithelium. 
given the different techniques employed to study transporter gene expression, direct 
comparison of gene expression values between different studies is not appropriate. 
Different microarrays employ different probes with altered hybridisation affinities.  similarly 
several Pcr primer sequences are commercially available which may all have different 
rNA hybridisation efficiencies.  After cDNA amplification, these slight variations in binding 
affinity may cause significant differences in expression analysis leading to unreliable 
comparisons between probes.  Additionally, the data analysis and relative expression 
calculations for both microarray and qPcr employ different internal standards and different 
housekeeping genes, making direct comparison between different studies impossible. 
Furthermore, the variation within the tissue sample under investigation (lung region, 
patient demographics, rNA extraction processes) may cause alterations in the gene 
expression level reported.  similarly, transporter gene expression levels in in vitro cultures 
are likely to be effected by factors such as culture medium and conditions, and length of 
the culture period.  the length of the culture period has been shown to impact transporter 
expression and functionality in caco-2 and calu-3 cell in vitro models [Hosoya et al., 
1996; Haghi et al., 2010].  It can therefore be postulated that differences in transporter 
gene expression observed between this study and observations reported in literature may 
be a result of changing transporter expression profiles with different culture conditions. 
therefore, although specific gene expression values should not be directly quoted against 
one another, however the trend in transporter expression levels may be compared. 
4.4.2. Protein transporter expression 
characterisation of Abc transporter protein expression and localisation in the lung 
and bronchial epithelium is limited, and even less researched for sLc and sLcO 
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transporters.  techniques most commonly employed to study protein expression 
and localisation in lung tissues and in vitro airway epithelial cultures are Western 
blotting and immunocytochemistry (Icc).  However, these do not lend themselves to 
the production of data in a high throughput manner as for DNA microarray or Pcr 
techniques.  
Another barrier for transporter protein expression is the lack of specific and reliable 
antibodies.  Although reliable and specific antibodies are now available for the more 
heavily researched transporters (MDr1, MrP1, MrP2 and bcrP), the reduced 
availability and specificity of antibodies for other transporter proteins is a major 
obstruction to transporter research.
the less specific nature of some transporter antibodies has been highlighted in the 
literature [Lacueva et al., 1998].  As such, to confirm transporter expression in the 
bronchial epithelium in vitro cell models, 3 different antibodies were employed in 3 
different protein expression techniques to increase the level of confidence of the data. 
Flow cytometry was used alongside Western blotting and Icc in these studies as it 
also provides quantitative information regarding transporter expression levels. 
4.4.3.  Abcb transporters in the lung 
4.4.3.1. Abcb1/MDr1
the exact function of MDr1 is largely unknown but is it commonly accepted that 
it acts to extrude waste products and protect the tissues from xenobiotic infiltration 
[Hamilton et al., 2001a].   Published data regarding Abcb1 expression in whole lung 
is conflicting.  bleasby and colleagues reported negligible expression (0-25% AsI) of 
Abcb1 in adult lung, foetal lung and lung tumour tissues.  similarly, expression levels 
for Abcb1 in the lung were shown to be low in the lung in comparison with other 
tissues (lung expression 0.008, adrenal expression 0.3) but double that found in the 
trachea [Nishmura and Naito, 2006].  In contrast, whilst Langmann and co-workers 
reported moderate Abcb1 gene expression in lung and tracheal human tissues, the 
authors indicated the fold increase in expression over the lowest expressing tissues 
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was 1 (on a linear scale of 0-5).  In agreement with Nishimura and Naito’s findings, one 
Affymetrix probe set investigated indicated moderate expression (50-75% present) of 
Abcb1 in whole lung tissue which was reduced in the bronchus (25-50% present).
Affymetrix, results for airway epithelial tissue indicated negligible gene expression (0-
25% present) in both large and peripheral airways and similarly Abcb1 expression in 
in vitro NHbE cell layers was also negligible (<0.001) as determined by qPcr.  the 
signal intensity for rt-Pcr detection of Abcb1 for undifferentiated NHbE in studies 
by Endter and colleagues indicated low expression [Endter et al., 2009].  However, 
reports by Lin and co-workers demonstrated Abcb1 expression at day 7 and stronger 
expression at days 14 and 21 for differentiated NHbE cell layers using rt-Pcr [Lin 
et al., 2007].  rt-Pcr studies of Abcb1 expression in normal bronchial epithelial 
cell scrapings also detected the gene in all samples analysed [Lechapt-Zalcman et 
al., 1997].  these differences not only highlight the impact of length in culture and 
differentiation at the AL interface, but also suggest alterations to the culture media 
and variations in the cell donor are likely to have significant influence on transporter 
gene expression.
In contrast with NHbE cells, submerged calu-3 cell cultures after 8 days generated 
moderate signal intensities for Abcb1 which increased to high levels of expression 
after 15 days, detected by rt-Pcr [Endter et al., 2009].  similarly in the qPcr results 
reported in this chapter, moderate relative Abcb1 expression levels (0.02-0.5) were 
observed after 21 days in culture for low passage calu-3 cell layers.  However, high 
passage cells cultured under the same conditions displayed low relative expression 
(0.001-0.2) of Abcb1.  Published literature has reported the overexpression of Abcb1 
in lung cancer cells [Yabuki et al., 2007], and the cancerous origin of calu-3 cells may 
explain the elevated levels of Abcb1 in the calu-3 cell line.  
regarding the expression of Abcb1 in lung disease, no difference was observed for 
Abcb1 expression between healthy and cOPD (emphysema) lung samples or with 
worsening stages of cOPD in large airway epithelial samples from the Affymetrix 
DNA microarray data.  similarly, no statistical difference was observed in the protein 
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expression of MDr1 in healthy, mild or severe cOPD samples [van der Deen et al., 
2006].  the impact of smoking on transporter expression has also been considered 
in the literature for Abcb1/MDr1.  From Affymetrix analysis, one Abcb1 probe set 
indicated the increased expression of Abcb1 in the lungs of emphysema patients 
who currently smoke.  Published studies have shown no significant difference in 
Abcb1 expression between smokers and ex-/non- smokers, however, the range 
and variability of Abcb1 expression in the smoker subset was substantially greater 
[Lechapt-Zalcman et al., 1997].  
Published reports regarding transporter gene expression in rat lung are limited. 
However, moderate expression (50-75% AsI) of abcb1a has been reported in whole rat 
lung [bleasby et al., 2006].  similarly, high expression (75-100% present) of abcb1a/1b 
was demonstrated in rat lung using Affymetrix DNA microarray techniques.  Although 
both abcb1a and 1b expression has been detected in both rat and murine lung tissue, 
abcb1b was shown to be more highly expressed than abcb1a [croop et al., 1989; 
brady et al., 2002].  Additionally, it has also been demonstrated that mdr1b is more 
highly expressed than mdr1a in rat lung tissue [brown et al., 1993; brady et al., 2002]. 
Likewise, rL-65 cell layers demonstrated moderate expression levels (0.02-0.5) for 
abcb1b but negligible expression levels (<0.001) for abcb1a using qPcr, irrespective 
of the culture medium.  
these results suggest that although Abcb1 is likely to be expressed in the lung (albeit 
at low to moderate levels in comparison with other organs), expression in the bronchial 
epithelium is likely to be negligible.  this suggests, in agreement with published findings 
that MDr1 may have a more important role in the lung capilliary endothelium than 
the bronchial epithelium [bosquillon, 2010].  Abcb1 expression in calu-3 cell layers 
altered with passage number, and was higher than for NHbE cultures in literature 
[Endter et al., 2009] and in data reported in this chapter.  If Abcb1 expression is 
indicative of MDr1 expression and functionality in calu-3 cell layers then both the 
passage number and potential over-activity of MDr1 functionality compared with in 
vivo lung tissue samples should be taken into consideration.  
122ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdƌĂŶƐƉŽƌƚĞƌ'ĞŶĞĂŶĚWƌŽƚĞŝŶǆƉƌĞƐƐŝŽŶ
Protein expression of MDr1 at ~170 kDa in calu-3 cells by Western blotting has been 
reported in a number of studies [Florea et al., 2001; Hamilton et al., 2001a; Patel et 
al., 2002; brillault et al., 2009].  Western blotting using the mouse anti-human MDr1 
(c219) antibody in this study produced a protein band at ~170 kDa for caco-2 and 
MDckII-MDr1 controls but at ~150 kDa for all calu-3 cell samples.  On closer scrutiny 
of the study by Hamilton and co-workers who also used the c219 mouse anti-human 
MDr1 antibody the protein band for calu-3 is also ~20 kDa lower than for the caco-
2 controls.  the c219 antibody detects the highly conserved amino acid sequence 
VQEALD and VQAALD in MDr1 and MDr3 transporters respectively [schinkel et al., 
1991; beaulieu et al., 1995; van Den Elsen et al., 1999] and whilst it detects MDr1 
(~170 kDa) it also detects MDr3 at ~150 kDa [Jette et al., 1995; scheffer et al., 
2002].  Additionally, the c219 antibody has been shown to cross react with p185c-erbb2 
glycoprotein which shares a similar sequence homology (VQgNLE) [Liu et al., 1997; 
chan and Ling, 1997].  the protein is unlikely to be MDr3 given there was no Abcb4 
gene expression in calu-3 cells in these studies.  Additionally, human lung epithelial 
samples have been shown not to express the MDr3 transporter [scheffer et al., 2002]. 
the reason for the lower molecular weight protein band for calu-3 cells with the c219 
antibody could be degradation of the MDr1 protein during cell lysis or altered post 
translational modifications such as a different degree of glycosylation.  In agreement 
with literature, the lack of c219 antibody specificity highlights the need to use a screen 
of antibodies to assess transporter protein expression in cells and tissues [schinkel et 
al., 1991; Lacueva et al., 1998].  the use of multiple antibodies and different protein 
expression detection techniques in these studies should aid confirmation of MDr1 
expression and limit the possibility of non-specific protein detection.
Flow cytometry using both anti-human MDr1 antibodies (UIc2 and Mrk16) showed 
a positive shift in fluorescence intensity for calu-3 cell layers, indicating the presence 
of MDr1 expression.  In agreement with Western blotting, the mean intensity of 
fluorescence was greater for high passage calu-3 cell layers compared with low 
passage cells for both antibodies tested, however, the difference in population 
shift was 7-8 fold lower for the Mrk16 antibody.  Very low expression of MDr1 
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was demonstrated via flow cytometry for NHbE cell layers at passage 2 with both 
antibodies tested.  However, at passage 3, ~80% of the cells were observed to have 
an increase in fluoresecent signal intensity, indicating high MDr1 expression with the 
UIc2 antibody.  In contrast, this was not observed for identically cultured passage 3 
NHbE cells tested with the Mrk16 antibody.  these differences may be due to non-
specific binding of UIc2 to other proteins than MDr1, however no reports regarding a 
lack of specificity for UIc2 have been published.  Alternatively, UIc2 may have a higher 
affinity than Mrk16 for its complimentary amino acid residues, or the conformation 
of MDr1 sterically hindered Mrk16 binding.  It is also possible that mutations of the 
amino acid sequence for MDr1 have arisen in calu-3/NHbE cells in the sequence 
recognised by Mrk16 and resulted in reduced binding affinity. 
similarly, for the positive and negative control cells, UIc2 generated higher shifts in 
fluorescent intensities in comparison with Mrk16.  Whilst binding of Mrk16 to the 
negative control cell lines (HEk293, MDkcII Wt cells) was minimal (relative MFI 1.3), 
UIc2 was higher (MFI 2.5 and 2.0, respectively).  MDckII cells have been shown to 
express canine mdr1 protein [goh et al., 2002], however, there are no reports detailing 
the cross-reactivity of UIc2 with canine mdr1 to date.  In agreement with Western 
blotting data, a positive shift in fluorescence intensity was clearly observed with both 
UIc2 and Mrk16 antibodies for MDckII-MDr1 cells indicating the maintenance of 
MDr1 expression in the transfected cell line.  
In agreement with localisation of MDr1 on the apical mucosal surface of human 
bronchial epithelial tissue [Lechapt-Zalcman et al., 1997], MDr1 was also found to be 
localised on the apical cell surface of both calu-3 and NHbE cells in these studies. 
the intensity of expression of MDr1 in all three in vitro models was comparable 
between the different techniques employed.  there is conflicting literature regarding the 
localisation of MDr1 in in vitro models.  In agreement with our findings, Hamilton and 
colleagues also demonstrated localisation of MDr1 on the apical cell surface of calu-
3 cells [Hamilton et al., 2001a], whereas others have reported basolateral expression 
[Florea et al., 2001].  Differential localisation of MDr1 in calu-3 cell layers may have 
arisen due to differences in in vitro cell culture methodology.  Lin and colleagues 
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concluded NHbE cells expressed low levels of MDr1 on the apical cell surface from 
rh123 and fexofenadine functionality experiments [Lin et al., 2007] and Madlova and 
co-workers postulated MDr1 expression was localised to the basolateral surfaces of 
NHbE cells from their functionality experiments with 3H-digoxin [Madlova et al., 2009]. 
However localisation was not confirmed experimentally in either study. 
In agreement with literature, the c219 antibody detected protein bands at ~140 kDa 
and ~100 kDa for rat duodenal cell lysates [Demeule et al., 1999], however, no distinct 
protein bands were detected for rL-65 cell layer lysate preparations.  In contrast, Icc 
images indicated MDr1 localisation on the apical side of rL-65 cell layers in both 
scM and sFM cultures.  Although both antibodies showed positive apical staining, 
that observed for UIc2 was more profuse and of greater intensity.  Although it has 
been reported that UIc2 cross-reacts with rat [Jakob et al., 1997], no such reports 
exist for Mrk16.  As for human samples, it could be postulated that the binding affinity 
for Mrk16 with rat MDr1 is lower than for UIc2, owing to the reduced intensity of 
fluorescent signal.  In agreement with positive apical expression of MDr1 in rL-65 
cell layers, campbell and co-workers showed apical expression of mdr1a/b in rat 
bronchial epithelium in line with localisation both in the rL-65 rat airway epithelial in 
vitro cultures and with MDr1 in human data [campbell et al., 2003].  based on gene 
expression and published literature which demonstrated higher expression of mdr1b 
in rat lung, it is also more likely mdr1b is expressed in rL-65 cell layers [brown et al., 
1993; brady et al., 2002].  
Whilst transporter gene expression profiling can be conducted in a high throughput 
manner generating a plethora of data, the translation of gene expression into functional 
transporter proteins is less well understood.  gene profiling, by either Pcr, or DNA 
microarray based technology, only takes a snapshot view of the genes being transcribed 
at the time of harvesting.  For this reason, a high gene expression may not translate 
to a high protein expression downstream.  this was demonstrated for Abcb1/MDr1 
expression in calu-3 cell layers which displayed higher levels of gene expression for 
low passage cells than high passage cells.  However, the protein expression of MDr1 
detected using multiple techniques and different MDr1 antibodies all suggested 
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greater expression of MDr1 for high passage calu-3 cell layers, contradictory to 
gene expression data.  there is limited and conflicting data regarding the expression 
and localisation of Abc transporters in the lung and in bronchial epithelial in vitro 
models.  Furthermore, there are no published studies which report protein expression 
profiling to the same degree as for transporter gene expression, due to the limitations 
of laboratory tools.
4.4.3.2. Other Abcb transporters
Although Abcb4 shares a high level of homology with Abcb1 it has not been detected 
in the lung [van der Deen et al., 2005].  DNA microarray studies showed negligible 
expression (0-25% AsI) for Abcb4 in human lungs and similar levels of negligible 
expression (0-25% present) were demonstrated for Affymetrix microarray data in 
human lung, bronchus and airway epithelium.  Low levels of Abcb4 expression in the 
lung were also identified using qPcr, and interestingly, both found higher expression 
in human tracheal tissue, although this was still at a low level in comparison with other 
tissues investigated [Langmann et al., 2003; Nishimura and Naito, 2006].  
similarly to Abcb4, Abcb11 has not been detected in the lung to date and is thought to 
be almost exclusively expressed in the liver [gerloff et al., 1998].  Abcb11 expression 
in the lung was too low to be quantified in qPcr studies by Nishimura and Naito, and 
also negligible expression in the lung was also reported by Langmann and colleagues 
[Langmann et al, 2003; Nishimura and Naito, 2006].  both published DNA microarray 
data and that conducted in these studies also showed negligible expression (0-25% 
AsI, 0-25% present).  to date, no published reports for Abcb4 or Abcb11 expression 
in human bronchial epithelial in vitro cell cultures are available, however, the negligible 
to low expression levels (<0.02) demonstrated in NHbE and calu-3 cell layers using 
qPcr indicate they are also not likely to be present in these systems.  
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4.4.4.  Abcc transporters in the lung 
4.4.4.1. Abcc1
Of the Abcc transporters, expression of Abcc1 has been the most extensively 
studied.  Affymetrix DNA microarray data indicated moderate to high expression 
(>50% present) in whole lung, bronchus and airway epithelial tissues.  these findings 
are in general agreement with other microarray studies for whole lung tissue [bleasby 
et al., 2006] and rt-Pcr studies [kool et al., 1997; Langmann et al., 2003; Nishimura 
and Naito, 2006].  Endter and colleagues also demonstrated high expression of 
Abcc1 in submerged calu-3 and NHbE cell cultures [Endter et al., 2009], similar 
to the moderate expression levels (0.02-0.5) for Abcc1 in the same differentiated 
in vitro models tested in this chapter.  Other individual studies have also detected 
Abcc1 transcripts in differentiated calu-3 and NHbE cells layers in agreement with 
our findings [Hamilton et al., 2001b; Lin et al., 2010].  
With consideration of Abcc1 expression in airway disease, whilst no difference 
in expression levels were noted in cOPD samples with the Affymetrix microarray, 
published reports have shown lower protein expression of MrP1 in the bronchial 
epithelium of patients with cOPD [van der Deen et al., 2006].  Published literature 
demonstrated lower expression of Abcc1 and Abcc5 in the nasal epithelium of 
cystic fibrosis patients compared with healthy subjects [Hurbain et al., 2003].  Whilst 
no difference was observed in the expression of any of the Abcc1 probe sets, Abcc5 
was more highly expressed (75-100% present) in normal lung tissue in comparison 
with negligible expression (0-25% present) in cystic fibrosis lung tissue from Affymetrix 
microarray data, in agreement with published observations. 
Whilst one probe set for Abcc1 indicated no change in expression with the impact of 
smoking in agreement with published literature [brechot et al., 1996], a different probe 
set indicated higher expression of Abcc1 in ex-smokers compared with smokers 
in the cOPD lung.  this is in line with a study by van der Deen and co-workers 
who observed lower expression of MrP1 in bronchial epithelial tissue from cOPD 
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patients who currently smoked in comparison with ex-smokers [van der Deen et al., 
2006].  Furthermore, single nucleotide polymorphisms of Abcc1 in bronchial biopsies 
of cOPD patients that directly impact inflammation and lung function have also been 
identified [siedlinski et al., 2009; budulac et al., 2010].  
4.4.4.2. Abcc2
Negligible expression (0-25% present) of Abcc2 was observed in lung, bronchus 
and bronchial epithelial tissues from Affymetrix DNA microarray data.  this was in 
agreement with DNA microarray data by bleasby and co-workers [bleasby et al., 
2006] and for rt-Pcr studies concerning Abcc2 expression in human lung tissues 
and lung cancer tissues [kool et al., 1997; Langmann et al., 2003; Nishimura and 
Naito, 2006].  In contrast, Endter and colleagues reported moderate expression of 
Abcc2 in both NHbE cultures and calu-3 cells.  However, qPcr results outlined in 
this chapter indicated low expression (0.001-0.02) in differentiated NHbE cell layers 
and calu-3 cell layers at both passages tested.  Another study by Li and co-workers 
reported high expression levels of Abcc2 in calu-3 cells at the same level as Abcc1 
[Li et al., 2010].  the elevated Abcc2 expression levels in calu-3 cell layers observed 
in other studies are unlikely to be explained by the cancerous origins of the cell line, 
particularly as similarly low levels were observed for NHbE cell layers.  therefore, 
either Abcc2 is expressed in bronchial epithelium, and expression levels are under-
represented by whole lung tissue gene expression data, or the culture conditions for 
the in vitro models cause an over-expression of Abcc2 transcripts.  
Negligible expression (0-25% AsI) of abcc2 was reported in rat lung tissue by DNA 
microarray analysis [bleasby et al., 2006], and was in agreement with expression of 
Abcc2 in human lung (0-25% AsI).  similarly, negligible expression of abcc2 was 
also observed for rL-65 cell layers cultured in either scM or sFM as analysed by 
qPcr detailed in this chapter.
Whilst studies by sandusky and co-workers showed expression of MrP2 in 14 out 
of 32 lung carcinoma tissue samples, expression in healthy lung tissue was low 
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[sandusky et al., 2002].  However, MrP2 has been reported to be expressed on 
the apical side of calu-3 cell layers [Li et al., 2010].  Additionally, other immuno-
localisation studies with NHbE cells cultured at an AL interface have detected MrP2 
on all membrane regions [torky et al., 2005].  However, results from this chapter show 
that MrP2 was not detected in differentiated calu-3 cells layers at either low or high 
passage.  In agreement with our findings, immunocytochemical staining revealed the 
absence of MrP2 in 16HbE14o- cells [van der Deen et al., 2007].  MrP2 is unlikely 
to be expressed in the lung given the negligible levels of gene expression observed 
for the majority of reports in the lung.  Additionally the low gene expression levels for 
Abcc2 are in agreement with the absence of MrP2 protein expression.  However, in 
vitro culture methodology and individual variability may influence MrP2 expression 
levels. 
4.4.4.3. Other Abc transporters
Fewer reports exist concerning the gene expression of other Abcc transporters.  the 
general consensus in literature from the DNA microarray [bleasby et al., 2006] and 
qPcr studies [Langmann et al., 2003; Nishimura and Naito, 2006] is that Abcc5 has 
high expression, whereas Abcc6 and Abcc7 are moderately expressed in human 
lungs.  Additionally, Abcc4 and Abcc12 have low to moderate expression, and 
Abcc3 and Abcc11 are both expressed at low levels [kool et al., 1997; Langmann et 
al., 2003; bleasby et al., 2006; Nishimura and Naito, 2006].  these levels are in general 
agreement with the trends in expression levels for Abcc observed for Affymetrix DNA 
microarray data in whole lung.  However, Affymetrix microarray data suggested higher 
levels of Abcc3 for human bronchial epithelial tissue samples in comparison with 
whole lung.  this trend was also observed with qPcr data for bronchial epithelial cell 
models which showed moderate Abcc3 gene expression (0.02-0.5) in all cell layers 
tested.  similarly, in vitro NHbE and calu-3 cell cultures demonstrated moderate and 
high expression of Abcc3 respectively [Endter et al., 2009], and in agreement with 
observations in this chapter.  
the general consensus from published studies suggests Abcg2 is moderately 
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expressed in lung tissues [Langmann et al., 2003; bleasby et al., 2006, Nishimura 
and Naito, 2006].  Although Affymetrix DNA microarray also indicated that in whole 
lung tissue, Abcg2 was highly expressed (75-100% present), expression levels in 
both large and peripheral airway epithelia were negligible (0-25% present).  similar 
expression levels were demonstrated for calu-3 cell layers and NHbE cultures 
reported in this chapter which were found to have negligible (<0.001) and low (0.001-
0.02) expression, respectively, determined by qPcr.  However, expression levels 
determined by rt-Pcr in undifferentiated calu-3 and NHbE cultures demonstrated 
low and moderate expression levels, respectively.  In general, these studies suggest 
that although Abcg2 is likely to be expressed in the lung, it is unlikely to be present 
in bronchial epithelial cells.
the expression and localisation of other Abc transporters that were not investigated in 
these studies has been reported in the literature.  MrP1 expression has been reported 
for 16HbE14o- cells [van der Deen et al., 2007], NHbE [Lehmann et al., 2001] and 
basolateral localisation has been reported in calu-3 cells [Hamilton et al., 2001b] and 
on ciliated cells of the bronchial epithelium [brechot et al., 1998].  Absence of MrP3 
and MrP5 expression, weak staining for MrP4 and strong detection of MrP1 and 
bcrP have been observed for 16HbE14o- cells [van der Deen et al., 2007].  
4.4.5. sLc and sLcO transporters
In general transporter gene expression levels in published literature for the sLc and 
sLcO transporters in human lung tissue were largely in agreement those found with 
Affymetrix DNA microarray data [bleasby et al., 2006; Nishimura and Naito, 2006]. 
Interestingly, the same Affymetrix probe sets for sLc22A3, sLcO1c1 and sLcO2b1 
which showed moderate expression levels (50-75% present) for whole lung data 
were negligible (0-25% present) for bronchial epithelium tissue samples.  However, 
published expression levels of sLc22A3 in bronchial epithelial in vitro cultures and 
those reported in this chapter were in accordance with whole lung expression data.
the most noticeable disagreement between whole lung expression and in vitro 
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models was for sLcO1b3.  both Affymetrix DNA microarray and published microarray 
expression for sLcO1b3 in lung tissue indicated negligible expression levels (0-25% 
present, 0-25% AsI) in agreement with negligible (<0.001) and low (0.001-0.02) 
expression levels for NHbE cells expression data in this chapter and published 
expression levels for NHbE cultures [Endter et al., 2009].  However, moderate to high 
expression was observed for submerged calu-3 cultures [Endter et al., 2009] and for 
differentiated cell layers at both passages reported in this chapter.  Previous studies 
have indicated an overexpression of OAtP1b3 in small cell lung cancer, providing a 
potential explanation for the overexpression of sLcO1b3 in calu-3 cells [Monks et 
al., 2007].
there were also several differences observed for sLc and sLcO transporter gene 
expression between published levels in submerged, well plate cultured calu-3 cells, and 
calu-3 layers exposed to an AL interface for 21 days reported in this chapter.  sLc22A4, 
sLcO1A2, sLcO1b1, sLcO1c1 and sLcO2b1 were reported to have moderate to 
high expression in submerged cultures of calu-3 cells determined by rt-Pcr [Endter et 
al., 2009], but were found to be negligible (<0.001) from qPcr data in AL cultured calu-
3 cell layers.  NHbE cells and NHbE transporter expression levels were well matched 
between the studies with the exception of sLcO1A2 which was moderately expressed 
in NHbE passage 2 cells but not expressed in NHbE cultures in literature [Endter et al., 
2009].  
there are limited reports of transporter gene expression in healthy lung airway mucosa. 
In agreement with observations outlined in this chapter, upper airway epithelium (1st to 
3rd generation/trachea to large bronchi) displayed very low expression of sLc22A1-3 
but high expression of sLc22A4 and 5 [Horvath et al., 2007].  Detection of sLc22A1-
5 expression via rt-Pcr has also been reported in a separate study for calu-3 and 
16HbE14o- cells, with highest expression levels of sLc22A5 in agreement with qPcr 
results from this chapter [Ehrhardt et al., 2005].  In contrast, gene expression of sLcO 
transporters in healthy lung epithelium has not been investigated to date.  
there was no impact of medium supplementation on the gene expression of the 
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transporters investigated in rL-65 cells.  Additionally, transporter expression levels of 
sLc and sLcO transporters investigated for rL-65 cell layers were also comparable 
with literature.  the only difference observed for trends in gene expression were for 
slc22a3 which had negligible expression (<0.001) in rL-65 cell layers but moderate 
expression (50-75% AsI) was observed in whole rat lung [bleasby et al., 2006].  In 
contrast, slc22a1-3 were shown to be expressed on rat tracheal epithelial tissue [Lips 
et al., 2005; Lips et al., 2007].  From the transporters investigated, transporter gene 
expression in rL-65 cell layers appears to be in agreement with levels reported in rat 
lung tissues, with the exception of slc22a3.  
4.5. cONcLUsION
the impact of culture conditions on cell morphlogy and physiology was demonstrated 
in chapter three.  It was therefore postulated that culture conditions could also 
impact the expression and functionality of transporter systems.  Although transporter 
gene expression data has been published for in vitro airway cell lines, no studies for 
differentiated in vitro bronchial epithelial cells layers are available to date.  these 
studies have shown that differentiated layers of calu-3 and NHbE cells display 
considerable similarities for transporter expression data with whole lung and bronchial 
epithelial tissues.  there was a high degree of variability in Abcb1 expression levels 
in NHbE and calu-3 cells and similarly, literature for Abcb1 expression was found to 
be equally as inconsistent.  MDr1 localisation was confirmed on the apical surface of 
both NHbE and calu-3 cells at both passage ranges, but with lower expression at low 
passage compared with high passage.  In rL-65 cells, expression levels of abcb1a 
were negligible whilst abcb1b was moderately expressed.  Although rat mdr1a/1b 
transporters were not clearly detected by western blotting for rL-65 cell layers, 
positive apical localisation was determined using Icc, in agreement with studies in rat 
bronchial epithelial tissues.  these results suggest that the bronchial epithelial in vitro 
models tested may provide a good model of the bronchial epithelial pharmacology 
in vivo.  However, the functionality of these transporters in the in vitro models now 
remains to be assessed.  
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chapter Five
characterisation of 
AtP binding cassette (Abc) 
transporter Functionality 
5. cHArActErIsAtION OF AtP-bINDINg cAssEttE (Abc)  
 FUNctIONALItY
5.1. INtrODUctION
In chapter Four it was observed that, AL interface cultures of calu-3, NHbE and rL-65 
cell models expressed MDr1 or mdr1a/mdr1b on the apical cell surface.  In contrast 
the MrP2 transporter protein was not detected by Western blotting in calu-3 cells. 
Whilst MDr1 is the most well characterised and heavily investigated Abc transporter 
its binding specificity and mechanism of action are still largely unknown [glavinas et 
al., 2004; kimura et al., 2007; crowley and callaghan, 2010].  MDr1 has been well 
characterised in other epithelial tissues of the gI tract, kidney, liver and blood brain 
barrier.  Whilst there are a few reports regarding MDr1 in the airway epithelium there 
is much debate concerning functionality and contribution to inhaled drug trafficking 
[Van der Deen et al., 2005; bosquillon, 2010]. 
Information regarding the functionality of MDr1 in bronchial epithelial in vitro 
cultures is conflicting [bosquillon, 2010].  Net secretory transport of rh123, which 
was significantly diminished in the presence of verapamil was observed for NHbE 
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[Lin et al., 2007], 16HbE14o- and cFbE41o- cells [Ehrhardt et al., 2003].  similarly, 
in calu-3 cells the bA polarised transport of rh123 was reduced in the presence 
of ciclosporin A [Hamilton et al., 2001a] and net secretory transport of ciclosporin A 
abolished by quinidine [Patel et al., 2002].  bruilliant and colleages also observed 
a bA>Ab polarised MDr1-mediated transport of moxafloxacin in calu-3 cell layers 
which was inhibited by verapamil and Psc833 [brillault et al., 2009].  these studies 
all concluded the involvement of an apically located MDr1 efflux pump in the in vitro 
models.  In contrast, Florea and co-workers postulated basolateral localisation and 
functionality of MDr1 in their calu-3 cells after they observed AtP-dependent net 
absorptive transport of flunisolide which was inhibited by verapamil and Psc833 
[Florea et al., 2001].
Other published studies have concluded a negligible impact on drug transport, or an 
absence of MDr1 in bronchial epithelial in vitro cell cultures.  No polarised transport 
of digoxin, vinblastine or ciprofloxacin was observed in calu-3 epithelial cultures 
[cavet et al., 1997].  In agreement, Madlova and colleagues also found no polarised 
transport of 3H-digoxin in 14 day old calu-3 cell layers but found low efflux ratios 
sensitive to gF120918A after 21 days in culture only with high passage cells [Madlova 
et al., 2009].  similarly, no asymmetric transport of fexofenadine [Lin et al., 2007] and 
very low permeability of 3H-digoxin (P
app
 <0.8 x 10-6 cm/s) was observed for NHbE cell 
cultures with marginal asymmetric 3H-digoxin transport (Ab>bA) which was reversed 
in the presence of gF120918A [Madlova et al., 2009].
In isolated perfused rat lung models both tronde and colleagues and Madlova and 
co-workers observed an absence of functional mdr1a/b given the MDr1 substrate 
losartan was highly transported across the air-blood barrier [tronde et al., 2003b] 
and gF120918A did not have any significant effect (p>0.05) on 3H-digoxin transport 
[Madlova et al., 2009].  In contrast, the transfer of idarubicin from the perfusate into the 
lung tissue was concluded to be partly controlled by mdr1a/b due to the enhancement 
of absorption in the presence of MDr1 modulators cinchonine and rutin [kuhlmann 
et al., 2003].  Additionally, increased uptake of rhodamine 6g in the presence of 
verapamil and gF120918A was observed in isolated perfused rabbit lung [roerig 
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et al., 2004].  However, the studies by kuhlmann and roerig both added inhibitor 
compounds to the perfusion solution and were thus able to modulate transporters on 
both the endothelial cells of the pulmonary capillaries and at the airway epithelium. 
As postulated by bosquillon, the transporter(s) affected is/are more likely to be at the 
capillary endothelium site in the lung [Francombe et al., 2008; bosquillon, 2010].
In vivo studies conducted on mdr1a knock-out mice (mdr1a(-/-)) showed that after 
IV digoxin administration, drug concentrations in the lungs were 3.6 fold higher in 
mdr1a(-/-) mice than in wild type mice [Leusch et al., 2002].  conversely, after 
intratracheal instillation of digoxin to mdr1a(+/+) and mdr1a(-/-) mice no difference was 
observed in either maximum serum digoxin concentrations or the concentration-time 
profiles in both strains tested [Manford et al., 2008].  these findings again, highlight 
that in mice, mdr1a is more likely to be expressed and functional on the capillary 
endothelium than the airway epithelium [bosquillon, 2010].  One human study by 
ruparelia and co-workers observed the reduction of 99mtc-sestamibi concentration 
(MDr1 and MrP1 substrate [Hendrikse et al., 1998]) in the lungs of healthy smokers 
and cOPD sufferers compared with healthy, non-smoker human lungs [ruparelia et 
al., 2008].  this observation could be attributed to an up-regulation of MDr1 in the 
lungs of smokers but also, in agreement with studies by van der Deen and co-workers 
may also be to down regulation of MrP1 [van der Deen et al., 2007; bosquillon 
2010].
Differences in culture conditions (AL vs LL culture), length in culture, growth medium 
and supplementation have previously been shown in chapters three and Four to 
impact cell morphology and gene and protein expression.  these factors are also 
likely to contribute towards the conflicting reports regarding MDr1 functionality in the 
lung and bronchial epithelium.  Over the past decade, knowledge regarding substrate 
and inhibitor specificity has increased and an appreciation for multiple transporter 
involvement for compounds is emmerging.  It is now understood that substrates 
used in the aforementioned studies, including rh123 [van der sandt et al., 2000], 
ciprofloxacin [Park et al., 2011] and also inhibitor compounds gF120918A [de bruin et 
al., 1999] Psc833 [childs et al., 1998; Myllynen et al., 2006], ciclosporin A [kamisako 
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et al., 1999; kageyama et al., 2005; gupta et al., 2006; Myllynen et al., 2006] quinidine 
[Yabuuchi et al., 1999; Ohashi et al., 1999] and verapamil [Yabuuchi et al., 1999; 
Myllynen et al., 2006] are not specific for MDr1 alone and also target other Abc, 
sLc, sLcO transporters as well as the cYP450 system.  
5.2. AIMs
this chapter focuses on ascertaining the functionality of primarily MDr1 in calu-
3, NHbE and rL-65 in vitro cell models alongside positive and negative MDckII-
MDr1 transfected and wild type controls to gain an understanding of its potential 
functionality in the bronchial epithelium in vivo.  these studies have aimed to take 
an impartial approach to transporter functionality, taking into consideration all known 
Abc, sLc and sLcO transporters for the substrates and inhibitors used.  specifically, 
the objectives were to:
 screen calu-3 cell layers for functionality of MDr1 and MrP2 using 
 3H-digoxin and 3H-pravastatin, respectively
 compare and contrast 3H-digoxin trafficking between different in vitro  
 bronchial epithelial models (calu-3, NHbE and rL-65 cell layers) and  
 positive and negative controls (MDckII-MDr1 and MDckII-Wt cells)
 characterise the trafficking of 3H-digoxin in all in vitro models and 
 define/suggest the transporters most likely involved in the  
 bronchial epithelium
5.3. rEsULts
5.3.1. screening transporter functionality
the impact of substrate concentration on flux of 3H-digoxin and 3H-pravastatin was 
investigated to ensure permeability studies were conducted at concentrations where 
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transporter mediated substrate trafficking was not saturated.  A linear correlation 
between flux and substrate concentration was observed for both 3H-digoxin (25 nM 
– 100 µM) and 3H-pravastatin (100 nM – 10 mM) (Figure 5.1).  3H-digoxin and 3H-
pravastatin were therefore used at 25 nM and 100 nM concentrations, respectively 
throughout these studies.
the permeability of tritiated compounds known to interact with drug transporters, 
digoxin (MDr1, MrP, OAtP), pravastatin (MrP2, OAtP) and taurocholate (bsEP, 
MrP3, OAtP) were screened in calu-3 cells at low and high passage (Figure 5.2). 
Net secretory transport of 3H-digoxin was observed for calu-3 cells at both low and 
high passage ranges.  the bA transport of 3H-digoxin was significantly higher (p<0.01) 
for low passage cells (8.54 x 10-6
 
cm/s) in comparison with high passage cells (4.1 
x 10-6 cm/s) generating efflux ratios of 7.4 and 2.7 respectively.  In contrast there 
was no significant difference in the Ab 3H-digoxin P
app
 between the passage ranges 
tested.  3H-pravastatin and 3H-taurocholic acid had P
app
 values < 1 x 10-6 cm/s and no 
significant difference (p>0.05) was observed between Ab and bA transport of either 
substrate at any passage tested.
the permeability of 3H-digoxin across differentiated layers of NHbE cells was more 
variable than for calu-3 cells despite originating from the same 61 year old, Hispanic 
non-smoker subject (Figure 5.3).  In the first batch of cells revived (batch 1) net 
secretory transport of 3H-digoxin was observed producing an efflux ratio of 2.3 at 
passage 2.  In contrast, passage 3 cells generated significantly lower (p<0.01) 3H-
digoxin P
app
 values in both absorptive and secretory directions, and the efflux ratio 
was reduced from 2.3 to 0.7.  3H-digoxin transport in this instance does not appear 
reflective of MDr1 expression which was more highly expressed in passage 3 NHbE 
cells compared with passage 2 (Figure 4.7).  the second batch of NHbE cells had a 
significantly lower (p<0.05) Ab 3H-digoxin P
app
 after 21 days compared with 23 days, 
and both were significantly higher (p<0.05) than batch 1.  No significant difference was 
observed for bA 3H-digoxin P
app
 between all batches tested, likely due to large intra-
batch variation.  Efflux ratios for batch 2 cells were between 1.0-1.3, indicating no net 
137ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdWŝŶĚŝŶŐĂƐƐĞƩĞ ? ZdƌĂŶƐƉŽƌƚĞƌ&ƵŶĐƟŽŶĂůŝƚǇ
Figure 5.1. Flux of 3H-digoxin and 3H-pravastatin across Calu-3 cell layers at various 
concentrations
Flux of various concentrations of (A) 3H-digoxin (25 nM – 100 µM) and (b) 3H-pravastatin (100 
nM – 1 mM) across calu-3 cell layers cultured on 12 well, 0.4 µm transwell® inserts.  cells 
were seeded at a density of 1 x 105 cells/cm2 and cultured at the AL interface for 21 days. 
cells were incubated in sbs for 60 min prior to and throughout the duration of functional 
experiments.  cells were tested at either low passage (25-30) or high passage (45-50) in both 
absorptive (Ab) and efflux (bA) directions.  Data are represented as mean ± sd of 3-4 cell 
layers. ** indicates p<0.01 for bA flux of 100 µM 3H-digoxin after 2h between low and high 
passage calu-3 cells.
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Figure 5.2. Transport of tritated substrates across Calu-3 cells layers
transport of 25 nM of 3H-digoxin, 100 nM 3H-pravastatin and 217 nM 3H-taurocholic acid 
across calu-3 cell layers in (A) low passage (25-30) and (b) high passage (45-50) cells in both 
absorptive (Ab) and secretory (bA) directions.  cells were seeded on to 12 well transwell® 
inserts at a density of 1 x 105 cells/cm2 and cultured at the AL interface for 21 days.  cells were 
incubated in sbs and maintained at 37°c prior to and throughout the duration of functional 
experiments. Data are represented as mean ± sd of 3-4 cell layers. ** indicates a significant 
difference (p<0.01) between Ab and bA substrate P
app
 value.  Efflux ratios (bA P
app
/Ab P
app
) 
are stated above each condition.
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Figure 5.3. Transport of 3H-digoxin  across  NHBE cell layers
transport of 25 nM of 3H-digoxin at 37°c across NHbE cell layers cultured on 24 well, 0.4 
µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  cells were 
seeded at a density of 1.65 x 105 cells/cm2 and raised to the AL interface 48 hours after 
seeding.  Experiments were conducted on two batches of NHbE cells from the same donor 
at either passage 2 or 3, after 21 days or 23 days (#) in air-liquid interface culture. cells were 
incubated in sbs containing 1% v/v DMsO for 60 min prior to and throughout the duration of 
functional experiments. Data are represented as mean ± sd of 3-4 cell layers. * and ** indicate 
a significant difference (p<0.05) and (p<0.01), respectively between 3H-digoxin P
app
 values 
indicated.  Efflux ratios (bA P
app
/Ab P
app
) are stated above each condition.
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asymmetric transport of 3H-digoxin whereas net secretory transport was observed for 
batch 1 (efflux ratio 2.3).  
the permeability of two broad specificity substrates 3H-digoxin (MDr, OAtP) and 
rh123 (MDr1, MrP, Oct) was investigated in rL-65 cells to screen for transporter 
activity (Figure 5.4).  No asymmetric transport of 3H-digoxin was observed for rL-65 
cells in all culture conditions tested (efflux values ~ 1.0).  3H-digoxin transport was not 
significantly different (p>0.05) in both Ab and bA directions after 21 days in culture 
compared with 8 days in scM cultures.  there was also no significant difference 
(p>0.05) in Ab 3H-digoxin P
app
 between sFM and scM after 8 days, however bA 
transport was significantly lower (p<0.01) in scM cultures.  P
app
 values for rh123 
were all below 1.1 x 10-6 cm/s for all culture conditions tested.  Although a significant 
difference was observed between absorptive and secretory rh123 P
app
 for cell layers 
cultured in scM for 8 days, the low efflux ratio (1.4) did not indicate a secretory 
transport process.  rh123 P
app
 values for rL-65 cell layers cultured in sFM for 8 days 
or scM for 21 days were significantly lower (p<0.01) and no significant difference 
(p>0.05) was observed for absorptive and secretory rh123 P
app
.  
5.3.2.  characterisation of 3H-digoxin transport 
5.3.2.1. Dependency on cellular energy
the influence of temperature and sodium azide (to deplete cellular energy) on 3H-
digoxin transport in in vitro bronchial epithelial cell layers was investigated.  Net 
secretory transport of 3H-digoxin was observed for both calu-3 and NHbE cells as 
well as MDckII-Wt (negative control) and MDckII-MDr1 (positive control) cells at 
37°c (Figure 5.5A).  At 4°c both Ab and bA 3H-digoxin P
app
 and efflux ratio were 
significantly reduced (p<0.01) in all cell types investigated (Figure 5.5b).  sodium 
azide was used to probe the AtP dependency of 3H-digoxin trafficking in the cell 
models.  based on values stated in literature [Hamilton et al., 2001a], and preliminary 
experiments in calu-3 cells demonstrating a plateau in AtP levels (and with no impact 
on tEEr values), exposure to 15 mM sodium azide for 3 hours was selected (Figure 
5.6).  sodium azide 15 mM had no significant (p>0.05) impact on 3H-digoxin P
app
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Figure 5.4. Transport of 3H-digoxin and Rh123 across RL-65 cell layers
transport of (A) 25 nM of 3H-digoxin and (b) 5 µM rh123 across rL-65 cell layers cultured 
on 12 well, 0.4 µm transwell® inserts at 37°c in both absorptive (Ab) and secretory (bA) 
directions.  cells were seeded at a density of 1 x 105 cells/cm2 cultured at the AL interface in 
sFM for 8 and scM for 8 and 21 days.  cells were incubated in sbs for 60 min prior to and 
throughout the duration of functional experiments. Data are represented as mean ± sd of 4-
6 cell layers. * and ** indicate significant differences of (p<0.05) and (p<0.01), respectively 
between substrate P
app
 values highlighted.  Efflux ratios (bA P
app
/Ab P
app
) are stated above 
each condition.
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Figure 5.5. The impact of temperature on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cell/cm2 and 1.65 x 105 cells/cm2, respectively and cultured at 
the AL interface for 21-22 days.  cells were incubated in sbs at (A) 37°c (control) or (b) 4°c 
for 60 min prior to and throughout the duration of functional experiments. Data are represented 
as mean ± sd of 3-4 cell layers. * and ** indicate a significant difference (p<0.05) and (p<0.01) 
respectively between the 3H-digoxin P
app
 value at  4°c (b) and control conditions at 37°c (A). 
Efflux ratios (bA P
app
/Ab P
app
) are stated above each condition.
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Figure 5.6. ATP depletion in Calu-3 cells treated with various concentrations of sodium 
azide
relative % of AtP present in calu-3 cells at low (25-30) and high (45-50) passage treated with 
1.5 to 150 mM  sodium azide for 1-6 hours.  calu-3 cells were seeded on to 12 well transwell® 
inserts at a density of 1 x 105 cells/cm2 and cultured at an air-liquid interface for 21 days before 
experimentation.  Data are represented as mean ± sd for n = 3 samples.
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across MDckII-Wt, calu-3 low passage and NHbE cell layers (Figure 5.7), despite a 
reduction in AtP levels in the cells to 18%, 49% and 80% relative to non-treated cells 
respectively (table 5.1).  In contrast transport of 3H-digoxin was significantly reduced 
in MDckII-MDr1 cell layers in both absorptive (p<0.05) and secretory (p<0.01) 
directions.  similarly, bA 3H-digoxin transport for high passage calu-3 cell layers was 
also significantly reduced (p<0.05) in the presence of 15 mM sodium azide.  
5.3.2.2. chemical inhibition of transporter-mediated trafficking mechanisms
In the presence of 1 µM Psc833 there was a significant decrease (p<0.01) in 3H-
digoxin secretory transport in all cell types tested (Figure 5.8), resulting in reduced 
efflux ratios for all cell line layers tested.  In MDckII-MDr1 and both calu-3 passages 
there was also a significant increase (p<0.01) in Ab 3H-digoxin P
app
 whilst there was a 
significant decrease (p<0.01) for NHbE cells.  similarly, a decrease in efflux ratio for 
all cell types except NHbE was observed in the presence of 30 µM verapamil (Figure 
5.9).  there was a significant increase (p<0.01) in 3H digoxin Ab P
app
 for all cell types 
incubated with verapamil and a significant decrease (p<0.01) in bA 3H-digoxin P
app
 for 
all cells except NHbE cells where there was a significant increase (p<0.01).  
3H-digoxin transport was significantly reduced (p<0.01) in the bA direction for all 
bronchial epithelial cell types with 30 µM Mk571 but no significant difference (p>0.05) 
was observed for MDckII cells (Figure 5.10).  A significant increase (p<0.01) in 3H-
digoxin Ab P
app
 was seen for all cell types with the exception of NHbE cells where it 
was significantly decreased (p<0.01).  Additionally, there was a marked decrease in 
efflux ratio for 3H-digoxin for all cell types tested.  In contrast, 10 µM indometacin had no 
significant impact (p>0.05) on 3H-digoxin P
app
 in calu-3 cells at either passage, whilst 
there was a significant increase in Ab 3H-digoxin P
app
 in MDckII-Wt cells (p<0.01) 
and MDckII-MDr1 and NHbE cells (p<0.05) (Figure 5.11).  Additionally, a significant 
decrease in bA 3H-digoxin transport was observed for both MDckII cell types (p<0.05) 
and NHbE cells (p<0.01).  the presence of 1 mM probenecid had no significant impact 
(p>0.05) on 3H-digoxin transport in MDckII-Wt, MDckII-MDr1 or calu-3 low passage 
cell layers (Figure 5.12).  However, 3H-digoxin P
app
 was significantly reduced (p<0.01) 
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Figure 5.7. The impact of metabolic inhibitors on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cell/cm2 and 1.65 x 105 cells/cm2, respectively and cultured at the 
AL interface for 21-22 days.  cells were incubated in (A) sbs (control) or (b) sodium azide 15 
mM in sbs (metabolic inhibitor of oxidative phosphorylation) for 60 min prior to and throughout 
the duration of functional experiments. Data are represented as mean ± sd of 3-4 cell layers. 
* and ** indicate a significant difference (p<0.05) and (p<0.01), respectively between the 3H-
digoxin P
app
 value in the presence of sodium azide (b) and control conditions (A).  Efflux ratios 
(bA P
app
/Ab P
app
) are stated above each condition. 
0
1
2
3
4
5
6
7
8
9
10
MDCKII-WT  MDCKII-MDR1  Calu-3 Low  Calu-3 High  NHBE
W Ă
ƉƉ
 ? 
?ǆ
 ? 
? ? ? Đ
ŵ 
?Ɛ 
?
AB
BA
0
1
2
3
4
5
6
7
8
9
10
MDCKII-WT MDCKII-MDR1  Calu-3 Low  Calu-3 High  NHBE
W Ă
ƉƉ
 ? 
?ǆ
 ? 
? ? ? Đ
ŵ 
?Ɛ 
?
AB
BA
&ŝŐƵƌĞ ? ? ? PdŚĞŝŵƉĂĐƚŽĨŵĞƚĂďŽůŝĐŝŶŚŝďŝƚŽƌƐŽŶ ?, ĚŝŐŽǆŝŶƚƌĂŶƐƉŽƌƚ

ĂƉƉ
A 
B 4.8                 9.9                28.8              4.2              0.9 
4.7                 9.8                25.9                4.9              1.3 
** 
* 
* 
P
a
p
p
 (
1
 x
 1
0
-6
 c
m
/s
)
P
a
p
p
 (
1
 x
 1
0
-6
 c
m
/s
)
146ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdWŝŶĚŝŶŐĂƐƐĞƩĞ ? ZdƌĂŶƐƉŽƌƚĞƌ&ƵŶĐƟŽŶĂůŝƚǇ
Table 5.1. Impact of 3 hour incubation in sodium azide 15 mM on ATP levels in in vitro 
epithelial models
relative % of AtP present in epithelial in vitro cell models treated with sodium azide 15 mM for 
3 h. calu-3 cells were seeded on to 12 well transwell® inserts at a density of 1 x 105 cells/cm2, 
and NHbE cells onto 24 well transwell® inserts at 1.65 x 105 cells/cm2 and both cultured at an 
air-liquid interface for 21 days before experimentation. MDckII cells were seeded on 12 well 
transwell® inserts at a seeding density of 5 x 105 cells/cm2 and cultured under submerged 
conditions for 5 days.  relative levels of AtP are presented (sodium azide treated sample/
control sample x 100) and are represented as mean ± sd for n=3 cell layers (calu-3, MDckII 
cells) and n=1 (NHbE cells).
  sodium Azide
 cell type 15mM
 calu-3 Low 48.6 ± 7.0
 calu-3 High 53.7 ± 5.3
 NHbE 80.4
 MDckII-Wt 17.6 ± 4.0
 MDckII-MDr1 28.8 ± 6.8
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Figure 5.8. The impact of PSC833 on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cells/cm2 and 1.65 x 105 cells/cm2, respectively and cultured at 
the AL interface for 21-22 days.  cells were incubated in (A) sbs (control) or (b) 1 µM Psc833 
in sbs, for 60 min prior to and throughout the duration of functional experiments. Data are 
represented as mean ± sd of 3-4 cell layers. * and ** indicate a significant difference (p<0.05) 
and (p<0.01), respectively between the 3H-digoxin P
app
 value in the presence of Psc833 (b) 
and control conditions (A).  Efflux ratios (bA P
app
/Ab P
app
) are stated above each condition. 
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Figure 5.9. The impact of verapamil on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cells/cm2 and 1.65 x 105 cells/cm2, respectively and cultured at the 
AL interface for 21-22 days.  cells were incubated in (A) sbs (control) or (b) 30 µM verapamil 
in sbs, for 60 min prior to and throughout the duration of functional experiments. Data are 
represented as mean ± sd of 3-4 cell layers. * and ** indicate a significant difference  (p<0.05) 
and (p<0.01), respectively between the 3H-digoxin P
app
 value in the presence of verapamil (b) 
and control conditions (A).  Efflux ratios (bA P
app
/Ab P
app
) are stated above each condition. 
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Figure 5.10. The impact of MK571 on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cells/cm2 and 1.65 x 105 cells/cm2, respectively and cultured at 
the AL interface for 21-22 days.  cells were incubated in (A) sbs (control) or (b) 30 µM Mk571 
in sbs, for 60 min prior to and throughout the duration of functional experiments. Data are 
represented as mean ± sd of 3-4 cell layers. * and ** indicate a significant difference (p<0.05) 
and (p<0.01), respectively between the 3H-digoxin P
app
 value in the presence of Mk571 (b) 
and control conditions (A).  Efflux ratios (bA P
app
/Ab P
app
) are stated above each condition. 
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Figure 5.11. The impact of indometacin on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cells/cm2 and 1.65 x 105 cells/cm2, respectively and cultured 
at the AL interface for 21-22 days.  cells were incubated in (A) sbs (control) or (b) 10 µM 
indometacin in sbs, for 60 min prior to and throughout the duration of functional experiments. 
Data are represented as mean ± sd of 3-4 cell layers. * and ** indicate a significant difference 
(p<0.05) and (p<0.01), respectively between the 3H-digoxin P
app
 value in the presence of 
indometacin (b) and control conditions (A).  Efflux ratios (bA P
app
/Ab P
app
) are stated above 
each condition. 
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Figure 5.12. The impact of probenecid on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cells/cm2 and 1.65 x 105 cells/cm2, respectively and cultured at the 
AL interface for 21-22 days.  cells were incubated in (A) sbs (control) or (b) 1mM probenecid 
in sbs, for 60 min prior to and throughout the duration of functional experiments. Data are 
represented as mean ± sd of 3-4 cell layers. * and ** indicate a significant difference (p<0.05) 
and (p<0.01), respectively between the 3H-digoxin P
app
 value in the presence of probenecid (b) 
and control conditions (A).  Efflux ratios (bA P
app
/Ab P
app
) are stated above each condition. 
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in both Ab and bA directions in NHbE cells whereas only the Ab 3H-digoxin P
app
 was 
significantly increased (p<0.01) in calu-3 cells at high passage.
5.3.2.3. biological inhibition of MDr1 functionality
binding of both UIc2 and Mrk16 antibodies after transport experiments was 
confirmed in all cells tested using Icc techniques (Figure 4.4 and 4.5).  As such, the 
secretory 3H-digoxin P
app
 was significantly reduced by pre-incubation with 15 µg/ml 
Mrk16 antibody in MDckII-MDr1 (p<0.01) and calu-3 low passage cells (p<0.05) 
which reduced the efflux ratio from 21.7 to 15.6 and 7.4 to 7.0, respectively (Figure 
5.13).  In contrast no significant difference (p>0.05) in 3H-digoxin P
app
 was observed 
in any other cell types tested.  similarly, pre-incubation with 20 µg/ml UIc2 antibody 
significantly increased Ab (p<0.01) and (p<0.05) bA 3H-digoxin P
app
, which reduced 
the efflux ratio from 21.7 to 14.3 in MDckII-MDr1 cells (Figure 5.14).  A significant 
(p<0.01) decrease in 3H-digoxin Ab P
app
 for calu-3 low passage cells and increase in 
NHbE cells was also observed with pre-incubation in UIc2 20 µg/ml.   
the UIc2 shift assay was used to assess the influence of chemical inhibitor compounds 
on the binding affinity of the anti-human MDr1 antibody (UIc2), thus aiding the 
assessment of their interaction with MDr1.  to compensate for sample variability in 
the UIc2 shift assay, only differences of 10% to control were considered significant.  In 
the presence of 1 µM Psc833 there was enhanced fluorescence intensity for MDckII-
MDr1 cells (relative MFI 1.8) and smaller increases in fluorescence intensity were 
observed for calu-3 cells at low (1.27) and high passage (1.26) and NHbE (1.16). 
In contrast a difference of less than 10% in fluorescence intensity was observed for 
MDckII-MDr1 cells and therefore not considered significant. (Figure 5.15).  All the 
other chemical compounds tested (namely 30 µM verapamil, 30 µM Mk571, 10 µM 
indometacin and 1 mM probenecid) did not elicit alterations in UIc2 binding above the 
10% cut off and were not considered different to control (Figures 5.16 – 5.19).  
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Figure 5.13. The impact of MRK16 (MDR1-inhibitory antibody) on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cells/cm2 and 1.65 x 105 cells/cm2, respectively and cultured 
at the AL interface for 21-22 days.  cells were incubated in (A) sbs (control) or (b) 15 µg/ml 
Mrk16 in sbs, for 60 min prior to and throughout the duration of functional experiments. 
Data are represented as mean ± sd of 3-4 cell layers. * and ** indicate a significant difference 
(p<0.05) and (p<0.01), respectively between the 3H-digoxin P
app
 value when pre-incubated 
with Mrk16 (b) and control conditions (A).  Efflux ratios (bA P
app
/Ab P
app
) are stated above 
each condition. 
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Figure 5.14. The impact of UIC2 (MDR1-inhibitory antibody) on 3H-digoxin transport 
transport of 25 nM of 3H-digoxin across epithelial cell models cultured on 12 well or 24 well, 
0.4 µm transwell® inserts in both absorptive (Ab) and secretory (bA) directions.  MDckII-Wt 
(negative control) and MDckII-MDr1 (positive control)  were seeded at a density of 5 x 105 
cells/cm2  and cultured under submerged conditions for 5 days.  calu-3 and NHbE cells were 
seeded at a density of 1 x 105 cells/cm2 and 1.65 x 105 cells/cm2, respectively and cultured at 
the AL interface for 21-22 days.  cells were incubated in (A) sbs (control) or (b) 20 µg/ml UIc2 
in sbs, for 60 min prior to and throughout the duration of functional experiments. Data are 
represented as mean ± sd of 3-4 cell layers. * and ** indicate a significant difference (p<0.05) 
and (p<0.01), respectively between the 3H-digoxin P
app
 value when pre-incubated with UIc2 (b) 
and control conditions (A).  Efflux ratios (bA P
app
/Ab P
app
) are stated above each condition.
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Figure 5.15. Binding affinity of UIC2 to epithelial cell in the presence of PSC833
Flow cytometry for 1 x 105 cells of (A) low passage calu-3 cells; (b) high passage calu-3 cells; 
(c) NHbE cells passage 2, (D) MDckII-Wt and (E) MDckII-MDr1cells cultured on 12 well 
(A, b, D and E) or 24  well (c) transwell® inserts at the AL interface for 5 (D and E) or 21 (A-
c) days. samples incubated with 0.2 µg / 100 µl UIc2 (mouse anti-human MDr1) antibody 
and labelled with goat anti-mouse Igg FItc-tagged secondary antibody (1:1000). black line 
shows histogram for control samples incubated with UIc2, red line shows histogram for cells 
pre-incubated with 1 µM Psc833 for 10 min prior to and during incubation with UIc2. relative 
MFI (Psc833 MFI / control MFI) stated on. results are from a total of 3 x 104 events.  All viable 
cells were gated and dead cells ruled out by size and granularity from previous optimisation 
experiments with propidium iodide. 
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Figure 5.16. Binding affinity of UIC2 to epithelial cell in the presence of verapamil
Flow cytometry for 1 x 105 cells of (A) low passage calu-3 cells; (b) high passage calu-3 cells; 
(c) NHbE cells passage 2, (D) MDckII-Wt and (E) MDckII-MDr1cells cultured on 12 well 
(A, b, D and E) or 24  well (c) transwell® inserts at the AL interface for 5 (D and E) or 21 (A-c) 
days. samples incubated with 0.2 µg / 100 µl UIc2 (mouse anti-human MDr1) antibody and 
labelled with goat anti-mouse Igg FItc-tagged secondary antibody (1:1000). black line shows 
histogram for control samples incubated with UIc2, red line shows histogram for cells pre-
incubated with 30 µM verapamil 10 min prior to and during incubation with UIc2. relative MFI 
(verapamil MFI / control MFI) stated on. results are from a total of 3 x 104 events.  All viable 
cells were gated and dead cells ruled out by size and granularity from previous optimisation 
experiments with propidium iodide. 
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Figure 5.17. Binding affinity of UIC2 to epithelial cell in the presence of MK571
Flow cytometry for 1 x 105 cells of (A) low passage calu-3 cells; (b) high passage calu-3 cells; 
(c) NHbE cells passage 2, (D) MDckII-Wt and (E) MDckII-MDr1cells cultured on 12 well 
(A, b, D and E) or 24  well (c) transwell® inserts at the AL interface for 5 (D and E) or 21 (A-
c) days. samples incubated with 0.2 µg / 100 µl UIc2 (mouse anti-human MDr1) antibody 
and labelled with goat anti-mouse Igg FItc-tagged secondary antibody (1:1000). black line 
shows histogram for control samples incubated with UIc2, red line shows histogram for cells 
pre-incubated with 30 µM Mk571 10 min prior to and during incubation with UIc2. relative 
MFI (Mk571 MFI / control MFI) stated on. results are from a total of 3 x 104 events.  All viable 
cells were gated and dead cells ruled out by size and granularity from previous optimisation 
experiments with propidium iodide. 
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Figure 5.18. Binding affinity of UIC2 to epithelial cell in the presence of probenecid
Flow cytometry for 1 x 105 cells of (A) low passage calu-3 cells; (b) high passage calu-3 cells; 
(c) NHbE cells passage 2, (D) MDckII-Wt and (E) MDckII-MDr1cells cultured on 12 well 
(A, b, D and E) or 24  well (c) transwell® inserts at the AL interface for 5 (D and E) or 21 (A-c) 
days. samples incubated with 0.2 µg / 100 µl UIc2 (mouse anti-human MDr1) antibody and 
labelled with goat anti-mouse Igg FItc-tagged secondary antibody (1:1000). black line shows 
histogram for control samples incubated with UIc2, red line shows histogram for cells pre-
incubated with 1 mM probenecid 10 min prior to and during incubation with UIc2. relative MFI 
(probenecid MFI / control MFI) stated on. results are from a total of 3 x 104 events.  All viable 
cells were gated and dead cells ruled out by size and granularity from previous optimisation 
experiments with propidium iodide. 
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Figure 5.19. Binding affinity of UIC2 to epithelial cell in the presence of indometacin
Flow cytometry for 1 x 105 cells of (A) low passage calu-3 cells; (b) high passage calu-3 cells; 
(c) NHbE cells passage 2, (D) MDckII-Wt and (E) MDckII-MDr1cells cultured on 12 well 
(A, b, D and E) or 24  well (c) transwell® inserts at the AL interface for 5 (D and E) or 21 (A-c) 
days. samples incubated with 0.2 µg / 100 µl UIc2 (mouse anti-human MDr1) antibody and 
labelled with goat anti-mouse Igg FItc-tagged secondary antibody (1:1000). black line shows 
histogram for control samples incubated with UIc2, red line shows histogram for cells pre-
incubated with 10 µM indometacin 10 min prior to and during incubation with UIc2. relative 
MFI (indometacin MFI / control MFI) stated on. results are from a total of 3 x 104 events. 
All viable cells were gated and dead cells ruled out by size and granularity from previous 
optimisation experiments with propidium iodide. 
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5.4. DIscUssION
5.4.1. substrate permeability screening
Additional to its high lipophilicity and ability to cross the plasma membrane by passive 
diffusion, the cardiac glycoside digoxin has been well characterised as an MDr1 
substrate [de Lannoy and silverman, 1992; rautio et al., 2006].  As such, digoxin 
has been recommended in the literature as the choice substrate probe for MDr1 
[rautio et al., 2006; keogh and kunta, 2006] and is an FDA approved drug molecule 
for MDr1 permeability screening of candidate drug compounds [Huang et al., 
2007].  However, in the last decade it has been shown that digoxin is a substrate for 
transporters other than MDr1, namely MDr3 [smith et al., 2000], OAtP1b3 [kullak-
Ublick et al., 2001] and OAtP4c1 [Mikkaichi et al., 2004; Yamaguchi et al., 2010]. 
In contradiction to studies by kullak-Ublick and co-workers, OAtP1A2, OAtP1b1, 
OAtP1b3 and OAtP2b1 were shown not to transport digoxin, but the compound 
was found to be an inhibitor for OAtP1b1 and OAtP1b3 transporters [taub et al., 
2011].  Variations in transporter cloning methods and transfection into different in 
vitro cell models may influence transporter functionality.  Whilst overlap of substrates 
and inhibitors between MDr1 and bcrP has been reported [de bruin et al., 1999; 
Litmann et al., 2000; Pavek et al., 2005] digoxin has been shown not to be a substrate 
for bcrP [taipalensuu et al., 2004; Pavek et al., 2005; Yue et al., 2009].  there also 
remains the possibility that digoxin is trafficked by a transporter yet to be identified 
[Acharya et al., 2008; kimoto et al., 2010; taub et al., 2011].
similarly, the apical efflux transporter MrP2 shares some substrate overlap with 
MDr1 [Evers et al., 1998; chan et al., 2004].  However, MrP2 has been shown not 
to contribute significantly to digoxin transport [Lowes et al., 2003; taipalensuu et al., 
2004].  the hydroxymethylglutaryl-coA reducase inhibitor pravastatin is a substrate 
for MrP2 [Yamazaki et al., 1997; sasaki et al., 2002], bsEP [Hirano et al., 2005], 
bcrP [Matsushima et al., 2005], OAtP1b1 [Hsiang et al., 1999; Nakai et al., 2001; 
seithel et al., 2007], OAtP1b3 [seithel et al., 2007] and OAt3 [Nakagami-Hagihara et 
al., 2002].  taurocholic acid is an established substrate for bsEP [green et al., 2000; 
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stieger et al., 2000], MrP3 [Hirohashi et al., 2000], OAtP1A2 [kullak-Ublick et al., 
1995], OAtP1b1 [Abe et al., 1999; Hsiang et al., 1999; cui et al., 2001], OAtP1b3 
[Abe et al., 2001; Letschert et al., 2004] and OAtP4A1 [Fugiwara et al., 2001].  
transport of 3H-pravastatin and 3H-taurocholic acid in calu-3 cells was not polarised 
and was below 1 x 10-6 cm/s in both absorptive and secretory directions in both 
passages tested.  this suggests that bsEP, MrP2, MrP3, bcrP, OAtP1A2, 
OAtP1b1, OAtP1b3 and OAPt4A1 transporters were absent or not functional in 
calu-3 cells at both low and high passages.  this is in agreement with negligible to 
low expression of bsEP, bcrP, OAtP1A2 and OAtP1b1 in calu-3 cells in chapter 
Four (tables 4.9-4.10).  Although moderate gene expression levels were detected for 
MrP3, OAtP1b3 and OAtP4A1 transporters, functionality data indicates these are 
unlikely to be present or active in calu-3 cell layers.  However, it has been reported 
that taurocholate transport by human MrP3 was minimal in comparison with rat mrp3 
[Akita et al., 2002].
Limited functional data regarding transporters for 3H-pravastatin and 3H-taurocholic 
acid exists in the literature for the lung and for bronchial epithelial models.  Pravastatin 
was found to reduce fentanyl lung:plasma partitioning 6 fold in sprague-Dawley rats 
administered IV [Elkiweri et al., 2009] indicating a pravastatin-mediated inhibition of 
transporter(s) in the lung, however similarly to MDr1 in vivo studies, this interaction 
is likely to take place at the capillary endothelium or alternatively at the basolateral 
side of epithelial cells.  to date no other studies regarding these substrates in the lung 
have been published.   
to date, the only published report of MrP2 functionality in bronchial epithelial cells 
was conducted by Li and co-workers who, contradictory to our studies observed an 
MrP2-dependent excretion of glutathione-s-bimane from calu-3 cells [Lin et al., 
2007].  However, studies by van de Water and co-workers demonstrated glutathione-
s-bimane efflux in cell lines that did not express MrP2 at both gene and protein levels 
indicating the involvement of other transporters [van de Water et al., 2007].  
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both MrP2, OAtP1b3 have been reported to be over expressed in non-small cell lung 
cancer tissue [Monks et al., 2007].  However, despite the cancerous nature of calu-
3 cells, no functionality of these transporters was observed in our cultures.  to date 
there are no functional reports concerning MrP3, OAtP1A2, OAtP1b1, OAtP1b3 or 
OAtP4A1 in the lung or bronchial epithelial in vitro cell models. 
transporter mediated trafficking of 3H-digoxin was not saturated up to 100 µM, in 
agreement with reports for other cell lines where the maximum solubility of digoxin 
was below concentrations that would saturate transport mechanisms [keogh and 
kunta, 2006].  As outlined in the introduction to this chapter, MDr1 functionality in 
bronchial epithelial in vitro models is conflicting, however, net secretory transport of 
3H-digoxin was observed for calu-3 cells after 21 days in AL culture at both passages 
but to a greater extent than previously reported [Madlova et al., 2009].  Interestingly, 
identical medium, supplementation, seeding density, and culture conditions were used 
in these studies and those by Madlova and co-workers.  Additionally, cells were used 
at a similar passage range and experiments conducted after 21 days of AL interface 
culture.  this highlights the variability of transporter functionality either due to batch 
variations of serum or user handling.
3H-digoxin transport for passage 3 NHbE cells observed in these studies produced 
similar P
app
 values and Ab P
app
>bA P
app
 to work published by Madlova and co-workers 
with NHbE passage 2 cells [Madlova et al., 2009].  3H-digoxin P
app
 values reported for 
passage 2 NHbE cells in these studies were ~10 fold higher than values reported for 
3H-digoxin and rh123 in the literature [Lin et al., 2007; Madlova et al., 2009] in light of 
maintained polarised cell layers throughout the duration of functionality experiments. 
the differences in medium supplementation may play a role in explaining these 
differences in drug trafficking, however primary cultures of human bronchial epithelial 
cells from different donors are also likely to vary in transporter expression and 
functionality between individuals.  this variability may be dependent on genetic and/
or environmental factors such as disease, smoking and inhaled exposure to drugs or 
pollutants [van der Deen et al., 2006; van der Deen et al., 2007].  
163ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdWŝŶĚŝŶŐĂƐƐĞƩĞ ? ZdƌĂŶƐƉŽƌƚĞƌ&ƵŶĐƟŽŶĂůŝƚǇ
3H-digoxin transport in calu-3 cells is unlikely to be mediated by MrP2 and OAtP1b3 
given the low and symmetric transport of 3H-pravastatin and 3H-taurocholic acid, which 
have previously been shown to be substrates for one or both of these transporters. 
Although MrP1 has been identified on the basolateral membranes of calu-3 cells, it 
is not established to transport 3H-digoxin and also the basolateral location of MrP1 
would not be predicted to drive net secretion of 3H-digoxin [Hamilton et al., 2001b]. 
the other established substrates for 3H-digoxin are MDr1 and OAtP4c1 which 
had moderate and low gene expression in calu-3 cells at low and high passage 
respectively.  MDr1 protein expression was greater in high passage calu-3 cells 
compared with low passage cells, which opposes the levels of net secretory transport 
observed at each passage.  given this discrepancy in MDr1 protein expression and 
functionality it seems unlikely MDr1 is solely responsible for 3H-digoxin trafficking in 
calu-3 cell layers.  
similarly for NHbE cell layers, MDr1 is also unlikely to mediate 3H-digoxin transport 
given that gene and protein expression levels in the model were negligible to low. 
Additionally, the lower efflux ratios (0.7-2.3) signify a reduced level of net secretory 
3H-digoxin transport and in line with lower MDr1 expression, in comparison with other 
cell models tested.  Digoxin is known to have modest passive permeability and Ab 
3H-digoxin P
app
 levels for calu-3 cell layers were observed to be in a similar range to 
NHbE P
app
 data, suggesting predominantly passive diffusion of 3H-digoxin in NHbE 
cell layers.  Additionally, the reduced permeability of 3H-digoxin in passage 3 NHbE 
cell layers may be explained by the multi-layered morphology (>8 layers) which was 
not apparent for passage 2 cells (Figure 3.6).
No asymmetric transport of 3H-digoxin was observed for rL-65 cell layers cultured 
in either medium or different length of culture period.  In contrast negligible to low 
efflux values (1.4-2.6) for rh123 were observed for rL-65 cells under all conditions 
tested.  3H-digoxin and rh123 are substrates for both mdr1a and mdr1b [schinkel 
et al., 1997; takeuchi et al., 2006; suzuyama et al., 2007], however, in general the 
P
app
 for both of these substrates in rL-65 cells was low, and all below the P
app
 for the 
paracellular marker 14c-mannitol (table 3.1).  this, together with statistically similar 
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(p>0.05) substrate P
app
 values in both directions, suggests negligible functionality of 
mdr1a or b (and other rat transporters able to traffic these substrates) in rL-65 cell 
layers.  this is in agreement with published functional studies of mdr1a and 1b in IPrL 
that have demonstrated mdr1a/b transporters have negligible effects on transport of 
drug substances across the airway epithelium in rats [tronde et al., 2003b; Madlova 
et al., 2009].  However, Francombe and colleagues have reported an increase in 
rh123 absorption from IPrL models with the presence of gF120918 (MDr1, bcrP 
inhibitor) in the instillate and perfusate solutions [Francombe et al., 2008].  this may 
indicate that although mdr1a/1b is unlikely to be present in rat airway epithelium, other 
rh123 and gF120918 sensitive transporters may be expressed and functional.  
5.4.2.  characterisation of 3H-digoxin transport
5.4.2.1. Dependency on cellular energy
conducting permeability experiments at low temperature acts as a general inhibitor 
of cell metabolism [Florea et al., 2001].  At 4°c the asymmetric transport of 3H-digoxin 
was abolished by a significant reduction (p<0.01) in both Ab and bA directions to below 
1 x 10-6 cm/s in all cell types tested.  A reduction in temperature both reduces cellular 
metabolism, and may reduce the instance of conformational shape changes required 
for transporter-mediated substrate translocation.  this indicated the contribution of 
transporter-mediated 3H-digoxin trafficking, particularly in the secretory direction, 
across all cell layers tested.  Florea and co-workers observed a similar elimination of 
asymmetric flunisolide transport across calu-3 cells at 4°c [Florea et al., 2001].  
sodium azide is a well-established metabolic inhibitor that inhibits cytochrome 
oxidase thus preventing the production of AtP via oxidative phosphorylation [tsubaki, 
1993].  In the presence of 15 mM sodium azide, whilst AtP levels for both MDckII-
Wt and MDckII-MDr1 cell types were below 30% of untreated cells, only significant 
reductions for 3H-digoxin Ab P
app
 (p<0.05) and bA P
app
 (p<0.01) were observed in 
MDr1 transfected cells.  the reduction in bA transport with sodium azide corresponded 
to the level for bA 3H-digoxin P
app
 in Wt cells indicating the inhibition of the MDr1 
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transfected component and highlighting the presence of non-AtP dependent trafficking 
mechanisms for 3H-digoxin in MDckII cells.  this also rules out the involvement of 
canine AtP dependent transporters such as mdr1 and other mrp transporters in 3H-
digoxin trafficking in MDckII cells.  In contrast sLc and sLcO transporters do not 
require AtP for transport and would not be affected by such treatment [koepsell et al., 
2007; Hagenbuch and gui, 2008].  
similarly, no impact of 15 mM sodium azide was observed for calu-3 cells at low 
passage but a significant reduction (p<0.05) was seen in bA 3H-digoxin P
app
 for high 
passage cells despite reductions in AtP levels of 48.6% and 53.5%, respectively.  the 
results suggest that ~10% of 3H-digoxin bA trafficking in calu-3 cells at high passage 
was mediated by an AtP-dependent transport process such as an Abc transporter. 
Likewise, Hamilton and colleagues showed a similar AtP-dependent efflux mechanism 
of rh123 transport in calu-3 cells with 15 mM sodium azide [Hamilton et al., 2001a]. 
the level of AtP depletion required to completely inhibit the functionality of Abc 
transporters without jeopardising the integrity of the cell layers is unknown, but Florea 
and co-workers reported a concentration of 3 mM sodium azide (~ 5 times lower than 
in these experiments) did not fully inhibit MDr1 in calu-3 cells [Florea et al., 2001]. 
these results suggest that 3H-digoxin bA P
app
 is likely to be mainly mediated by an AtP-
independent transporter system(s) rather than AtP-dependent Abc transporter(s). 
Whilst no difference was observed in 3H-digoxin transport for NHbE cells, sodium 
azide only caused a reduction in AtP levels to 80% of control cells which may not be 
sufficient to inhibit AtP-dependent transporter processes in these cells.  
It has been established that unlike healthy cells which obtain AtP mostly by the 
catabolism of glucose via oxidative phosphorylation processes in the mitochondria, 
cancerous cells predominantly produce AtP via the cytosolic glycolysis pathway at 
a much higher rate and with the production of lactic acid, even in aerobic conditions 
[kim and Dang, 2006].  this phenomenon termed the Warburg effect may be present 
in calu-3 cells which are from a cancerous origin.  However, as approximately a 50% 
reduction was achieved with oxidative phosphorylation inhibitor, sodium azide, it was 
not deemed necessary to pursue glycolysis inhibitors in this instance.
166ŚĂƉƚĞƌ ? 琀 ŚĂƌĂĐƚĞƌŝƐĂƟŽŶŽĨdWŝŶĚŝŶŐĂƐƐĞƩĞ ? ZdƌĂŶƐƉŽƌƚĞƌ&ƵŶĐƟŽŶĂůŝƚǇ
5.4.2.2. characterisation of transporter drug trafficking by chemical inhibition
the ciclosporin analogue, Psc833 developed as a specific MDr1 inhibitor has also 
been shown to inhibit other Abc transporters, namely bsEP [childs et al., 1998], 
MrP2 [bohme et al., 1993], MrP4 [van de Water et al., 2007] and bcrP [http://www.
solvobiotech.com/documents/Psc_833-flyer.pdf].  Additionally it has been observed 
that Psc833 has a non-MDr1 mediated inhibition which is yet to be identified but 
postulated to involve OAtP transporter(s) [Mayer et al., 1997; cvetkovic et al., 1999; 
bourasset et al., 2003].
Psc833 caused a significant reduction (p<0.01) in the bA P
app
 of 3H-digoxin in both 
MDckII-Wt and MDckII-MDr1 cell types.  Whilst Psc833 would be predicted to 
inhibit the MDr1-mediated transport of 3H-digoxin in MDckII-MDr1, the reduction 
may be not predicted for MDckII-Wt cells.  Expression of canine transporters, namely 
mdr1, mrp1 and mrp2 has been demonstrated in MDckII cells [goh et al., 2002] and 
it is probable that other canine Abc, sLc or sLcO transporters which have yet to 
be identified may also be functional in MDckII cells.  It is therefore likely that the 
abolition of net secretory 3H-digoxin transport is due to inhibition of one or several 
canine transporter proteins, innate to the canine kidney, in MDckII-Wt cells.  the 
decrease in 3H-digoxin bA P
app
 in MDckII-MDr1 cells, simultaneous with an increase 
in Ab P
app
 is indicative of inhibition of an apical efflux pump and in this instance, can 
be attributed to the transfected human MDr1 transporter.  However, 3H-digoxin bA 
P
app
 in MDckII-MDr1 cells was not reduced to the same level as MDckII-Wt cells 
either indicating only a partial decrease in MDr1 function or an up-regulation of other 
transporters which traffic 3H-digoxin in MDckII-MDr1 cells.  A significant decrease 
(p<0.01) in 3H-digoxin bA P
app
 alongside a significant increase (p<0.01) in Ab P
app
 was 
also observed for calu-3 cells at both passages tested.  As MrP2 functionality has 
been ruled out previously and 3H-digoxin is not an established substrate for bcrP 
or MrP4, transporters indicated are MDr1 and OAtP.  From the absence and small 
impact of AtP reduction on bA 3H-digoxin P
app
 in low and high passage calu-3 cells 
respectively, the primary 3H-digoxin transport mechanism seems unlikely to be an 
AtP-dependent Abc transporter.  Although it has been implicated that Psc833 has 
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an inhibitory effect on OAtP transporters, the specific transporter(s) have not yet been 
characterised [cvetkovic et al., 1999; bourasset et al., 2003].  In contrast, both Ab 
and bA 3H-digoxin P
app
 were reduced significantly (p<0.01) in NHbE cells indicating 
the inhibition of uptake transporters present at both the apical and basolateral poles.
Additional to its established function as an MDr1 inhibitor [keogh and kunta, 2006; 
Lin et al., 2007; Endter et al., 2007; bruilliant et al., 2009], verapamil has also been 
observed to have inhibitory effects on MrP1 [goh et al., 2002; Perrotton et al., 2007; 
siissalo et al., 2009], MrP2 [Myllynen et al., 2006], bsEP [Wang et al., 2003], Oct1 
and 2 [Niesetal, 2011], OctN1 and 2 [Yabuuchi et al., 1999; Wagner et al., 2000; 
Ohashi et al., 2001] as well as a postulated impact on OAtP transporters [Petri et al., 
2006].  In all cell types tested except NHbE cells, a significant increase in Ab 3H-digoxin 
P
app
 was observed alongside a significant reduction (p<0.01) in bA P
app
 resulting in a 
reduction in efflux ratio in the presence of 30 µM verapamil.  In contrast to inhibition 
with Psc833, a significant increase (p<0.01) was observed in Ab P
app
 for MDckII-Wt 
cells potentially indicating the inhibition of a non-MDr1 canine apical efflux/basolateral 
uptake transporter(s) by verapamil.  this difference was not observed in calu-3 cells 
suggesting both Psc833 and verapamil modulate the same transporters in these 
cells.  In contrast an increase in both Ab and bA P
app
 was observed with NHbE cells 
with verapamil which may suggest a more complex inhibition of multiple uptake and 
efflux transporters.  
Verapamil is unlikely to modulate bsEP and MrP2 transporter systems in calu-3 
cells as both were not shown to be functional in earlier studies.  Although MDr1 is 
present in calu-3 cells, the experiments with sodium azide imply an AtP-independent 
mechanism for 3H-digoxin transport in calu-3 cells.  Digoxin is an anionic molecule 
and not an established transporter for the cationic transporters (Oct and OctN) 
that verapamil has been reported to modulate.  Analogous to Psc833, verapamil is 
postulated to have a modulatory effect of OAtP transporters but specific transporters 
have not been established.  From the perspective of established AtP-independent 
transporters for 3H-digoxin trafficking, OAtP1b3 or OAtP4c1 may be potential 
candidates for further investigation of Psc833 and verapamil inhibition.  
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Mk571 is widely accepted as an MrP inhibitor and it’s inhibition of MrP1, MrP2, 
MrP4 and MrP5 has been documented [gekeler et al., 1995; van Aubel et al., 
1998; chen et al., 1999; renes et al., 1999].  Additional to its interaction with Abc 
transporters, it has also been shown to have inhibitory effects on OAtP2b1 and 
OAtP1b3 transporters with just 1 µM concentrations of Mk571 inhibiting 60% of 
OAtP1b3 mediated transport [Letschert et al., 2005; Letschert et al., 2006].  It has 
been demonstrated that Mk571 does not inhibit MDr1 mediated transport [gekeler 
et al., 1995] and additionally work by Lowes and co-workers showed no inhibition of 
the net secretory transport of 3H-digoxin in the presence of Mk571 in MDckII-MDr1 
cell layers in line with our findings [Lowes et al., 2003].  
One study by Matsson and colleagues reports Mk571 mediated inhibition of MDr1 
after conducting acetoxymethyl ester (calcein AM) uptake studies in MDckII-MDr1 
cells [Matsson et al., 2009].  calcein AM (established MDr1 substrate) is non-
fluorescent cell permeable compound which once inside the cell, is hydrolysed by 
intracellular esterases to calcein, which is fluorescent and not an MDr1 substrate 
[Holló et al., 1994].  In the presence of Mk571, Matsson and colleagues observed an 
increase in intracellular calcein levels, and attributed this to Mk571 mediated MDr1 
inhibition [Matsson et al., 2009].  However, other studies have shown that calcein is 
a substrate for several MrP transporters including MrP2 [Prime-chapman et al., 
2004].  It has been established in both these studies and in literature that MDckII-Wt 
and MDckII-MDr1 cells express functional canine transporters, amongst them mrp2 
[goh et al., 2002].  therefore, a possible explanation for the increase in intracellular 
calcein observed in these studies may be the inhibition of canine mrp2-mediated 
calcein extrusion from MDckII-MDr1 cells.
In both MDckII cell types, no significant impact of Mk571 was observed for bA 3H-
digoxin P
app
 highlighting Mk571 does not inhibit MDr1-mediated 3H-digoxin transport. 
In contrast bA 3H-digoxin transport was significantly reduced (p<0.01) in calu-3 and 
NHbE cells indicating a non-MDr1 secretory transport mechanism for 3H-digoxin. 
this is supported by flow cytometry data which showed no impact of Mk571 on UIc2 
affinity for MDr1.  bA 3H-digoxin transport is unlikely to be mediated by MrP2 given 
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this was not functional in calu-3 experiments with 3H-pravastatin.  Additionally, MrP1 
is not known to traffic 3H-digoxin, and the basolateral location in calu-3 cells [Hamilton 
et al., 2001b] would not account for the secretory effect.  3H-digoxin transport for 
other MrP transporters has not been characterised, but given no decrease in 3H-
digoxin transport was observed in the presence of AtP depleting agent sodium azide, 
Abc transporters are unlikely to be the sole mediators of 3H-digoxin transport.  A 
significant increase in bA 3H-digoxin P
app
 in the presence of Mk571 was observed for 
all cells except NHbE.  this indicates an Mk571-mediated inhibition of apical efflux 
or basolateral uptake transporter(s).  OAtP1b3 was not shown to be functional in 
calu-3 cells and no transcripts for OAtP2b1 were detected.  It is therefore unlikely 
that the changes in 3H-digoxin transport are mediated by these transporters in calu-3 
cells, however Mk571 modulatory effects on other OAtP transporters have yet to be 
determined.  
the ability of probenecid to inhibit MrP1 [Hooijberg et al., 1999; Zhou et al., 2008] 
MrP2 [Huisman et al., 2002], MrP3 [Zamek-glishzczynski et al., 2003], MrP4 [van 
Aubel et al., 2002] MrP5 [Jedlitschky et al., 2000] and MrP6 [Iliás et al., 2002] has 
been demonstrated.  Additionally, probenecid has been shown to inhibit OAt1-4 
[Wada et al., 2000; takeda et al., 2001; Enomoto et al., 2002; Hashimoto et al., 2004]. 
No reports for modulation of OAtP transporters by probenecid have been published 
to date.
there was no impact of probenecid on the transport of 3H-digoxin in either MDckII 
cells or calu-3 cells at low passage.  Whilst the Ab 3H-digoxin P
app
 was significantly 
increased (p<0.05) in high passage calu-3 cells there was no change in efflux ratio for 
3H-digoxin in the presence or absence of probenecid.  this indicates no involvement of 
MrP1-6 transporters in 3H-digoxin transport in these cells.  Although probenecid has 
been shown to inhibit OAt transporters, no gene expression for any OAt transporters 
was detected in calu-3 cells and 3H-digoxin trafficking by these transporters is 
uncharacterised.  In contrast, both Ab and bA 3H-digoxin P
app
 were significantly 
reduced in NHbE cells indicating the functionality of a probenecid-sensitive transport 
mechanism in NHbE cells.
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Indometacin has been shown to inhibit MrP1 [Leite et al., 2007], MrP2 [El-sheikh 
et al., 2006] MrP4 [Adachi et al., 2002; reid et al., 2003] and MrP6 [Ilias et al., 
2002].  It has also been reported to have an inhibitory action on OAt1-4 [khamdang 
et al., 2002; buckhardt and buckhardt, 2011].  the potential for indometacin-mediated 
interactions with OAtP transporters has not been reported to date.  No significant 
difference (p>0.05) in 3H-digoxin transport for calu-3 cells at either passage range was 
observed in the presence of indometacin.  As a significant increase (p<0.01) in Ab P
app
 
and decrease (p<0.05) in bA P
app
 was observed for MDckII-Wt with indometacin, it 
could be postulated that an indometacin-dependent trafficking of 3H-digoxin is present 
in MDckII cells.  As this was not observed with probenecid or sodium azide, it is 
unlikely this effect is OAt or MrP mediated, however, interactions of indometacin 
with other AtP-independent transporter mechanisms have yet to be substantiated.  In 
NHbE cells, indometacin significantly increased Ab 3H-digoxin P
app
 whilst significantly 
decreasing (p<0.01) bA P
app
, indicating the involvement of an indometacin-sensitive 
apical efflux or basolateral uptake system similar to MDckII cells.
5.4.2.3. biological probing of MDr1 functionality
UIc2 and Mrk16 are specific antibodies for MDr1 that bind to different extracellular 
loops of the MDr1 transporter [Michisch et al., 1992; Mechetner and roninson., 
1992].  As such they are able to functionally inhibit MDr1 by fixing the transporter in 
a certain conformational state thus altering the binding affinity of chemical modulators 
[Mechetner et al., 1997; Nagy et al., 2001; 1997; Park et al., 2003; goda et al., 2006]. 
As predicted, no impact was observed for
 
3H-digoxin trafficking in MDckII-Wt cells. 
However, the significant decreases observed in 3H-digoxin P
app
 with UIc2 (p<0.05) 
and Mrk16 (p<0.01) pre-treatment, indicated the inhibition of MDr1-mediated 3H-
digoxin trafficking in MDckII-MDr1 cells.  Whilst the Mrk16 antibody significantly 
reduced (p<0.05) bA 3H-digoxin transport in calu-3 low passage cells in line with the 
inhibition of an apical efflux pump, the reduction in efflux ratio (7.4 to 7.0) and the 
absolute P
app
 values (which decreased from 4.96 ± 0.2 x 10-6 cm/s to 4.43 ± 0.2 x 10-6 
cm/s – 82 - 98% of control values) suggest the impact was minimal.  Additionally, no 
reduction in efflux ratio was observed for low passage calu-3 cell layers with UIc2, 
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further indicating the absence of MDr1-mediated 3H-digoxin trafficking in these cells. 
Neither inhibitory antibody tested had any impact on 3H-digoxin transport in high 
passage calu-3 cells, indicating no involvement of MDr1 for 3H-digoxin transport. 
similarly, no reduction in bA 3H-digoxin P
app
 was observed for either MDr1 inhibitory 
antibody indicating no involvement of MDr1 in 3H-digoxin trafficking in NHbE cell 
layers.
the extent of MDr1 inhibition by Mrk16 and UIc2 has been reported as partial 
(10-40%), variable and largely dependent on the substrate under investigation [goda 
et al., 2006].  based on the assumption that bA 3H-digoxin P
app 
for MDckII-MDr1 
above the bA P
app
 observed for MDckII-Wt cells is the transfected MDr1 mediated 
component, then a 20% and 30% reduction in MDr1 mediated bA 3H-digoxin transport 
was observed for UIc2 and Mrk16 antibodies respectively.  If 3H-digoxin is only partly 
trafficked by MDr1 in calu-3 cells, partial inhibition with the inhibitory antibodies may 
not be detected in in vitro permeability experiments due to experimental variation.  It has 
been postulated that due to the multiple binding sites present in MDr1 [Martin et al., 
2000] different sites of action for the inhibitory antibody and the substrate may create 
false negative results [Lowes et al., 2003].  However, this is unlikely as decreases in 
efflux ratio for 3H-digoxin in MDckII-MDr1 cells in the presence of Mrk16 (21.7 to 
15.6) and UIc2 (21.7 to 14.3) were generated in these studies.  Additionally, Mrk16 
has also been established to increase the uptake of 3H-digoxin in placental epithelial 
cells [Ushigome et al., 2000].  
the UIc2 shift assay first established by Mechetner and co-workers is based on the 
understanding that MDr1-ligand interactions alter the conformation of MDr1 which 
increases the affinity of UIc2 antibody for MDr1 [Mechetner and roninson,1992; 
Mechetner et al., 1997; Park et al., 2003].  Either direct or indirect immunofluorescent 
detection via flow cytometry is used to analyse the shift in fluorescence intensity of 
UIc2 in the presence of MDr1 substrates/inhibitors than with the antibody alone 
[Mechetner et al., 1997].  this phenomenon has been shown to be restricted to the 
UIc2 antibody as studies by Mechetner and colleagues have shown this not to occur 
with Mrk16 [Mechetner et al., 1997].  In the presence of 1 µM Psc833, the binding 
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of the specific MDr1 UIc2 antibody was enhanced above 10% relative to control in 
all cells except MDckII-Wt in the rank order MDckII-MDr1 > calu-3 low passage > 
calu-3 high passage > NHbE.  this indicates the presence of functional MDr1 in all 
bronchial epithelial cells tested, and similar to MDr1 expression levels from chapter 
Four.  the impact of Psc833 on increasing the binding affinity of UIc2 in the cells 
tested in these studies is in agreement with other published work for other MDr1-
expressing cell lines [goda et al., 2006].
In contrast to Psc833, no difference above the 10% level from control was observed for 
any of the other chemical inhibitors tested.  this is predicted for Mk571, indometacin 
and probenecid which have been established not to modulate MDr1 functionality 
[gekeler et al., 1995; keogh and kunta, 2006].  However, verapamil is an established 
inhibitor of MDr1 [keogh and kunta, 2006] but no difference in UIc2 binding affinity 
in MDckII-MDr1 cells or any other cell type tested was observed above the 10% 
level.  this phenomenon has also been reported by goda and co-workers who report 
that established MDr1 inhibitors (verapamil, quinine and nifedipine) have no impact 
on UIc2 affinity to MDr1 [goda et al., 2006].  this could also be explained by the 
interaction of verapamil with an alternative binding site on MDr1 to UIc2 and highlights 
the complexity and relative lack of understanding of MDr1 functionality.  
5.5. cONcLUsION
reports on the functionality of MDr1 and MrP2 transporters in bronchial epithelial in 
vitro cell models are conflicting.  this chapter has used 3H-digoxin to assess transporter 
mechanisms present in bronchial epithelial cell layers in vitro and employed several 
different approaches to probe the specific mechanism of transport.  the results have 
highlighted the transporter-mediated trafficking of 3H-digoxin across calu-3 cell layers 
at both low and high passages.  Net secretory efflux of 3H-digoxin was higher at 
low passage, however the various inhibition studies undertaken in this work did not 
highlight a different mechanism of 3H-digoxin transport with different passage number. 
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this may indicate that the transporter(s) responsible for 3H-digoxin trafficking in calu-3 
cell layers are more highly expressed at low passage, and that researchers should be 
mindful of the passage number when conducting and interpreting permeability studies. 
Whilst MDr1-mediated trafficking of 3H-digoxin in calu-3 cell layers could not be ruled 
out, these studies have indicated that it has a minimal involvement, and that it is 
unlikely to be the sole transporter involved in 3H-digoxin transport.  these studies also 
indicate that sLcO transporters (potentially OAtP4c1 on the basolateral membrane) 
may be involved in the trafficking of 3H-digoxin in calu-3 cells layers (particularly as 
gene expression was detected at moderate levels in calu-3 cells in chapter Four), 
however, further studies need to be conducted to confirm this.  there is also the 
possibility of the involvement of other OAtP transporters not considered in these 
studies as substrates have not been established yet (OAtP5A1, OAtP6A1) as well as 
other yet undiscovered transporter proteins.  the mechanism of 3H-digoxin trafficking 
in NHbE cell layers is less clear given the variability 3H-digoxin P
app
 with passage and 
batch effects.  However, these studies also indicate that 3H-digoxin is unlikely to be 
mediated by MDr1 in the bronchial epithelium.  In contrast, no transporter-mediated 
trafficking of 3H-digoxin was observed in rL-65 cell layers.
It is clear from these studies that assumptions regarding transporter functionality 
should not be made on the basis of permeability with one substrate and one inhibitor 
compound.  It is becoming increasingly apparent in published literature that there is 
considerable overlap in specificity of substrates and inhibitors for different transporters. 
Due to the lack of specific substrate and inhibitor compounds, it is necessary to employ 
a panel of chemical inhibitors and/or alternative methods are required In order to 
define the transporter(s) involved in substrate trafficking across epithelial barriers. 
Only then can the permeability of drug substances across the bronchial epithelial 
barrier be fully characterised.  
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6. gENErAL DIscUssION
the lung has gained increasing interest as a site for drug delivery over the years 
for both local targeting of therapeutics for treating respiratory diseases, and for the 
inhalation of systemic therapeutic moieties [Hillery, 2001].  However, whilst there 
is a plethora of research regarding particle size, device development and particle 
deposition, research regarding the absorptive and secretory mechanisms of drug 
molecules across the epithelium, and to the site of action is much more limited 
[Patton et al., 2010].  Well characterised in vitro models have been established and 
drug transport mechanisms reasonably understood for the main sites of oral drug 
absorption (small intestine), metabolism (liver) and secretion (kidney).  In contrast, 
airway epithelial in vitro models and airway epithelial drug absorption are less well 
characterised [bosquillon, 2010].  the establishment of reliable in vitro bronchial 
epithelial models with fully characterised permeability properties, including transporter 
functionality would provide an ideal platform for the development of novel, effective 
treatments with high bioavailability for both airway and systemic diseases.
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6.1. brONcHIAL EPItHELIAL IN VITRO cELL cULtUrE MODELs
In the past decade the acceptance and use of in vitro cell culture models for 
permeability screening of drug candidates and disease modelling has become 
widespread [Forbes and Ehrhardt, 2005].  these studies have focussed on the 
characterisation of selected bronchial epithelial cell in vitro models to assess their 
morphological and functional suitability as permeability screening tools.  Employment 
of in vitro models has had significant implications for high throughput permeability 
screening of potential therapeutic compounds, enhancing the understanding of drug 
trafficking at the molecular level and reducing the use of in vivo testing [Mathias et al., 
2002].  However, unless these models are representative of permeability across the 
bronchial epithelium in vivo, or a correlation to the in vivo situation can be deduced, 
these efforts may be futile.  
Permeability characteristics, particularly concerning the localisation and functionality of 
drug transporters in the bronchial epithelium have remained relatively uncharacterised 
in comparison with other epithelial barriers.  Additionally, there are several conflicting 
reports in literature, particularly regarding the expression and functionality of MDr1 
in bronchial epithelial cells and tissues [bosquillon, 2010].  Herein, the properties of 
the three in vitro models characterised in this thesis will be summarised and their 
effectiveness as a model of bronchial epithelial permeability discussed.  Additionally 
the potential uses for each model in current and future in vitro permeability research 
will be considered. 
6.1.1. calu-3 cell layers
It has been previously demonstrated that calu-3 cell layers cultured at an AL interface 
provide the closest in vitro representation of in vivo bronchial epithelial morphology, 
comprising a pseudostratified columnar epithelium of ciliated and secretory phenotypes 
[grainger et al., 2006].  studies in chapter three of this thesis have shown that these 
morphological characteristics are maintained between passage 25 – 50 indicating 
that calu-3 cell layers can be used as an accurate and reliable morphological 
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model throughout this passage range.  Additionally, the barrier properties of calu-3 
cells (measured by tEEr and paracellular P
app
) were shown to be suitable for use 
as a permeability screening tool at both low and high passage ranges suggesting 
a minimum window of 25 passages over which calu-3 cells can be reliably used 
as a physiologically relevant in vitro model when cultured as outlined in section 
2.2.1.2.  relative to primary bronchial epithelial cell cultures that require more costly 
supplemented serum free growth media and lengthy harvesting procedures, calu-3 
cell culture is more economic due to the lower cost of consumables and reduced labour 
required.  Importantly, calu-3 cells are commercially available and their successful 
culture as bronchial epithelial cell layers has been widely used and published. 
Whilst the cancerous origin of calu-3 cells confers immortality, enabling the cells to be 
passaged multiple times before senescence, it may have the disadvantage of altering 
transporter protein expression and functionality in the cells.  several transporters 
(Abcb1/MDr1, sLcO1b3/OAtP1b3) have been shown to be overexpressed in 
lung cell cancers [campling et al., 1997; Monks et al., 2007] and hence, calu-3 cell 
layers may also express different transporters in comparison with non-malignant 
cells, resulting in altered permeability characteristics to that found in vivo.  Evidence 
of overexpression of Abcb1 and sLcO1b3 was shown in these studies as calu-3 
cell layers demonstrated ~15 fold higher expression levels in comparison with NHbE 
cell layers.  However, gene expression for other transporters was reasonably well 
matched between calu-3 and NHbE cell layers.  Additionally, transporter expression 
profiles are known to vary between individuals [Mattson et al., 2011].  As calu-3 cells 
are sourced from adenocarcinoma cells from a single 25-year old male patient, it is 
unknown how representative this individual is of the human population.  
In general, the gene expression for the majority of Abc, sLc and sLcO transporters 
tested appeared constant between low and high passage number.  Abcb1/MDr1 
gene and protein expression however, did differ between the passage ranges 
tested but in agreement with other studies MDr1 gene expression did not correlate 
to protein expression [shirasaka et al., 2009].  Experiments detailed in this thesis 
have shown MDr1 protein expression was increased ~4 fold in later passage calu-
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3 cells in comparison with low passage cells and in agreement with observations by 
Madlova and colleagues [Madlova et al., 2009].  trafficking of 3H-pravastatin and 
3H-taurocholic acid produced symmetrical Ab/bA P
app
 <1 x 10-6 cm/sec suggesting 
only passive permeability of these compounds and highlighting an absence in 
functionality of established transporters for these substrates in calu-3 cell layers. 
Although the net secretory transport of 3H-digoxin was greater for low passage calu-
3 cells, the net direction of transport of 3H-digoxin was similar as was the impact of 
chemical and biological inhibitors at different passage number.  this may indicate the 
same transporters are functional in both low and high passage cells but the level of 
expression is reduced with higher passage number.  
this work is in agreement with other published data which have demonstrated that 
calu-3 cells, cultured at an AL interface, possess in vivo-like morphology and barrier 
characteristics similar to that of native bronchial epithelial cells [grainger et al., 2006]. 
their commercial availability and large passage range in which they retain their in vivo-
like properties also makes them an attractive in vitro model for both small scale studies 
and high throughput permeability screening.  Whilst characterisation of transporter 
expression and functionality is in its infancy in the lung and for in vitro airway models, 
transporter gene profiling data discussed in chapter Four suggests calu-3 cell layer 
transporter expression may be representative of transporter gene expression in vivo. 
Further clarification of transporter systems present in the airways is required to assess 
the pharmacological relevance of the model, but at present, calu-3 cell layers present 
the strongest candidate for a gold standard in vitro bronchial epithelial cell culture 
model.
6.1.2. NHbE cell layers
Despite NHbE cells being the most directly derived in vitro cell model from native 
bronchial epithelium, the morphology of primary cell layers is not as representative 
of the pseudostratified, columnar epithelium in vivo as calu-3 cell layers.  Ideal 
morphological differentiation may not be achieved either due to suboptimal medium 
composition or the primary cell source not possessing the capacity for differentiation. 
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However, NHbE cells do form cell layers 2-3 cells thick with a secretory phenotype 
when cultured at an AL interface.  As NHbE cells have not been immortalised either by 
transformation or extracted from a cancerous origin, the expression and functionality 
of transporter proteins may be more representative of those found in vivo.  
One drawback of using NHbE cells for permeability screening is the short timeframe 
(only 1 passage from these studies) in which they are operational for permeability testing 
and morphologically representative of the bronchial epithelium before undergoing 
senescence.  As such, only a limited number of experiments may be undertaken, thus 
not making the model suitable for high throughput screening.  Additionally, NHbE 
cells are less economically viable than immortalised cell lines given the greater cost 
of medium components and increased labour intensity, particularly if isolating cells 
directly from tissues.  
these studies have demonstrated the inherent unreliability of commercial NHbE cell 
culture regarding morphology and functionality even when donor source and passage 
variables are controlled.  the range of 14c-mannitol P
app
 in these studies was 0.30-
1.49 x 10-6 cm/s for cells from the same donor, cultured under identical conditions at 
the same passage.  this degree of variability in 14c-mannitol P
app
 in NHbE cell layers 
was also reported by Madlova and colleagues [Madlova et al., 2009].  the variation in 
cell layer integrity and morphology may lead to less consistent permeability data for 
screened substrates, making data interpretation more complex and less reliable.  
Whilst NHbE cells have a role within bronchial epithelial in vitro modelling, their use as 
a high throughput permeability screen is limited.  One advantage of NHbE cells over 
calu-3 cells is the ability to screen multiple batches of cells from different donors to 
understand variation in transporter expression and functionality between individuals. 
they also offer a good platform to compare expression of transporters in both healthy 
and diseased airway.  this would both help to validate the calu-3 cell layer model and 
gain a better understanding of transporter expression in different patient populations.
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6.1.3. rL-65 cell layers
For the first time, these studies have cultured and characterised cell-line derived rat 
bronchial epithelial cell layers to investigate their potential as a model for permeability 
screening.  When cultured in sFM for up to 8 days, cell layers exhibit similar morphology 
and barrier properties to existing human airway epithelial models.  rL-65 cell layers 
displayed similar levels of variability for tEEr and paracellular P
app
 found with other 
established in vitro models.  Furthermore, the commercial availability and relative 
ease of culture make it an attractive in vitro alternative to drug permeability screening 
in the rat.  
the expression of a limited selection of transporters and absence of net secretory 
transport of 3H-digoxin suggest interspecies differences exist in transporter 
expression and functionality between human and rat.  However, it has not yet been 
fully established how representative rL-65 cell culture layers are of transporter 
expression for rat in vivo.  
Whilst there is an awareness of interspecies differences in drug handling, 
pharmacokinetic and safety studies of candidate drugs in in vivo animal models are 
required for regulatory drug approval (guidance notes ucm070246) [http://www.fda.
gov].  With the rat being the most commonly used animal in airway epithelial in vivo/ex 
vivo modelling [sakagami, 2006] there is therefore a need to understand interspecies 
differences in drug permeability and absorption between rat and human lungs.  A rat in 
vitro cell culture model would help to enhance the understanding of these interspecies 
differences, and may help identify novel therapeutic moieties that may have not 
been developed due to poor absorption in rat in vivo.  relative to in vivo and ex vivo 
experimentation, a rat in vitro model also offers a cheaper alternative to studying 
drug permeability in the rat.  Although such a model is unlikely to replace the need 
for ex vivo and in vivo drug testing, it may help reduce and refine the experimentation 
required.  the primary role of an in vitro rat bronchial epithelial cell model would 
be to further investigate the permeability of compounds where inconsistencies arise 
between human in vitro and rat in vivo testing.  
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6.2. LIMItAtIONs OF IN VITRO PErMEAbILItY MODELLINg
Whilst permeability modelling using in vitro culture models is now a widely accepted 
technique, there are still several limitations associated with its use.  the series of 
transport experiments conducted in chapter Five highlighted the current limitations 
and lack of specific tools available for functional transporter research.  Although the 
net secretory transport of 3H-digoxin which was inhibited at 4°c and by the presence 
of verapamil and Psc833 initially suggests MDr1 involvement, further probing of 
the transporter mechanism revealed the majority of 3H-digoxin transport was AtP 
independent, unaffected by biological MDr1 inhibition and also reduced by non-MDr1 
chemical inhibitor compounds.  In agreement with other publications which probed the 
mechanism of 3H-digoxin transport in other in vitro cell lines, the specific trafficking 
mechanism(s) could not be elucidated in calu-3 cell layers [Lowes et al., 2003; 
taipalensuu et al., 2004].  Herein, the current limitations of transporter permeability 
screening will be addressed in detail alongside potential strategies to improve the 
quality of future drug transporter research.  
6.2.1.  standardisation of in vitro cell culture models
6.2.1.1. Passage effects
currently, there are no standardised culture conditions for bronchial epithelial in vitro 
cell models and several different methodologies are published in literature [cavet et 
al., 1997; Hamilton et al., 2001; Ehrhardt et al., 2005; Madlova et al., 2009; Li et al., 
2010].  studies in chapter three have demonstrated that the paracellular permeability 
of both calu-3 and NHbE layers was not significantly affected by passage number. 
Nevertheless, a range for 14c-mannitol permeability was observed for all cell models, 
which may influence cell layer integrity, and alter the permeability of substrates through 
the cell layers.  Additionally, different levels of transporter expression and functionality 
were observed between low and high passage calu-3 cell layers.  Furthermore, 
NHbE cell layers demonstrated altered trafficking properties of 3H-digoxin at different 
passage number.  this highlights that the passage number of calu-3 cells should 
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be taken into consideration and the passage range standardised when conducting, 
interpreting and comparing permeability data.  
serum free medium with a defined composition such as that used in NHbE cell culture, 
is able to be more easily and consistently replicated between different laboratories 
than a serum based medium (although the exact composition of proprietary media 
is not always disclosed).  A variety of basal media for calu-3 cells has been reported 
including DMEM/Ham F12 [grainger et al., 2006; Madlova et al., 2009] and Eagle’s 
minimal essential medium (EMEM) [cavet et al., 1997; Ehrhardt et al., 2005].  the 
different salt compositions varies between these basal media may have an impact on 
cell growth and phenotype.  Importantly, the impact of serum source on cell growth, 
differentiation and lifespan of in vitro cultures is widely appreciated [schneider et al., 
1978; Mather, 1998].  standardisation of intra-laboratory serum source and batch is 
attainable, however, achieving this globally is less feasible.  
6.2.1.2. AL vs LL interface culture
Early permeability studies with calu-3 cells were largely conducted on cell layers 
cultured under submerged conditions [cavet et al., 1997; grainger et al., 2006]. 
However, more recently permeability screening using calu-3 cell layers cultured at an 
AL interface is more commonly reported.  this was particularly driven by grainger and 
colleagues who demonstrated greater morphological representation of the bronchial 
epithelium with calu-3 cell layers cultured at an AL interface [grainger et al., 2006]. 
ciliated and secretory cell phenotypes are present on the apical surface of bronchial 
epithelium and as such, AL interface culture is more representative of the environment 
in vivo.  However, the calu-3 cell line is derived from submucosal gland acini which 
would not naturally be exposed to an AL interface in vivo, but appears to be influenced 
by atmospheric exposure [grainger et al., 2006].  
Whilst calu-3 cell lines can be cultured both at an AL and LL interface, conversely, 
Ehrhardt and co-workers have shown 16HbE14o- morphology best mimics native 
airway epithelium when cultured using submerged conditions [Ehrhardt et al., 2002]. 
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given 16HbE14o- cells possess many similar characteristics to basal cells in vivo they 
are likely to be of basal origin [godding et al., 1998; Ehrhardt et al., 2002].  basal cells 
in vivo are not exposed to an AL interface and have negligible secretory properties 
[godding et al., 1998], thus submerged culture provides a better match of the native 
environment for these cells in the lung, and hence, they are more representative of 
airway epithelium when cultured under these conditions.  
6.2.1.3. Length of culture period
these studies have demonstrated enhanced MDr1 expression with increasing time in 
culture.  Additionally, MDr1 functionality in bronchial epithelial in vitro cell culture was 
also shown to vary with culture length [Madlova et al., 2009].  similarly the expression 
and functionality of other transporters are also likely to be impacted by the length 
of the culture period.  currently, there is no standardisation for length of bronchial 
epithelial cell layer culture, however, some studies suggest that 21 days may allow 
for more optimal differentiation and expression and functionality of transporters, 
better mimicking the in vivo environment [Madlova et al., 2009; Haghi et al., 2010]. 
Nevertheless, few published studies regarding NHbE and calu-3 cell layer culture are 
conducted after 21 days and most published work reports permeability in 8-21 day old 
cell layers making the comparison of inter-laboratory permeability data more difficult.
6.2.1.4. seeding density
there are no standard seeding densities for calu-3 and NHbE cells and ranges 
between (1 x 105 – 1 x 106 cells/cm2 and 1 x 105 – 3 x 105 cells/cm2, respectively) 
have been used amongst different laboratories [shen et al., 1994; cavet et al., 1997; 
Hamilton et al., 2001; Ehrhardt et al., 2003; Lin et al., 2007; Madlova et al., 2009]. 
these studies have demonstrated that seeding density can have a direct effect on 
tEEr and barrier properties of rL-65 cell layers and it is likely this could be replicated 
in other bronchial epithelial cell layers.  the cell seeding density impacts on the time 
to produce confluent cell layers and determines when proliferation, differentiation 
and maturation occurs [Volpe, 2008].  As such, permeability characteristics and 
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transporter functionality may differ during the culture period and cell layers tested after 
the same length in culture, but seeded at different cell densities, may display different 
permeability characterisitics.  Furthermore, higher seeding densities deplete medium 
supplements at a faster rate, thereby accelerating local pH concentration changes as 
a result of increased metabolic loading.  Extreme low or high seeding densities may 
even prevent the formation of functional cell layers altogether.  
6.2.1.5. culture substratum
Although the impact of substratum was not investigated in these studies, there are 
reports that ciliated and secretory phenotypes in tracheal cultures have only been 
achieved through culture on a collagen substratum [kim, 1985; Wu et al., 1990].  In 
contrast, other studies have reported that NHbE cell layers cultured in the absence 
of a collagen substratum produce mucin and possess a ciliated phenotype [stewart 
et al., 2011].  Additionally, these studies, in agreement with other reports, have also 
shown that calu-3 cells are able to differentiate into ciliated and secretory phenotypes 
without the need for a collagen substratum [grainger et al., 2006; Madlova et al., 
2009].  
Over the years, considerable effort has been spent investigating and optimising suitable 
biocompatible and bioactive surfaces for in vitro cell culture studies [Jiao and cui, 
2008].  to date, the most commonly used culture material is tissue culture plastic which 
comprises a synthetic polystyrene substrate treated by oxygen plasma polymerisation 
and etching which involves direct bombardment with reactive oxygen species (the 
plasma).  this technique improves the wettability of the material by imposing a direct 
physical modification (pitting) of the surface but, also, provides an ionic interaction, 
attracting key extracellular matrix proteins from the serum in the culture media, and 
evoking a direct interaction with the cells themselves.  However, although traces or 
low amounts of key extracellular matrix proteins (collagen, fibronectin) are present in 
serum, they are lower in concentration than albumin, which constitutes the majority of 
proteins attached to the tissue culture plastic in serum containing cultures [Jiao and 
cui, 2008; romano et al., 2011].  biological surface modifications include pre-coating 
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the culture surface with proteins found in the extracellular matrix, namely collagen, 
fibronectin and laminin.  these biological substrates provide motifs for cell interaction, 
physical flexibility and a 3D structure for improved nutrient exchange [Ingber and 
Folkman, 1989].  coating with poly-L-lysine has also been shown to increase cell 
attachment by electrostatic attraction.  the impact of the substratum has been shown 
to impact differentiation of a wide range of cells, and it is therefore likely it may also 
have an impact on the phenotype of bronchial epithelial cells in vitro [bledi et al., 
2000].
In summary, there are several factors which play a crucial role in the differentiation and 
maturation of bronchial epithelial cell layers in culture.  these influence the integrity 
of the cell layers and are also likely to affect transporter expression and functionality. 
Furthermore, the lack of standardised culture methodology for in vitro bronchial 
epithelial cell models is likely to enhance inter-laboratory variability in permeability 
screening, and prevent direct comparison of data.  A drive towards standardised 
culture methods for calu-3 may not only aid characterisation of the model but help to 
further understand transporter mechanisms present in the bronchial epithelium, thus 
providing an opportunity for the emergence of a ‘gold standard’ bronchial epithelial in 
vitro cell culture model.  
6.2.2. Limits of gene transporter detection
Although transporter gene expression profiling tools can determine transporter mrNA 
levels in a relative quick, high throughput manner, it is unknown how this relates 
to protein expression.  Disparity between gene and protein expression levels for 
Abcb1/MDr1 are highlighted in chapter Four, where late passage calu-3 cell layers 
demonstrated higher protein levels of MDr1 in comparison with low passage cells, 
despite having lower gene expression.  In agreement with these findings, shirasaka 
and colleagues concluded MDr1 functionality could not be estimated from mrNA 
levels in various cell types screened in their investigations [shirasaka et al., 2009]. 
Additionally, there are several different tools available for analysis of gene expression 
including rt-Pcr, qPcr and microarray.  the data obtained from these techniques 
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can be analysed by a variety of different formats and, as outlined in chapter Four, 
are not always directly comparable.  At best, transporter gene expression provides a 
guide, indicating which transporters may or may not be likely to be expressed.
6.2.3. Limitations of protein transporter detection
Whilst many transporter gene expression tools can be performed with minimal 
sample volumes in a relatively high throughput manner, the detection of protein 
expression and localisation in cell and tissue samples tends to be slower and more 
labour intensive.  As such, several published reports exist detailing transporter gene 
expression levels in whole lung tissue [Langmann et al., 2003; bleasby et al., 2006] 
and for several bronchial epithelial in vitro cell lines [Endter et al., 2009].  However, the 
gene expression data in chapter Four describes transporter gene expression levels 
for the first time in calu-3 and NHbE cell layers differentiated at an AL interface.  In 
contrast, protein expression and localisation of transporters in bronchial in vitro cell 
culture models is not so widely reported and to date, no such in depth, simultaneous 
screen of all Abc, sLc and sLcO transporter protein expression or localisation exists 
for either lung tissue or for airway in vitro cell culture models.  
the most established methods published in literature for protein detection in airway 
epithelial cell layers are Western blotting and immunocytochemistry (Icc) [Hamilton 
et al., 2001a; Hamilton et al., 2001b; Florea et al., 2001].  However, these techniques 
are reasonably labour intensive and are not high throughput.  Detection of transporter 
proteins via Western blotting poses several challenges. transporter proteins typically 
constitute a very small proportion of protein present in whole cell lysate and such low 
concentrations may make detection challenging.  However, Western blotting does 
provide an increased level of confidence in antibody specificity over other techniques 
by reporting the molecular weight of the detected protein.  Icc is a less labour intensive 
technique, and also has the advantage of determining transporter localisation on the 
cell layer.  However, it does not provide information on specificity of the antibody. 
One of the main drawbacks of Western blotting and Icc is that despite densitometry, 
quantification of expression is qualitative.  Other protein detection techniques such as 
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flow cytometry and ELIsA have the advantage of producing quantitative information for 
transporter expression and are more easily adaptable to a high throughput approach. 
However, only few reports use these techniques in literature for characterisation of 
transporter proteins, likely as they offer little advantage over other techniques and 
do not provide information regarding transporter localisation [Anderle et al., 1998; 
scheffer et al., 2002].
Previously, one of the major limitations for detection of protein transporter expression 
was the lack of specific antibodies for Abc, sLc and sLcO transporters.  there are 
several commercially available antibodies against MDr1 which have been established 
in the literature to be specific and reliable [Lacueva et al., 1998].  Additionally, the 
development and availability of other commonly investigated transporters (MrP1-
4, bcrP) has improved over the last decade.  Even since this work was initiated, 
the availability of antibodies for other transporters (particularly MrP5-9, Oct, OAt, 
OAtP transporters) has soared.  However, whilst these newer antibodies are being 
validated for specificity and reliability in transporter research, in the meantime the 
lack of reliable, established and specific antibodies for transporters remains a major 
limitation to transporter protein expression research.  
6.2.4.  transport studies
6.2.4.1. Experimental conditions
typically, transport experiments are carried out in glucose-containing buffers such as 
Hbss or krebs buffer solution (kbs).  Usually, permeability studies are conducted 
at pH 7.4 on both sides of the cell layer, which may not be representative of in vivo 
conditions.  the pH of conducting airway secretions reported is generally between 
5.5-6.5, and studies have indicated this may alter with disease or infection [Lansley 
and Martin, 2001; coakley et al., 2003].  the pH affects the ionisation of therapeutic 
molecules, impacting the partitioning capacity across the cell layer.  In general, weak 
acids are ionised in more basic conditions and conversely weak bases are ionised 
in acidic conditions.  Unionised molecules more easily partition across the plasma 
membrane and the degree of ionisation may also impact on the affinity of transporter 
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interactions [Volpe, 2008].  However, acidic mucopolysaccharides were detected on the 
surface of calu-3 and NHbE cell layers after multiple washings with Pbs indicating that 
a mucus layer would still be present in permeability experiments, potentially creating a 
micro-environment at the apical cell surface.  Additionally, the agitation rate of the cell 
layers during the experiment can impact significantly on substrate permeability.  Without 
agitation, the unstirred water layer on either side of the cell layer causes a concentration 
gradient effect within each compartment, reducing substrate transport [Volpe, 2008].  
6.2.4.2. substrate specificity
In recent years, it has become apparent that transporter mediated substrates often 
show specificity for more than one transporter [Al-shawi et al., 2005; Zhou et al., 2008]. 
transporter mediated trafficking of endogenous waste products and cell nutrients 
by multiple systems would be evolutionary advantageous in maintaining normal 
cell physiology in the event of malfunction or temporary inhibition of one pathway. 
therapeutic moieties with similar chemical motifs as endogenous compounds are 
therefore also likely to be transported by multiple transporter mechanisms.  this 
presents a problem when using predominantly transporter mediated substrates to 
study the functionality of a single transporter.  It is likely that the cell line or tissue 
under investigation may express other transporters able to traffic the substrate, and 
thus permeability data will be a representation of all functional transporters in the 
system.  these studies have highlighted the multi-transporter specificity of digoxin, 
pravastatin, taurocholic acid and rh123, all common substrates widely published for 
their use in determining the functionality of solitary Abc transporters.  
Of interest, digoxin is an FDA approved substrate (guidance notes ucm070246) for 
investigating the contribution of MDr1 inhibition or induction of drug candidates [http://
www.fda.gov].  However, this screening method may inadvertently also detect the 
influence of other transporters able to mediate the trafficking of 3H-digoxin that could 
be present and functional in the models employed.  Hence, screening for an interaction 
with MDr1 in isolation would not be achieved.  Furthermore, caco-2 cell studies are 
recommended for FDA approval (guidance notes ucm070246) [http://www.fda.gov], yet 
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Lowes and co-workers alluded to a non-MDr1 pathway for digoxin secretion in caco-2 
cells, highlighting that one or more transporters for 3H-digoxin may be present in the cell 
line [Lowes et al., 2003].  A non-MDr1 component to digoxin trafficking has also been 
alluded to in other studies, but to date the transporter involved has not been identified 
[taipalensuu et al., 2004].  this demonstrates the limitations of in vitro permeability 
screening and indicates the need to rethink permeability screening strategies.  
6.2.4.3. Inhibitor interactions
similarly to substrates, many chemical inhibitors have also been shown to possess 
multi-transporter specificity for the same reasons as described above in section 
6.2.4.2.  Additionally, an inhibitor compound can elicit its inhibitory effect by acting 
in a competitive or non-competitive fashion.  In competitive inhibition, the inhibitor 
compound is a substrate for the same transporter(s) as the compound under 
investigation [Whiteley, 2000].  the competitive inhibitor compound is added in a much 
higher concentration than the substrate and thus is able to compete with the substrate 
for transporter binding and translocation, reducing the trafficking of the substrate of 
interest (e.g. verapamil and Mk571).  conversely, a non-competitive inhibitor will 
bind to an alternative binding site other than the substrate binding site causing a 
conformational change in the transporter and inhibiting its function (eg Psc833) 
[Advani et al., 1998].  In either case, the substrate is prevented from binding to the 
transport, and transporter mediated trafficking is inhibited.  Although the majority of 
inhibitor compounds used in published permeability studies elicit their inhibitory action 
competitively, it is important to note that not all inhibitors of transporter-mediated drug 
trafficking (non-competitive inhibitors) are substrates for that transporter [taub et al., 
2011].  there have been several reports claiming that therapeutic drug compounds 
which inhibit the trafficking of known transporter-mediated compounds are substrates 
for that transporter without confirming the mechanism of inhibition [Horvath et al., 
2007; taub et al., 2011].  this has led to conflicting reports of transporter functionality 
and substrate specificity in literature.  A better understanding of both inhibitor mode 
of action and transporter specificity will also aid the characterisation of transporter 
functionality in in vitro models.
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6.2.4.4. Interpretation of results
6.2.4.4.1. Variability and reliability of paracellular markers
these studies, alongside established methodology for radiolabelled substrate transport 
experiments, simultaneously measure paracellular 14c-mannitol P
app
 alongside 
3H-substrate P
app
 to confirm the maintenance of cell layer integrity throughout the 
experiment.  Furthermore, the tEEr of each cell layer was measured prior to, and 
after the experiment, and only inserts with suitable resistance values were selected 
for the experiments and analysis, supplementing paracellular marker data.  transport 
experiments with fluorescent probes do not simultaneously measure paracellular P
app
 
throughout the experiment and the maintenance of barrier integrity is reliant on tEEr 
measurements alone.  Despite setting acceptance criteria for paracellular P
app
 and 
tEEr values (see 2.2.5.2) integrity of cell layers may still be variable.  this should be 
taken into account when interpreting substrate P
app
, however, this is not customarily 
reported in literature.  
6.2.4.4.2. Absolute permeability values
transporter efficiency varies between different substrates and species, and the 
expression level of transporters may also vary even in the same cell line [suzuyama 
et al., 2007].  Particularly, when multiple transporters may be involved in trafficking 
of substrates across the epithelial barrier, it is difficult to ascertain what value of P
app
 
indicates transporter involvement.  Historically, the efflux ratio has been used to identify 
the involvement transporter-mediated trafficking, and typically an efflux ratio >2 or <0.5 
has signified net secretion or absorption processes driven by transporter systems, 
respectively (guidance 05/Wc500090112) [http://www.ema.europa.eu].  However, the 
P
app
 value should also be considered, especially if low substrate P
app
 values in the 
range of the paracellular marker are obtained (<1 x 10-6 cm/s for these experiments), 
as differences observed between Ab and bA permeability may arise from the variability 
of cell layer integrity rather than from transporter mediated trafficking.  For example, 
net secretory transport of 3H-digoxin [Madlova et al., 2009] and rh123 [Lin et al., 2007] 
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has been reported based on P
app
 values ~ 0.3 – 0.8 x 10-6 cm/s.  However, these are 
in a similar range and showed comparable variation for reported levels of paracellular 
permeability (~0.2 – 1.3 x 10-6 cm/s).  Although P
app
 is an important measure detailing 
the movement of molecules per unit area and time independently of concentration, it 
can be difficult to contextualise the value in terms of magnitude of substrate transport. 
Perhaps, additionally quoting the % of substrate trafficked across the barrier in each 
direction for a specified, biologically relevant duration, may provide some relativity 
regarding the magnitude of substrate transport and aid data interpretation.  
6.2.5. Limitations of current strategies
Modelling and characterisation of permeability screening in bronchial epithelial in vitro 
cell cultures has improved steadily in the last 15 years, however, there is still much 
optimisation required.  some of the first studies in calu-3 cells reported transporter 
functionality using non-specific substrate and inhibitor compounds, albeit the lack 
of specificity and abundance of drug transporters was not fully appreciated at that 
time [Hamilton et al., 2001].  More recently, studies have investigated gene and/or 
protein expression of the transporter known to be trafficking the substrate under 
investigation [Ehrhardt et al., 2005].  However in many studies, the appreciation of 
multiple interactions with different transporters is not considered.  these present 
investigations aimed to consider all known interactions of substrates and inhibitors 
with transporters throughout the data collection and analysis.  
Undoubtedly the largest problem with current methods of drug permeability screening 
and in vitro characterisation techniques is the discrete collection of transporter 
expression and functionality data and the conclusions that are drawn from circumstantial 
evidence.  Although gene and protein expression data for several transporters may 
be obtained, the expression of the transporter does not correlate to functionality 
data.  Until the transporter protein can be directly linked with functional trafficking of 
a substrate, reports concerning transporter functionality in cell in vitro models will be 
unsubstantiated.  
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6.2.6.  Other strategies
6.2.6.1. transfected cells
transfecting a cell line with the transporter of interest provides a useful tool to enable 
more detailed studies of a transporter in relative isolation.  these studies used a MDr1 
transfected control cell line in order to ascertain the impact of chemical, metabolic and 
biological inhibition specifically on MDr1.  However, whilst expressing human MDr1, 
the MDckII transfected cell line also expresses functional canine transporters native 
to its origin.  canine transporters (mdr1, mrp1, mrp2) have been demonstrated to be 
present in MDckII cells and it is likely that other Abc, sLc and sLcO transporters 
found in dog kidney epithelial cells are also functional in the cell line [goh et al., 2002]. 
therefore, although human MDr1 is likely to be more highly expressed in MDckII-
MDr1 cells than canine transporters, the impact of canine transporter-mediated 
trafficking 3H-digoxin in these studies cannot be ruled out.  Additionally, the wild type 
control for MDckII cells is not a true negative control for the functionality of MDr1 
as canine mdr1 is also functional and has a similar substrate and inhibitor specificity 
to human MDr1 [goh et al., 2002].  recently, development of a low expression 
MDck cell line (MDck-LE) has been described which has been engineered to have 
very low levels of native transporters [Di et al., 2011].  this may provide improved 
properties for an epithelial transfection tool, aiding interpretation of permeability data. 
Additionally, transfection of a cell line with a transporter may alter the expression 
and/or functionality of other native transporters in the cell, so that transfected and wild 
type cells may express different levels of innate transporters [kuteykin-teplyakov et 
al., 2010].  
One drawback of transfected cell lines is that the degree of transfection may vary 
from lab to lab, and expression and functionality of the transfected transporter should 
be checked regularly [kuteykin-teplyakov et al., 2010].  For this reason comparing 
permeability data between different transfected cell batches and different laboratories 
should be done with caution, taking the variable levels of transfected transporter into 
account.  several stable transfected epithelial cell lines with transporters of interest 
192ŚĂƉƚĞƌ ? 琀 'ĞŶĞƌĂůŝƐĐƵƐƐŝŽŶ
are commercially available.  However, these are only available for a limited number 
of Abc transporters.  Additionally this would be a very expensive and time consuming 
permeability screen if permeability investigations for every known drug transporter were 
to be undertaken for every candidate drug compound.  For this reason, transfected 
cell lines are of particular use when exploring the physiology and pharmacology of a 
specific transporter or specific substrate-transporter interaction.
6.2.6.2. rNA interference
knock-down of transporter genes by sirNA or more recently shrNA to investigate 
the impact on substrate trafficking has also been employed [Xing et al., 2007].  Whilst 
offering a platform to compare substrate trafficking with and without the presence of 
a selected transporter in a system, this method suffers some similar drawbacks to 
transfected cell lines outlined in 6.2.6.1.  knocking down a transporter may alter the 
expression levels of other transporters in the cell [Higuchi et al., 2004; chen et al., 
2005].  Hence, ideally the gene and protein expression levels of all drug transporters, 
and particularly those established to traffic the substrate under scrutiny should be 
quantified.  Additionally, a true control cell line containing the same expression levels 
of other transporters in the knock-down cell line may be difficult to attain.  However, 
Wantanabe and co-workers did not find altered mrNA expression levels of bcrP or 
MrP1-6 with sirNA silencing of Abcb1 [Watanabe et al., 2005].  Another drawback 
is that the extent of gene knock-down is variable and never 100%.  knock-down of 
MDr1 gene expression by sirNA in cancer cell lines was reported to at best reduce 
expression by 65% despite optimisation of the technique [Wu et al., 2003].  Other 
reports of Abcb1 gene knock-down with sirNA are variable and range between 48-
90% [Nieth et al., 2003; Watanabe et al., 2005].  this still makes the interpretation of 
P
app
 data complex and problematic.
Additionally, the practicality of using sirNA techniques in bronchial epithelial cell 
line cultures presents an issue.  studies in this thesis have presented the argument 
for improved functional representation with 21 days in AL culture, however, sirNA 
gene silencing effects have been shown to be short lived, with return to baseline 
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after 72 hours [Wu et al., 2003].  As sirNA effects only last for ~ 24-72 hours [Wu et 
al., 2003], this technique is incompatible with permeability studies on differentiated 
bronchial epithelial cell layers.  Additionally, the long half-life of transporters (14-17 
hours for MDr1) may mask the effect of gene silencing [Pan et al., 2009].  shrNA and 
vector-based knock down have been shown to silence MDr1 expression in caco-2 
cells for up to 6 weeks [celius et al., 2004].  similarly to transfected cell line tools, 
these techniques are less economically viable given the need to quantify transporter 
expression alongside every functional result and are more suited to investigating the 
pharmacokinetics of specific transporters than for use as a high throughput screening 
method.
6.2.6.3. Inside out vesicles
Membrane preparations have been employed in the study of transport processes 
for over 40 years [steck et al., 1970].  the optimisation of techniques to generate 
and separate inside out and right-side out vesicles is well established and available 
commercially for a variety of purposes [steck et al., 1970; sharom et al., 1999]. 
Vesicular transport assays for Abc transporters are based on inside out vesicles 
commonly generated from transfected insect cell lines (e.g. sf9) where the intracellular 
NbDs are located on the outside of the vesicle.  the sf9 insect derived cell line 
is commonly used given its high susceptibility to transfection agents [glavinas et 
al., 2008]. the vesicles are incubated in solution with the substrate of interest, and 
after a set amount of time, can be quickly separated from the incubation solution via 
filtration with glass fibre filters or nitrocellulose membranes [glavinas et al., 2008]. 
the amount of substrate trapped within the vesicle can then be assessed by either 
radioactivity, fluorescence, HPLc or Lc/Ms [glavinas et al., 2008].  Additionally, an 
indirect set-up can be used whereby a chemical inhibitor can be added to investigate 
its modulatory effects on the trafficking of the substrate and can provide clarification of 
inhibitor mechanism (competitive/non-competitive) [bartholome et al., 2007]. 
Vesicular transport studies have the advantage of measuring functionality of 
a transporter across a single cell membrane without the interference of other 
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cellular processes (metabolism) and without the complexity of simultaneous apical 
and basolateral transporter systems.  However, compounds with good passive 
permeability are not retained within the vesicle, and transport of these compounds 
may be underestimated.  Additionally, it does not overcome the problem of multiple 
transporters found natively in the cell membranes from being present and functional 
in the vesicle system.  
6.3. FUtUrE PrOsPEctIVEs
Finding a technique that defines which transporter(s) mediate substrate trafficking 
in real time would be a gold standard approach in functional transporter research. 
However current tools do not have the capacity for such an experimental design.  Flow 
cytometry does show promise as a technique that has the capacity to link transporter 
protein expression alongside functionality.  the UIc2 shift assay first described 
by Mechetner and colleagues uses the MDr1 antibody (UIc2) which binds to an 
extracellular region on MDr1.  In the presence of a substrate interaction with MDr1, 
the conformation of the transporter alters the affinity of UIc2 which is observed as a 
shift in fluorescence intensity in flow cytometry analysis compared with the control 
[Mechetner and roninson, 1992; Mechetner et al., 1997].  However, not all established 
MDr1 substrates or inhibitors appear to be detected via this method, likely due to 
multiple binding sites on MDr1 or eliciting a conformational change that does not 
impact the affinity of UIc2.  Another drawback to this technique is the availability of 
suitable antibodies, and to date only the functionality of MDr1 and bcrP transporters 
can be analysed in this way [Mechetner et al., 1997; Hegedus et al., 2009].  
the impetus for increasing the awareness of drug-transporter trafficking has stemmed 
from the pharmaceutical industry, driven by guidelines set by the EMA and FDA 
regulatory authorities [Huang et al., 2007; http://www.ema.europa.eu].  the most 
recent guidance regarding drug transporters from the EMA in 2010 (guidance notes 
05/Wc500090112) recommends using in vitro systems to investigate candidate 
195ŚĂƉƚĞƌ ? 琀 'ĞŶĞƌĂůŝƐĐƵƐƐŝŽŶ
drugs for an interaction with 9 different transporters (MDr1, bcrP, bsEP, OAtP1b1, 
OAtP1b3, Oct1, Oct2, OAt1 and OAt3), selected from the current knowledge 
to elicit clinically relevant in vivo drug interactions [http://www.ema.europa.eu]. 
these guidelines are based on oral drug candidates and aid the understanding of 
oral bioavailability, liver metabolism and renal elimination of drug substances.  As 
such, relevance of these transporters in the permeability of substances in the lung is 
questionable, as highlighted in these studies.  
Is there any evidence of transporter mediated inhaled drug trafficking in the lung?  A 
small number of studies have investigated the mechanisms of inhaled drug transport 
across the bronchial epithelium.  Florea and co-workers showed AtP-dependent Ab 
transport of flunisolide in calu-3 cell layers where MDr1 was located on the basolateral 
membrane [Florea et al., 2001].  In contrast no significant difference in the absorptive 
or secretory transport of budesonide was observed in calu-3 cell layers [borchard et 
al., 2002].  Additionally, salbutamol has been shown to have net absorptive transport 
across both calu-3 and 16HbE14o- cell layer, likely as a consequence of interaction 
with an Oct transporter [Ehrhardt et al., 2005].  Ipratropium uptake into bEAs-2b cells 
has also been demonstrated to be OctN1 and OctN2 mediated [Nakamura et al., 
2010].  Other studies have also indicated formoterol interacts with Oct transporters 
[Horvath et al., 2007].
the relatively new field of in vitro based drug transporter research is helping to further 
characterise the permeability of therapeutic moieties across epithelial barriers and 
predict absorption in vivo.  the generation of crystal structures of transporters is 
enhancing the understanding of their mechanism of drug translocation [Aller et al., 
2009].  At the same time, advances in in silico and in vitro techniques are advancing 
to be able to model and predict the clinical impact of transporter systems [cooper et 
al., 2010; Longest and Holbrook, 2011].  Although some epithelial barriers remain well 
characterised many of the intricacies of drug-transporter interactions and transporter 
specificity remain unknown.  It is also plausible that other transport mechanisms yet 
to be identified may also be responsible for drug trafficking [taipalensuu et al., 2004]. 
current understanding of transporter functionality is hampered by the lack of specific 
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tools available.  continued advancements in transporter research are likely to improve 
the bioavailability of therapeutic agents, help better understand disease processes 
and may provide future targeting strategies for drug delivery.
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Biological Sample 
total rNA isolated 
rt using oligo(dt) 
primer in 3 to 5 direction 
cDNA Two-cycle labelling One-cycle labelling 
cRNA 
cDNA 
B 
B 
B 
B 
B 
B 
B B 
B 
B 
B 
cRNA 
IVt 
rt 
IVt 
IVt 
biotinylated 
ribonucleotide 
Analogue 
B B B 
B B B 
B B B 
Fragmentation 
Heat 
Mg2+ 
Hybridisation 
Gene Chip 
Data 
scan and analysis 
complimentary binding of crNA 
to probe oligonucleotides 
Fluorescent detection by 
streptavidin-phycoerythrin (PE) 
PROBE SET DESIGN 
- 11-20 oligonucleotide probes 
- Each probe is ~ 25 base pairs 
- bound to a silicon wafer 
DATA ANALYSIS 
- signal of expression intensity (comparable for 
same probe set in different samples) 
- % of probes that are positively detected in 
each probe set (more useful for comparing 
different probe sets in the same sample) 
biotinylated ribonucleotide 
Analogue 
Appendix A. Schematic of Affymetrix DNA microrray methodology
rNA is isolated from a biological sample and cDNA synthesised.  In vitro transcription (IVt) 
is then employed to synthesis biotinylated crNA via one-cycle labelling or via a two cycles if 
amplification is required.  the sample crNA is introduced to the Affymetrix gene chip.  the 
chip has a set of probe sets specific for a gene of interest.  Each probe set contains between 
11-20 oligonucleotide probes (~25 base pairs in length) bound to a silicon wafer.  the cDNA 
will bind to complimentary probes on the gene chip and is detected using fluorescence.  Data 
for these studies was represented as the % present - ie the % of probes in the probe set that 
were detected as having bound the crNA of the sample.
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Appendix B: Chemical structures of substrate compounds 
 
chemical structures and associated  molecular weight (MW) and water solubility 
for (A) digoxin, (b) pravastatin, (c) taurocholic acid, (D) rhodamine 123 and (E) 
mannitol. 
 
A D 
E 
E 
D 
C 
B 
A Dt ? ? ? ? ? ?, ?K^ŽůƵďŝůŝƚǇ ? ? ? ? ? ? ?ŵŐ ?ŵů
Dt ? ? ? ? ? ?
, ?K^ŽůƵďŝůŝƚǇ ?х ? ?ŵŐ ?ŵů
Dt ? ? ? ? ? ?
, ?K^ŽůƵďŝůŝƚǇ ?х ?ŵŐ ?ŵů
Dt ? ? ? ? ? ?
, ?K^ŽůƵďŝůŝƚǇ ?х ? ? ?ŵŐ ?ŵů
Dt ? ? ? ? ? ?
, ?K^ŽůƵďŝůŝƚǇ ? ? ? ?ŵŐ ?ŵů
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Appendix C:  Chemical structures of inhibitor compounds 
 
chemical compounds and associated molecular weights (MW) for (A) Psc833, 
(b) verapamil, (c) Mk571, (D) indometacin and (E) probenecid 
A D 
E 
E 
D 
C 
B 
A 
Dt ? ? ? ? ? ? ?
Dt ? ? ? ? ? ?
Dt ? ? ? ? ? ? Dt ? ? ? ? ? ?
Dt ? ? ? ? ? ?
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Appendix D: Secondary controls for immunocytochemistry images
secondary controls (to check for non-specific binding of the secondary antibody) for 
immunocytochemical staining of 3.7% w/v paraformaldehyde fixed (A) low passage calu-3 
cells; (b) high passage calu-3 cells and (c) NHbE cells passage 2 all cultured on 12 well 
transwell® inserts at the AL interface fore 21 days. (D) MDckII Wt (negative control) and (E) 
MDckII-MDr1 (positive control) both cultured on 12 well tranwell® inserts for 5 days under 
submerged conditions and (F) HEk293 (negative control) cells cultured on glass slides for 
2 days. Nuclear components are counter stained with propidium iodide and shown in red. 
,PDJHVDUHD]VWDFNRIDVVHPEOHGȝPWUDQVYHUVHVHFWLRQRIFHOOOD\HUV,PDJHVWDNHQ
with x 63 oil objective and 1 x optical zoom with an average of 4 frames per image.
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